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ABSTRACT 
An estimated 285 million people had diabetes in 2010 of whom 480,000 were <14 years of age 
and most likely had type 1 diabetes (T1D). Each year, an additional 76,000 cases are diagnosed 
and incidence is increasing. Because there is no cure for T1D, this is an issue of great public 
health concern, particularly in developing countries, which will need to continue providing care 
for communicable diseases while addressing the rising incidence of chronic diseases.  
To fully address the growing issue of T1D in developing countries, we need to better 
understand the true burden of the disease (incidence/prevalence), how it presents and progresses, 
and how to prevent early mortality. This dissertation represents the first attempt to describe these 
measures, in Rwandan youth and adolescents, with T1D and is based on collaboration with the 
Life For a Child program and the Association Rwandaise des Diabetiques.  
Our data suggest that the rates of T1D in Rwanda are relatively low compared to African-
Arabic countries, but similar to neighboring Tanzania. Incidence of recognized T1D has, 
however, increased over the last ten years, portending a larger issue in the near future. Additional 
efforts are needed to ensure proper and timely diagnosis, as it appears likely that cases are dying 
before diagnosis, or are being misdiagnosed, especially in those <5 years of age. 
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While the mortality rate in Rwanda was similar to several other African countries, it was 
significantly higher than rates seen in developed countries, and hypoglycemia was a major cause 
of death. We did, however, demonstrate that glycemic control could be improved in a country 
with limited resources, and confirmed that more frequent glucose monitoring is a potential 
intervention strategy.  
Though these results are promising, it is clear that further research and interventions are 
needed to adequately address T1D in Rwanda. Additional efforts are needed to address the issue 
of balancing glycemic control and fear of hypoglycemia, especially in this population where food 
insecurity is common. Finally, additional strides need to be taken towards making this program 
more sustainable long-term, so that proper care may be available well into the future.  
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1.0 INTRODUCTION 
 
Abdel Omran first described the phenomenon of the epidemiologic transition of disease in 1971 
as a process where “degenerative and man-made diseases displace pandemics of infection as the 
primary causes of morbidity and mortality.” This shift occurs as countries become more 
developed and design more comprehensive public health infrastructures which result in lower 
mortality due to communicable diseases and increases in average life expectancy.1 As people live 
longer, they have more time to develop chronic or non-communicable diseases (NCDs). This 
shift has already occurred in the United States, and can now be seen in developing countries. 
Globally, an estimated 8-14 million people die yearly due to such preventable NCDs; 80% of 
whom lived in developing countries.2 Currently, communicable diseases are the focus of most 
public health efforts in developing countries, but as more countries go through this transition, it 
will become increasingly necessary for officials to focus not just on communicable diseases, but 
on NCDs as well.  
This thesis will focus on one such NCD of increasing importance in the Developing 
World – diabetes. The rates of this disease have risen over the last several years and are expected 
to increase substantially into the future. While this disease was once thought of as a disease of 
the wealthy, it is quickly becoming a disease associated with low- and middle- incomes, with a 
disproportionate burden being carried by individuals of low socio-economic status. An estimated 
380 million people world-wide will be affected by this disease by 2025, with 18.7 million 
residing in sub-Saharan Africa.2 
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 2.0 BACKGROUND 
 
2.1 DEFINITION OF DIABETES MELLITUS 
 
To appreciate the individual burden of this disease in developing countries, it is necessary to first 
understand the basic pathophysiology of this disease. The term “diabetes” refers to an 
assemblage of diseases where there is a disruption of either the body’s ability to produce or 
respond to insulin (or both) resulting in increased levels of blood glucose (figure 1). Insulin is a 
peptide hormone that is released by β- cells located in the Islets of Langerhans of the pancreas. 
Insulin is used by liver, muscle and adipose cells to take up glucose from the bloodstream for 
energy production. When insulin is not present in sufficient levels or is unable to be used by the 
cells properly, those cells are unable to function properly and glucose builds up in the 
bloodstream resulting in hyperglycemia. However, if insulin levels are too high, this can lead to 
low sugar levels, or hypoglycemia.  
 
 
 
2 
 
 Figure 1. Insulin Production and Action2 
While there are several sub-groups that fall under the “diabetes” heading, the two most 
common are type 1 and type 2.2–4   
Clinical diagnosis of diabetes is often driven by the development of complications, acute 
or chronic. Most patients with T1D present with symptoms of hyperglycemia such as, polydipsia, 
polyuria, polyphagia, blurred vision, sudden weight loss, and some ketoacidosis. The American 
Diabetes Association (ADA) diagnostic criteria for diabetes mellitus consists of one of the 
following: a blood hemoglobin A1c (HbA1c) measurement of ≥6.5%, fasting plasma blood 
glucose measurements ≥126 mg/dL (7.0 mmol/L), a two-hour plasma glucose level ≥200mg/dL 
(11.1 mmol/L) during an oral glucose tolerance test (OGTT) (consumption of 75 g of glucose 
after an overnight fast), or a random plasma glucose of ≥200 mg/dL (11.1 mmol/L) in a person 
with symptoms of hyper- or hyperglycemic crisis.4,5 
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 2.1.1 Classification and Epidemiology of Diabetes 
 
The first guideline for diagnosis and classification of diabetes was published by the World 
Health Organization (WHO) in 1965. These guidelines are reviewed periodically, with the latest 
review having occurred in 1998.6 The WHO currently recognizes two main classes of diabetes, 
type 1 and type 2. Gestational diabetes and a category referred to as “other specific types” are 
also recognized, but are less common.  
Type 1 Diabetes  
Type 1 diabetes (T1D) has previously been called insulin-dependent diabetes mellitus (IDDM), 
because it results from autoimmune destruction of the insulin-producing beta cells (β-cells) of 
the pancreas leaving the patient dependent on insulin injections for glucose control and survival3. 
While the exact cause of T1D remains unknown, it is believed that it is the result of a 
combination of autoimmune, environmental, and genetic factors7. The destruction of β-cells may 
eventually lead to a total loss of insulin production, which renders insulin dependent cells unable 
to properly metabolize glucose resulting in hyperglycemia. This excess glucose is then passed 
out of the body in urine.8 T1D patients are usually diagnosed at younger ages, but it continues to 
present at all ages.  
T1D accounts for approximately 5-10% of diabetes in the United States.9 The SEARCH 
for Diabetes in Youth Study has estimated the incidence of T1D to be 19.0/100,000 with the 
highest incidence occurring in non-Hispanic whites and those aged 10 -14 years10 . More 
African-American youth present with diabetic ketoacidosis at onset than Caucasians (27.9% 
versus 21.8%) and they also have significantly worse glycemic control at every age group. 
However, poor glycemic control is associated with age in both races, as older youth have poorer 
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control than younger.11 T1D is most commonly diagnosed in children and youth, but can present 
at any age.  
Type 2 Diabetes  
Type 2 diabetes (T2D) is usually characterized by defects in insulin secretion along with insulin 
resistance in cells.4 In these patients, the ability to produce insulin does not completely 
disappear, but they instead become increasingly insulin deficient and/or resistant which also 
results in hyperglycemia. The disease presentation may range from predominantly insulin 
resistance with some loss of insulin production, to predominant loss of insulin secretion with 
some or no insulin resistance.3 Type 2 diabetes is typically found to be associated with obesity, 
diet, and physical inactivity.8  
 T2D is typically not diagnosed until the development of complications; up to one-fourth 
of all people with T2D may be undiagnosed. T2D is typically diagnosed after age 40, but is 
increasingly being diagnosed at younger ages. From 2002-2005 the rate of incident cases of T2D 
was 0.4/100,000 for youth under age 10, and 8.5/100,000 for youth over age 10. Rates of T2D 
are higher in US minority populations than in non-Hispanic whites. The rate of T1D was higher 
than the rate of T2D in non-Hispanic whites aged 10-19, but the Asian/Pacific Islander and 
American Indian youth populations had higher rates of T2D than T1D.12  This study also found 
that African-American youth were more likely to be overweight/obese, have increased LDL 
cholesterol, high blood pressure, high depression symptoms, and poorer diets as compared to 
Caucasians.11  
Gestational Diabetes 
Gestational diabetes is general carbohydrate intolerance with onset of pregnancy that may result 
in high blood sugar levels and then usually resolves postpartum. Women who are at high risk for 
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this are older women, with history of glucose intolerance, history of large babies, from high-risk 
ethnic groups, as well as any woman with elevated fasting or random blood sugar levels.3 Rates 
of gestational diabetes range from 2 – 10% of pregnancies, and 5-10% of women who have 
gestational diabetes are diagnosed with diabetes postpartum, the majority being T2D. 
Additionally, women who have had gestational diabetes have a 35-60% chance of developing 
diabetes in the next 10-20 years.13  
Other Specific Types 
Table 1 presents several of the other “specific types” of diabetes currently recognized by the 
WHO.  
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Table 1. Listing of the WHO diabetes etiological classification group “other specific types.” 3 
Genetic 
defects of β-
cell function 
Genetic defects 
in insulin 
action 
Diseases of the 
exocrine pancreas 
Endocrinopathies Drug or 
chemical 
induced 
Infections Immune 
mediated 
diabetes 
Genetic Syndromes 
Associated with diabetes 
Chromosome 
20, HNF4α 
(MODY1) 
Type A insulin 
resistance 
Fibrocalculous 
pancreatopathy 
Cushing’s syndrome Nicotinic acid Congenital 
rubella 
Insulin 
autoimmune 
syndrome 
Down’s syndrome 
Chromosome 
7, glucokinase 
(MODY2) 
Leprechaunism Pancreatitis 
 
Acromegaly Glucocorticoids Cytomegalovirus Anti-insulin 
receptor 
antibodies 
Friedreich’s ataxia 
Chromosome 
12, HNF1α 
(MODY3) 
Rabson- 
Mendenhall 
syndrome 
Trauma/ 
pancreatectomy 
Phaeochromocytoma Thyroid 
hormone 
 “Stiff Man” 
syndrome 
Huntingtons’s chorea 
Chromosome 
13, IPF-1 
(MODY4) 
Lipoatrophic 
diseases 
Neoplasia Glucagonoma α-adrenergic 
agonists 
  Klinefelter’s syndrome 
Mitochondrial 
DNA 3243 
mutation 
 Cystic fibrosis Hyperthyroidism Β-adrenergic 
agonists 
  Lawrence-Moon-Biedel 
syndrome 
  Haemochromatosis Somatostatinoma Thiazides   Myotonic dystrophy 
    Dilantin   Porphyria 
    Pentamidine   Prader-Willi syndrome 
    Vacor   Wolfram’s syndrome 
    Interferon-α 
therapy 
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Until the review in 1999, there was an additional category listed under the “other specific 
types,” which consisted of diabetes mellitus presenting in undernourished populations. These 
were previously classified as “Malnutrition-related Diabetes” (MRDM) and consisted of two 
subtypes 1) fibrocalculous pancreatic diabetes (FCPD) and 2) protein-deficient pancreatic 
diabetes (PDPD or PDDM). However, the board decided that there was no convincing evidence 
that malnutrition could actually cause diabetes. Therefore, as of 1999, the MRDM class was 
removed from WHO classification. PDPD is now considered only to be a form of diabetes 
mellitus that is modified by malnutrition and FCPD has been reclassified as a disease 
(fibrocalculous pancreatopathy) that may potentially lead to the development of diabetes (see 
table 1).3 
Differentiating between these classifications is difficult, as they present with many 
similar clinical features. Very few observational studies have been performed and therefore there 
are no clear-cut definitions for each. People within the same classification group may even 
present differently, further complicating the issue.  
 
2.2 RATES OF DIABETES WORLDWIDE 
 
In 2010 there were an estimated 285 million people with diabetes, including 6.6% of adults 
worldwide. While T2D accounts for 85-95% of all diabetes cases (possibly higher in low- and 
middle-income countries), T1D is the predominant form of the disease in children and 
adolescents.2 An estimated 480, 000 children aged 14 and under are thought to have diabetes, 
with 77,000 new cases being diagnosed each year.2,8 Geographic differences in rates can be seen 
in the results from the WHO DiaMond Study, an international registry system for patients with 
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T1D, which show a high variance in incidence. The rates range from <1/ 100,000 per year in 
South America and China to 49.9/100,000 in Finland.14,15  
 
2.3 RATES IN DEVELOPING COUNTRIES – AFRICA 
 
Understanding the burden of this disease is an important issue in developing countries as 
individuals here carry a disproportionate burden due to poverty and low access to health care. 
Yet it is in these countries that we know the least epidemiology. This is especially true on the 
African continent, which is comprised of the largest proportion of the world’s developing 
countries (about 36%).16  
It is estimated that in 2010 there were 12.1 million people with diabetes on this continent 
(about 4% of the world total), including 3.2% of the local adult population. This is expected to 
increase to 23.9 million by 2030, with the biggest increase in those aged 45 – 64 years.2 These 
data, however, are extrapolated from a limited number of studies and these are often dated.  
 
2.3.1 Type 1 Diabetes Epidemiology in Africa 
 
It is especially important to know the rates of T1D in these populations, as these people will have 
more time to develop complications if they are not treated properly, and they may have fewer 
productive years of life.    
Current estimates in Africa state that as of 2010, 35,700 children have type 1 diabetes, 
with 5,800 new cases diagnosed each year.2  Compared to developed countries, the mean age of 
presentation in Africa is later17–21  and in most countries there is a female preponderance.17,22–25 
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In Tunisia, however, there was no observed difference in sex,26 while one study in Nigeria found 
higher rates in boys than girls.27  
However, due to the paucity of epidemiologic studies in these countries, it is impossible 
to accurately estimate the true burden of disease. Type 1 incidence has been studied in five 
countries (Algeria, Tanzania, Tunisia, Libya, and Sudan) (table 2) and prevalence in only three 
(Sudan, Nigeria, Algeria) (table 3).28  
Prevalence Studies  
The prevalence of type 1 diabetes in school children (n=42,981 age 7 – 14 years) in Khartoum, 
Sudan was studied through use of a questionnaire.23 From July – October 1987, males and 
females in grades 1, 4, and 6 from randomly selected schools, were given a survey with 
questions about diagnosed diabetes, current insulin use, and diabetes symptoms. Thirty-four 
previously known cases were identified as well as 7 additional new cases. There were a total of 
41 cases resulting in a prevalence estimate of 0.95/1,000. In both sexes, prevalence increased 
with age and there were slightly more females than males in each age group, but the difference 
was not statistically significant. The prevalence rate was unexpectedly high and though this was 
a representative population (97% of school age children in Khartoum attend public elementary 
schools) it was possible that asymptomatic patients or those with no glucouria or ketonuria were 
missed. Additionally, the Northern Sudan populations are primarily of mixed Arab and Noba 
(black) decent, while the Southern population is ethnically pure African (black), possibly 
limiting the generalization of the results.23  
Questionnaires were also given to Nigerian Igbo school children, aged 5 – 17years (n = 
77,862), from three different school districts (Ezza, Ishielu, and Okaukwa) between June - 
August, 1990.29 This survey asked questions on demographic data, history of diseases, recent 
10 
 
doctor visits, drugs being taken, and about the presence of diabetes symptoms (enuresis, 
polyuria, polydipsia, polyphagia, and weight loss) in either the participant or their siblings. 
Fourteen children reported previously diagnosed diabetes and 12 new cases were identified for a 
total of 26 cases and an overall prevalence rate of 0.33/1,000. Boys were found to have a higher 
prevalence (0.38/1,000) than girls (0.25/1,000) and peak prevalence was found in those aged 14 
– 17 (0.74/1,000). The higher rate in boys could be explained by fewer girls being registered in 
schools or worse survival of females due to the beliefs of the Igbo tribe that girls are the inferior 
sex. It is additionally difficult to expand the prevalence rate from this study to the entire Nigerian 
country because it focuses on only one tribe that differs from other regional tribes in lifestyle, 
economic class, and diet.29  
A Type 1 diabetes registry in the Department (Province) of Oran, Algeria was used to 
identify all adolescent cases of diabetes in those aged less than 20 years (by December 31st, 
1988), with diagnosis of disease before age 15.30 Ascertainment rates of this registry were cross 
compared with the results of a questionnaire sent to local practitioners, and the results were 
highly correlated. Registry data from 1979 to 1988 was used and a total of 173 families were 
further examined. They determined a prevalence rate of 0.27/1,000 in this population. While 
ascertainment was indeed high applying the prevalence for a specific province to the entire 
country may not be representative of Algeria as a whole.30  
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Table 2. Prevalence estimates (per 100,000) of type 1 diabetes in African Countries.23,29,30 
Country Study Year(s) Age of 
Population 
# of Cases Prevalence/ 
100,000 
Sudan 1987 7 - 14 41 95 
Nigeria  1990 5 - 17 26 33 
Algeria 1979 - 1988 0 - 15 173 27 
 
Incidence Studies 
Examination of the same registry data in Oran, Algeria also allowed investigators to estimate the 
annual incidence of diabetes. The annual incidence had a mean of 4.4/100,000 new cases per 
year. The incidence increased at a steady rate from 1.6/100,000 in 1981 to 8.1/100,000 in 1988, 
suggesting that the burden of this disease is indeed increasing with time. It is, however, 
impossible to know for certain if this is a true increase in disease rates or if it is an increase in 
disease awareness and detection.30  
Registry data was also used to estimate the incidence of diabetes in Dar es Salaam, 
Tanzania.31 Data collected at the main hospital in the country, Muhimbili Medical Center, from 
January 1, 1982 to December 31, 1991 was used to identify 86 children between the ages 0 -19, 
who were diagnosed with diabetes during this time. There were slightly more males (n = 45) than 
females (n = 41) and only one patient that was diagnosed <5 years. The average annual incidence 
over this time period was 1.5/100,000 (range = 1.3 – 1.7/100,000) and incidence increased with 
age, with the highest rate seen in children ages 15 – 19 (3.4/100,000). Because most patients 
diagnosed with diabetes are cared for at this hospital, the authors believed that case identification 
was as complete as possible. However, it is still possible that children may have died before their 
diabetes was diagnosed, leading to an under-estimation of the actual incidence rate.31  
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In Tunisia, another incidence study was performed using data from WHO DIAMOND 
registries in three randomly selected districts (Beja, Monastir, and Gafsa).26 The study ran from 
Jan 1, 1990 to Dec 31, 1994 and 156 incident cases in children under the age of 20 were 
identified (79 male, 77 female). The average age at diagnosis was 11.18 ± 4.69, with a peak in 
incidence for those 10 – 14 years. The observed standardized overall incidence rate was 
6.95/100,000. Case ascertainment employed the capture-recapture method, and since all patients 
in these districts with diabetes are required to visit local outpatient offices for insulin, it is not 
likely that many cases were missed. The use of registry data also helped to ensure that all known 
cases were included in the analysis. However, it is still possible that there were un- or 
misdiagnosed cases that were not included.26  
WHO DIAMOND registry data were also used in Libya to look at the incidence of type 1 
diabetes.32 They used registry data from the city of Benghazi and identified 276 new cases 
between the ages of 0 – 14 years who were diagnosed between January 1, 1991 and December 
31, 2000. This resulted in an overall incidence rate of 8.3/100,000, which is higher than the 
previously estimated incidence of 7.0/100,000 collected from 1981 to 1990. They saw a 
significantly (p <0.001) different rate of incidence between females (9.1/100,000) and males 
(6.6/100,000), and an increase in incidence with age in both sexes until they peaked in those 
aged 10 – 14 years. Case ascertainment was mainly from records from the main diabetes clinic or 
from the local children’s hospital, and some discharge files from five additional area hospitals 
and 10 polyclinics were also used. The physicians in this city have a high awareness of diabetes, 
and there is a resident medical school with adequate access to diagnostic tools and management 
options. It is, therefore, believed that there are not many undiagnosed cases in the Benghazi area. 
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However, these assumptions may not be applicable to rural areas of this country thus the 
generalizability of these results to the rest of the country may not be high.32  
Incidence of type 1 diabetes in Sudan was estimated using the results of an ongoing 
registry from 1987 – 1990.22 Children that were eligible for this study were under the age of 15, 
living in Khartoum and had developed diabetes within the study time period. A total of 327 cases 
were reported over the four years, with 95% case ascertainment with the capture-recapture 
method. Over the time span of this study, the investigators saw a dramatic increase in incidence 
from 5.9/100,000 in 1987 to 10.1/100,000 in 1990, with the highest rates seen in children aged 
10 – 14 years. Though they saw a 76% increase in incidence, they believe that the incidence rate 
for 1987 was likely an underestimate as it was the first year the registry was in effect. It was also 
possible they missed children that were treated in private clinics and those who died before 
diagnosis, as it was common for children that presented with comas to first be treated for 
cerebral malaria or meningitis.22  
 
Table 3. Results of estimates of incidence rates (per 100,000) of type 1 diabetes in African 
Countries.22,26,30–32 
Country Study Year(s) Age of 
Population 
# of Cases Incidence/ 
100,000 
Sudan 1987 - 1990 0 - 15 327 10.1 
Tunisia 1990  1994 0 - 19 156 6.95 
Libya 1991 - 2000 0 - 14 276 8.3 
Tanzania 1982 - 1991 0 - 19 86 1.5 
Algeria 1979 - 1988 0 - 15 173 4.4 
 
 Each of the previous studies has their own strengths and weaknesses, with the biggest 
weakness being generalizability. The results of these studies may all be underestimates of the 
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true disease burden due to misdiagnosis, which has been reported to be high in this region,33 and 
death before diagnosis. Many cases may be missed due to death before diagnosis because of lack 
of diagnostic tools and decreased physician awareness. Several of the afore mentioned studies 
that used population surveys were able to identify new cases of diabetes in persons who were 
previously healthy and were living ‘normally’ with their disease unnoticed, thus supporting the 
idea that cases are indeed going undiagnosed.23,29 These previously unidentified cases highlight 
an ongoing debate in Africa: the difficulties of diagnosing and classifying types for this disease.  
 
2.4 DIABETES CLASSIFICATION IN AFRICA 
 
Intermediate forms of diabetes have been previously described in adolescent patients in Africa 
and span a wide variety of ketosis presentation and insulin requirement.34  There are reports of 
patients discontinuing their insulin, but who seldom develop ketoacidosis. These cases were 
previously placed under the classification of MRDM and also referred to as ‘tropical diabetes.’35 
Diagnosis for MRDM was based on: detection before age 30, history of weight loss and 
malnutrition, hyperglycemia and lack of ketosis (in most cases). Those diagnosed with the FCPD 
subtype of MRDM have calculi which can be assessed with abdominal radiography, and 
abnormal exocrine pancreatic function.36 It was previously suggested that diets based heavily on 
cassava consumption could potentially lead to the development of FCPD. It was thought the 
cyanogenic glucosides in the cassava root might be toxic to the pancreas, but a study by Swai et 
al, showed that higher exposure to dietary cyanide does not increase the prevalence of diabetes in 
Tanzania.37 Following a review of this and other similar studies by a WHO sponsored 
international workshop, it was decided that though malnutrition may exacerbate or change the 
expression of other types of diabetes there is no convincing evidence that it can actually cause 
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diabetes. Because the WHO no longer recognizes this category it has become a topic of debate as 
to how to properly classify patients in Africa properly.  
The WHO classification system before 1999 which was based on clinical factors and 
therapy has become outdated as rates of obesity increase and insulin is used more frequently as 
therapy regardless of diabetes type. The current system, therefore, focuses more on the etiologic 
and physiologic aspects of the disease. While this provides several benefits, it also introduces 
additional challenges as it does not yet have specific definitions for each of the types of diabetes 
and assumes that there is no overlap between the two main categories of type 1 and 2. To attempt 
to better characterize the etiology of the disease to define classification groups, autoimmunity, 
insulin sensitivity, and genetic risk are being examined.  
The most commonly used markers for autoimmunity are: islet cell antibodies (ICA), 
insulin antibodies, insulinoma-associated-2 antibodies (IA2A), and glutamic acid decarboxylase 
antibodies (GADA). β- cells are just one type of islet cell, and GAD is a protein that is also made 
by the β- cells. Zinc transporter 8 (ZnT8), an islet β- cell secretory granule membrane protein, 
has also been identified as an autoantibody antigen in type 1 diabetics.38 It is believed that these 
autoantibodies lead to the destruction of β-cells by the individuals own T-cells.  
Levels of C-peptides, which are produced in the same amount as insulin, are also often measured 
as a marker for insulin production. Insulin sensitivity is often measured through 
hyperinsulinemic-euglycemic clamps, but can also be estimated through the use of previously 
validated equations.39,40 Those patients with type 1 are typically autoimmune, ketosis prone, and 
insulin sensitive, while those with type 2 are non-autoimmune, rarely present with ketosis and 
have insulin resistance.39  
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A recent study from the American SEARCH for Diabetes in Youth group, found that 
when looking at autoimmunity and insulin sensitivity in patients under age 20 (n=2,291), the 
majority of the subjects fell into either the typical type 1 (autoimmune with insulin sensitivity, 
54.5%) or type 2 (non-auto immune and insulin resistant, 15.9%) categories.41 However, there 
were several that were classified in the other two non-traditional categories of autoimmune and 
insulin resistant or nonautoimmune plus insulin sensitivity, which suggests that even in the 
western world, the current classification system is limited. 
The accurate measurement of islet auto antibodies is notoriously difficult in non-research 
labs. Of the few studies performed in Africa, the prevalence of ICA in type 1 diabetic patients is 
highly variable. Low prevalence has been found in Tanzanians42 (8.6%) and Nigerians43 (10%) 
and higher amounts were seen in Ethiopians44 (43%) and South African Blacks45 (39.4%). High 
levels of GADA have also been found in South African Blacks, thus further supporting an 
immunological etiology.46  
A more recent etiological study in Ethiopia, however, supports the need for further 
studies in Africa. Of 69 patients being treated with insulin, only 42 (61%) were C-peptide-
negative and 35% were GADA-positive. An additional 38 (36%) had immunological or C-
peptide results that were inconsistent with the current classification system. These results, along 
with the high levels of malnutrition have led the authors to suggest that the inclusion of 
malnutrition-diabetes be re-evaluated.47  
Genes have long been thought to play a role in the development of T1D, as it seems to 
run in families. The genes responsible for coding the human leukocyte antigens (HLA) have 
been identified as genes that may predispose a person to developing T1D. These antigens may 
incorrectly identify β-cells as being foreign, leading to autoimmunity. Of the diabetic patients 
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living in the western world, over 90% of those with type 1 diabetes have one or both of the HLA-
DR3 or HLA-DR4 haplotypes.48  
Previous studies of class 1 antigens (HLA-A,B and C) in South Africa and Nigeria have 
shown significant associations with HLA-B8, B14, and B8/14, as well as a negative association 
with BW42. 19,49 Other studies on class II antigens (HLA-D, DR) have shown a positive 
association with HLA-DR4.19 Allele-specific tests have allowed identification of several HLA 
class II alleles in South African Zulu,50 as well as several point mutations (CTLA4 in Ghana and 
TLR3 in South African Zulu).51,52  
 
2.5 OVERVIEW AND EPIDEMIOLOGY OF COMPLICATIONS 
 
No matter what the etiology, uncontrolled glucose levels can lead to the development of 
complications. Acute complications include diabetic ketoacidosis and severe hypoglycemia, 
while chronic complications are classified as microvascular (neuropathies, nephropathy, or 
retinopathy) or macrovascular (atherosclerotic conditions: coronary artery disease, peripheral 
vascular disease, and cerebrovascular disease). The presence of one or a combination of several 
of these complications may lead to the most severe outcome – premature death.  
 
2.5.1 Acute 
 
Ketoacidosis 
A “normal” person with insufficient levels of glucose available will start to break down fat into 
ketones for use as an alternative energy source. Diabetic patients who have insufficient amounts 
insulin, may have elevated ketone levels because their bodies cannot utilize glucose as an energy 
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source. As the levels of ketones in the blood rise, the pH level drops in the patient, and the body 
tries to reduce the levels by expelling the ketones in urine or through the lungs. If the pH drops 
too low, the person can develop ketoacidosis (DKA), which is considered to be a medical 
emergency and can lead to coma and death. Ketoacidosis may occur at the onset of disease or if 
not enough insulin is being provided in therapy.8 The SEARCH study in the US found that 1 in 4 
diabetic children (both type 1 and type 2) presented with DKA at diagnosis. The prevalence 
decreased with age and was higher in those with type 1 diabetes than those with type 2.53 Race 
does not seem to have an effect on development of ketoacidosis,54 but adolescent girls are more 
likely to develop DKA than boys.55 In Addis Ababa, Ethiopia, a prospective study following 431 
diabetic patients from 1976 to 1990 found that 11% of patients presented with DKA at diagnosis 
and 38% (n=164) had at least one episode of ketoacidosis during follow up.56 An earlier study 
from Ethiopia found similar results (36.8% had at least one episode during follow up).21 In 
Tanzania, 75% (n=75) of children ages 5-18 years attending a diabetes clinic in Dar es Salaam 
(n=99) presented with DKA at diagnosis, while 89.9% had experienced at least one previous 
episode.57 A lower prevalence of DKA on admission was seen in an additional study from 
Tanzania where 23% presented upon diagnosis.58  
Severe Hypoglycemia 
Hypoglycemia is the leading limitation in the management of both type1 and type 2 diabetes. 
When a patient’s glucose level falls below 70 mg/dL, they may begin to feel symptoms which 
include dizziness, weakness, and confusion. If glucose levels fall below 55 mg/dL(severe 
hypoglycemia) the patient will often lose consciousness, and levels below 20mg/dL can also 
trigger seizures. Patients may show symptoms of hypoglycemia an average of twice per week, 
and 10-25% of patients with type 1 diabetes experience at least one severe episode a year.59 In 
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the DCCT 65% of patients with more intensive insulin control were reported to have suffered 
severe hypoglycemia over 6.5 years for follow up.60 Internationally, 20-30% of primary school 
children and 15-20% of teenagers experienced one severe hypoglycemic episode with either 
unconsciousness or seizures within a one year period.61 In Ethiopia, 10.2% (n=44) of patients 
had at least one severe hypoglycemic episode, three of whom died.56 General symptoms of 
hypoglycemia were reported in 55.6% (n=55) of children in Dar es Salaam, Tanzania.57  
 
2.5.2 Chronic 
 
Neuropathy 
There are two main classifications of neuropathies: peripheral and autonomic. Peripheral 
neuropathy (PDN) is nerve damage in the arms or legs, while autonomic neuropathy is a result of 
damage to the nerves of the autonomic system which regulate muscles of the heart, bladder, gut 
and other vital organs.62 One specific type of autonomic neuropathy, cardiac autonomic 
neuropathy (CAN) is especially common in patients with type 1 diabetes. It is the result of 
damage to the autonomic nerves that innervate the heart and blood vessels and can cause 
abnormalities in heart rate and hemodynamics. This then may result in abnormal heart rate, 
tachycardia, intolerance to exercise and orthostatic hypertension.63 Comparing rates of this 
disease can be difficult due to the differing strictness of definitions used for each study. 
However, neuropathy of some sort occurs in approximately 50% of patients with type 1 diabetes 
by 20 years of disease duration.63 CAN was also reported in almost 39% of patients after 25 
years of disease duration in the Pittsburgh Epidemiology of Diabetes Complication (EDC) 
study.64 Rates of neuropathy in Addis Ababa, Ethiopia, have been reported at 10.4% (7.9% had 
PDN and 2.5% had CAN).56 Significantly higher rates were seen in a small study from Soweto, 
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South Africa, where 35.3% (n=6) of patients with an average disease duration of 23 years had 
diagnosed neuropathy.65  
Retinopathy  
Diabetic retinopathy is the most common eye complication in diabetes.66  Retinopathy is caused 
by damage to the blood vessels in the retina from chronic hyperglycemia. Non-proliferative 
retinopathy (NPDR) is the early stage of the disease and is marked by the formation of 
microaneurysms (weakened outpouches) in the blood vessels of the retina. Over time these may 
hemorrhage and other vessels become blocked. To compensate for this damage, weaker vessels 
are formed in the retina or even in the vitreous. These weak vessels tend to hemorrhage causing 
bleeding into the eye, obscuring vision. This more advanced stage is referred to as proliferative 
diabetic retinopathy (PDR). Eventually, this damage may lead to blindness.67 Data from the 
National Health and Nutrition Examination Survey (NHANES) report the prevalence of diabetic 
retinopathy to be 28.5% among adults with diabetes in the US. It is slightly more common in 
men than women and non-Hispanic blacks have a higher rate than non-Hispanic whites.66 The 
Pittsburgh EDC study showed that almost 100% of their type 1 diabetic participants had 
developed retinopathy by 20 years duration, detected by fundus photography.68 The major risk 
factors for retinopathy seem to be male sex, higher HbA1c levels, longer duration, and higher 
systolic blood pressure.66 Reports from Africa range from 9.5% of type 1 diabetes patients in 
Ethiopia56 to 58.8% in Soweto, South Africa.65 A study in Dar es Salaam, specifically focusing 
on children ages 5-18, reported that 22.2% of their cohort had prevalent retinopathy.57  
Nephropathy 
Diabetic nephropathy is caused by prolonged damage to the capillaries of the kidneys and is 
most likely a result of metabolic dysfunction associated with chronic hyperglycemia, insulin 
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resistance and genetic susceptibility.69–71 Development of this disease starts with a thickening of 
the glomerulus of the kidney and as it becomes more damaged, more and larger proteins are 
filtered out in the urine. The first stage of diabetic nephropathy is called microalbuminuria and is 
a result of increased levels (30-299 μg/mg) of serum protein (albumin) being excreted in urine. 
As the disease progresses, the concentration of albumin in the urine increases (>300μg/mg), 
resulting in overt nephropathy (ON) and eventually in complete failure of the kidneys and End 
Stage Renal Disease (ESRD).5,69 Major predictors of nephropathy are disease duration, glycemic 
control, dyslipidemia and the presence of hypertension.72 Diabetic nephropathy is seen in 3.3% 
of the US population and 20-40% of all patients with diabetes.5,73  It is the single leading cause 
of ESRD.5 Though the prevalence of type 1 diabetes is lower, almost 50% of all ESRD cases are 
in patients with this disease.74 Additionally, 29% of type 1 diabetes patients develop 
microalbuminuria with in the first 20 years of developing diabetes.75 Two studies from Dar es 
Salaam, Tanzania report the presence of microalbuminuria in 29.3% of children aged 5-18 with 
average duration of 4.76 years,57 and 12% of patients with average age of 21 and disease 
duration of 3 years.76 Similar results were seen in Soweto, South Africa (11.8%),65 while a 
slightly lower percentage (6.0%) was seen in Addis Ababa.56  
Cardiovascular diseases 
Most macrovascular complications of diabetes come as a result of the development of 
atherosclerosis. Atherosclerosis is a progressive process in which the artery walls thicken from 
build-up of plaques. Plaques are formed when oxidized LDL damages the vessel walls and the 
body responds with white blood cells which absorb the LDL forming foam cells. These cells are 
unable to process the oxidized LDL and thus grow larger and then breakdown forming 
cholesterol rich plaques, which further activates the body’s response. These plaques, which also 
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reduce the diameter of the vessel, impede the flow of blood. If the plaques rupture, a clot may 
form and they may locally block blood flow or break off and travel to other areas and cause 
tissue damage or death there. The three most common complications of this process seen in 
diabetics are coronary artery disease, peripheral vascular disease and cerebrovascular disease.  
Coronary artery disease 
Coronary artery disease (CAD) is the development of atherosclerosis in the small vessels that 
supply the heart with blood. The major complication of this disease comes when the plaque 
ruptures causing a block in the vessel, depriving the local heart muscle of oxygen. This may 
cause damage to the tissue or tissue death. This may result in an immediate heart attack, or in 
later heart failure due to weakened muscles from oxygen deprivation. The relationship between 
hyperglycemia and CAD is not well understood. A few reports show that poor glycemic control 
can predict CAD,77 while most other studies have shown either a weak or no association.78,79 
However, change in glucose control in the absence of renal disease has since been found to 
predict CAD.77,80,81 CAD is currently the leading cause of diabetes related deaths in the US.82 
People with T1D are at a 10-fold increased risk of developing CAD than the general 
population.83  
Peripheral vascular disease 
Peripheral vascular disease (PVD) is the development of any atherosclerotic plaques in any areas 
other than the heart or brain. Reduction of blood flow to the legs and feet is commonly seen in 
diabetic patients and may lead to foot ulcers, gangrene, and in the most severe case –limb 
amputation. The most common predictors are disease duration, LDL cholesterol, heart rate, 
estimated glucose disposal rate, nephropathy, retinopathy, glycemic control, and low ankle 
brachial index.84 Hospital discharge data report that 45% of all amputations in the US are for 
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patients with diabetes. Patients with diabetes are at 15 times higher risk of amputation than those 
who do not.85 In the EDC study, 27% of patients with at least 25 years duration, reported PVD, 
with females having increased risk.84  
Cerebrovascular disease 
Cerebrovascular disease is caused by the presence of atherosclerosis in the vessels of the brain. If 
blood flow to the brain is interrupted, the un-oxygenated tissue will be damaged, or possibly die. 
This condition is also known as a stroke. Ischemic strokes occur when the blood supply is cut off 
due to a blockage (such as a dislodged clot from elsewhere in the body), while hemorrhagic 
strokes occur when a weaker vessel ruptures. Thrombotic strokes are a result of a clot that 
actually forms within the brain. Women with diabetes have been reported to have a 6-fold 
increased risk of ischemic stroke than those without diabetes.86  
There are currently no reports on the prevalence of these macrovascular complications in 
type 1 diabetic patients in Africa. This is due mainly to the high level of out of hospital mortality 
related to these complications, lack of death certificates with proper cause of death recording, 
lack of diagnostic facilities, or death from acute complications and renal disease before CAD can 
develop.  
 
2.5.3 Mortality 
 
Patients with T1D are at increased risk of death as compared to the general population.87 
Mortality due to diabetes has been studied internationally by the Diabetes Epidemiology 
Research International Study (DERI). This study found increased mortality in the US as 
compared to Finland, Israel, and Japan.88 As disease duration increases, cause of death shifts 
from primarily due to acute complications within the first 10 years, to chronic complications 
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after 20 years duration.87 In Africa, 1 in 20 deaths for those aged 20-79 years is due to some form 
of diabetes. In total, it is estimated that there were over 330,000 deaths from all types of diabetes 
in this region.2  
There have been relatively few studies in Africa that look at the mortality rates of 
children with T1D. As study of the effects of healthcare differences in Mozambique and Zambia 
examined how location (urban versus rural), variations and inequalities of care, availability of 
diagnostic tools and availability of insulin affected mortality. The life expectancy of a child with 
T1D living in rural Mozambique is estimated to be less than a year (0.6 years), 2.1 years in urban 
cities, and 3.8 in the capital city. For children >15 years, the estimated life expectancy is 2.9 
years in rural areas, 11.1 years for urban, and 20 years in the capital. In rural Zambia, life 
expectancy for children ages 0 – 14 years was 9.0 years in rural areas, 13.0 years in urban areas, 
and 18.0 years in the capital city. For children >15 years, the estimated life expectancy of a child 
living in a rural area is 14.0 years, 19.0 years for urban areas, and 27.0 years in the capital city.89  
A cohort of 88 T1D patients in Soweto, South Africa was followed for 20 years from 1982 to 
2002. By 2002, 21 patients had died, 28 were still alive, and 39 were lost to follow-up. They 
excluded those on whom they did not have complete data, and calculated a mortality rate of 43% 
(21/49), but due to the large number that were censored, they used Kaplan – Meier plots to 
calculate a hazard ratio (H) of 0.33 (20- year mortality risk). The mean duration of disease at 
time of death was 23 years and the average age at death was 33 (range 22 – 46) years. The most 
common cause of death was chronic renal failure (n = 9, 42.8%), and 6 (28.6%) died from 
hypoglycemia, 2 (9.5%) from acute infection, 2 (9.5%) from ketoacidosis, and 2 (9.5%) from 
unknown causes.65  
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Of 431 T1D patients in Addis Ababa, Ethiopia, 42 (9.7%) members of the cohort had 
died after 15 years of follow up (mean duration of disease at death of 9.2 ± 1.9 years). Acute 
complications of diabetes were the most common cause of death with 7 due to ketoacidosis, 3 to 
infections, and 3 to hypoglycemia. Six other patients died due to complications of nephropathy, 5 
to septicemia secondary to another infection, 3 due to gangrene, 3 due to tuberculosis, 1 due to 
stroke, and 11 others died due to miscellaneous or unknown causes. Survival at 5 years was 96%, 
at 15 years 82%, and at 20 years 63%.56  
 In Dar es Salaam, 5 year survival for a cohort of 272 patients was 71% when all known 
deaths were accounted for and 60% when all known and probable were included. Twelve 
patients died (32%) due to infection, 3 (8%) due to DKA, 2 (5%) due to hypoglycemia, and 4 
(11%) due to unknown causes.58  
 
2.5.4 Prevention of Complications 
 
The Diabetes Control and Complications Trial (DCCT) has demonstrated that maintaining a 
blood glucose level as close to the normal range as possible (goal of HbA1c <7%) reduces or 
delays the risk of developing long-term micro- and macro-vascular complications. The results of 
the DCCT showed a 76% decrease in risk of retinopathy, 60% less neuropathy, and 35-60% less 
kidney damage in those with tighter control.60 They also demonstrated that intensive treatment 
reduced the risk of any cardiovascular disease by 42% and the risk of nonfatal myocardial 
infarction, stroke, or death from cardiovascular disease by 57%. However, they also showed that 
there was an increased risk of hypoglycemia in the tight control group, thus implying that tight 
control is not without risk. 
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 Risk factors for each of the following complications also need to be monitored carefully 
to adequately prevent complications.  
Hypertension/blood pressure 
Blood pressure (BP) should be measured at each clinical visit as BPs over 115/75 mmHg are 
associated with increased cardiovascular events and mortality in people with diabetes.90 Each 
individual should have appropriate goals based on their age, therapy and treatment, but a systolic 
BP of <130 mmHg and a diastolic BP of <80mmHg are recommended. Usual treatment includes 
lifestyle modification and pharmacologic therapy of antihypertensives.5  
Dyslipidemia 
Dyslipidemia is more common in patients with diabetes (especially those with type 2 diabetes) 
and should be monitored as risk of cardiovascular events can be prevented through controlling 
these factors. Lifestyle modification and statin therapy are the two most common treatment 
methods. Presence of cardiovascular disease, age, and response to other treatment options are 
considered when choosing the best treatment option.5  
 
2.6 MANAGEMENT OF DIABETES 
 
To prevent complications adequate management of glucose levels is necessary. Ideally, diabetes 
management should be provided by a well-coordinated team of physicians, nurses, dieticians, 
pharmacists, and mental health professionals. Upon diagnosis a patient should also be provided 
with a detailed examination (table 4), so that the most effective management program may be 
designed. The family of the patient should be involved, but diabetes self-management education 
(DSME) should be the focus of the approach. DSME is:  
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“the ongoing process of facilitating the knowledge, skill, and ability necessary for 
diabetes self-care. This process incorporates the needs, goals, and life experiences of the 
person with diabetes. The overall objectives of DSME are to support informed decision-
making, self-care behaviors, problem-solving, and active collaboration with the health 
care team to improve clinical outcomes, health status and quality life in a cost-effective 
manner.” 5,91  
The age, daily schedule, physical activity level, diet, social situation, culture, and presence of 
complications for the patient should all be taken into consideration when designing specific 
treatment plans. All treatment regimens, however, should have the same goal: good blood 
glucose control.5  
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Table 4. Components of a comprehensive diabetes examination.5 
Medical History 
• Age and characteristics of onset of diabetes 
• Diet, physical activity, nutritional status, weight history, growth and development 
• Diabetes education history 
• Review of previous treatments and response to therapy 
• Current treatment (medications, diet, physical activity, results of glucose monitoring and 
ability to adjust accordingly) 
• Diabetic Ketoacidosis frequency, severity, and cause 
• Hypoglycemic episodes (awareness, frequency and cause) 
• History of diabetes related complications (Microvascular: retinopathy, nephropathy, 
neuropathy; Macrovascular: CHD, cerebrovascular disease PAD); psychosocial 
problems; dental disease) 
Physical Examination 
• Height, weight, BMI 
• Blood pressure 
• Fundoscopic examination 
• Thyroid palpation 
• Skin examination 
• Foot examination 
Laboratory Evaluation 
• HbA1c 
• Fasting Lipid profile (total, LDL and HDL cholesterol and triglicerides) 
• Liver function tests 
• Urine albumin excretion or urine albumin to creatinine ratio (A/C ratio) 
• Serum creatinine and calculated GFR 
• Thyroid-stimulating hormone (in type 1 diabetics, dyslipidemia or women over 50 years) 
Referrals 
• Dilated eye exam 
• Family planning for women of reproductive age 
• Registered dietician for medical nutrition therapy (MNT) 
• DSME 
• Dental examination  
• Mental health professional  
 
 There are two standard ways of monitoring glucose control: 1) patient self-monitoring of 
blood glucose (SMBG) and 2) hemoglobin A1c (HbA1c). The timing and number of SMBG 
depends on the particular needs and goals for the patient. Patients using multiple insulin 
injections are recommended to monitor at least three times per day, but for patients at higher risk 
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for hypoglycemia more tests may be needed. It is very important that patients using this method 
of control be educated in how to properly use their glucose meter, know when to test, and how to 
adjust their diet, exercise, insulin or other treatment options accordingly. Individual glucose 
targets will vary by patient and timing of the test,5 but table 5 shows a summary of the ADA 
recommendations.   
 
Table 5. Summary of glycemic goals for specific age groups.5 
Age Range 
(years) 
Pre-prandial goal 
(mg/dL) 
Peak post-
prandial goal 
(mg/dL) 
Bedtime/ 
Overnight 
(mg/dL) 
HbA1c (%) 
0 – 6 100-180 - 110-200 <8.5 
6 – 12  90 -180 - 100-180 <8 
13 – 19 90-130 - 90-150 <7.5 
19+ 70-130 <180 - <7.0 
 
 Another way to assess glucose control is through measuring glycated hemoglobin 
(HbA1c). Hemoglobin is the major protein in red blood cells and its main function is to transport 
oxygen in the blood stream. When glucose is present in the blood stream, it causes a glycation, of 
the hemoglobin molecules. The levels of glycated hemoglobin can then be used as a measure of 
the average glucose levels. Since red blood cells, and thus their hemoglobin molecules, are 
present in the blood stream for up to 90 days, this measurement can present a ‘snap shot’ of the 
average glucose levels of a person for the last 3 months.4 Results of the Diabetes Control and 
Complications Trial (DCCT) showed that patients who reached the goal of a HbA1c level <7% 
had much better outcomes, and therefore most physicians use this as a general goal for their 
patients.81 However, for children acceptable HbA1cs are slightly higher to reduce the risk of 
hypoglycemia. It is recommended that HbA1c tests be performed quarterly in patients who are 
not meeting glycemic goals or whose therapy has changed, but patients who are meeting goals 
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and are under consistent therapy need only two tests per year.5 There are several limitations to 
this test, however. Patients with conditions that affect their red blood cells (hemolysis or those 
with hemoglobin variants) or those with high blood loss or anemia may have HbA1c measures 
that do not accurately reflect their control. Also, as this test provides a picture of average control, 
it does not accurately reflect glycemic variability within a patient. Therefore, a combination of 
both glucose monitoring methods may be the best option.5  
 
2.6.1 Specific Therapy Approaches 
 
Type 1 diabetes 
For those diagnosed with T1D, insulin therapy is essential for survival and to reach glycemic 
goals. There are currently several types of insulin available, each with a different time course of 
action. When insulin is normally secreted by the pancreas, hexamers are formed by the binding 
of six individual insulin molecules. These hexamers must be broken down into dimers and 
monomers before they can enter the bloodstream. Scientists have found ways to manipulate this 
characteristic as well as combining additional products to control the action time of injected 
insulin.8  
Rapid acting insulin (Lispro, Humalog, NovoRapid/NovoLog, Apidra) was developed in 
such a way that hexamer formation is greatly reduced, resulting in absorption within 5-10 
minutes, with peak action at 1 hour. Short-acting insulins (Actrapid, Humulin Regular S, 
Insuman Rapid) have the same molecular structure as those secreted from the pancreas and begin 
to work 20 -30 minutes after injection with a peak at 1.5 – 2 hours. The effects can last for up to 
5 hours.8  
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In people without diabetes, there is always a low level of insulin in the blood to cover the 
glucose that is released from the liver between meals. This is known as basal or background 
insulin. Ideally, an insulin regimen should mimic the profile of a non-diabetic person’s natural 
response to prevent hyperglycemia and avoid hypoglycemia. Therefore basal insulin injections 
are also given to diabetic patients. These insulins are either intermediate-acting or long-acting.8  
There are two intermediate-acting insulins (NPH and lente). The action of NPH insulins is 
prolonged by adding protamine to short-acting insulin molecules. NPH insulin (Insulatard, 
Humulin I, Insuman Basal) will work after about 2 – 4 hours and last up to 8 or 9 hours. Lente 
insulins are prolonged by using excess free zinc to cause the binding of insulin monomers into 
lager crystals. These insulins (Monotard, Humutard) peak at 4 – 5 hours. A newer intermediate-
acting insulin, NPL, increases its effect time by adding protamine (like NPH). However if this is 
mixed with Humalog, it remains stable for at least one year.8  
The older long-acting insulins (Ultratard, Humulin Zn) started to work 2-4 hours post 
injection and lasted up to 24 hours, with a peak at 6-12 hours. However, in 2000 Lantus 
(glargine) was developed to provide better 24 hours basal coverage, by actually altering the 
insulin molecule itself. This causes the insulin to have a more even level of coverage over the 24 
hours, more closely mimicking the body’s natural secretions. Levemir (detemir) was then 
introduced in 2004, and its action and results are similar to those of Lantus (glargine).8  
The DCCT showed that intensive insulin therapy (three or more insulin injections per day 
or continuous subcutaneous insulin infusion) in patients with type 1 diabetes improved blood 
glucose levels and decreased complication rates. However, it was also found that the intensive 
treatment increased the rate of severe hypoglycemia.81 It is therefore recommended that patients 
use multiple injections a day of basal and prandial (meal coverage) insulin, choose doses of 
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insulin based on carbohydrate intake at meals and predicted physical activity, and use newer 
insulin analogs. It is also important that patients with type 1 diabetes also be screened for 
additional autoimmune diseases such as thyroid dysfunctions, vitamin B12 dysfunctions and 
celiacs disease if they have any symptoms.  
Type 2 diabetes  
T2D patients usually require oral medication therapy to aid with their diabetes control. The three 
established types of these drugs are those that increase insulin production, those that improve 
insulin sensitivity, and those that delay absorption of carbohydrates from the blood. There are 
several different drugs in each of these categories and the physician uses the patient’s symptoms 
and contraindications to decide which drug is most appropriate. 
Additional medical nutrition therapy (MNT) should be provided. For obese patients, a 
calorie, carbohydrate and fat restricted diet should be followed. Increased physical activity 
should also be included in the treatment regimens, as weight loss has been shown to reduce 
insulin resistance.4,5 In patients who present with weight loss or severe hyperglycemia, insulin 
may be prescribed.5  
 
2.7 DIABETES MANAGEMENT IN AFRICA 
 
In order to have the most effective treatment for diabetes, a patient must have access to proper 
diagnostic and monitoring techniques as well as to treatment options. However, in developing 
countries, many of the people affected by this disease will not have access to these necessary 
tools. In Mozambique only 18% of health care facilities have the ability to measure blood 
glucose levels and only 8% can test for urinary ketones (additional marker of diabetes).89  
Beran and Yudkin describe the health care situation in Africa as such:  
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“In most developing countries the main barriers to chronic disease control are inadequate 
financing and availability of staff … a dearth of information about disease burden and 
management, and the present orientation of health systems toward acute care.” 92 
Due to the history of focusing on communicable diseases in this region, most health care systems 
are geared towards treating diseases with shorter natural histories. They are not used to long term 
follow up and continuity of care across several specializations.93 In one report ranking 191 
countries by the overall performance of their health systems, 80% of African countries were in 
the fourth and fifth quintile and only one (Morocco) was in the top quintile.94  
 Health care in these countries also tends to be concentrated in the larger urban areas, 
which is usually too far from those in rural areas who often need assistance the most. Very few 
countries in Africa have had official health care assessments, especially specific to diabetes care, 
but for those who have, the most frequent findings have been: low patient attendance, consult 
time is too short to provide accurate patient education, insufficient staff, untrained staff, 
complications of diabetes are not properly (or often at all) monitored, glucose and blood pressure 
are in poor control, referral systems are lacking, and record keeping is very poor.95–101  
 Diabetes prevention (specifically for T2D) is practically non-existent in this region. As 
urbanization occurs and obesity rates rise, primary prevention through education will become 
increasingly necessary. Mass-media may become a useful means of providing education quickly 
to the people through commercials and soap-opera type shows.102  
The most pressing issue, however, is the lack of insulin availability to this region. A 
global survey by the International Diabetes Federation’s (IDF) Task Force on Insulin, Test 
Strips, and Other Diabetes Supplies of 35 countries, including several from Africa, showed that 
Africa had the lowest level of access to insulin for T1D patients.103 Half of the respondents 
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reported that patients could only access insulin less than 50% of the time. While cost was the 
major barrier to access, unavailability in rural areas, lack of education, transport difficulties and 
storage issues were additional barriers. The Congo, DRC, Cote d’Ivoire, Madagascar and Togo 
reported that 50-70% of their patients who required insulin were unable to access insulin because 
it was too expensive. Mali and Uganda reported that 25-49% of their patients had this problem, 
while Nigeria and Senegal reported that only 1-24% of their patients encountered this barrier. 
Seychelles was the only African country in this survey that reported that all of their patients who 
needed insulin could obtain it on a consistent basis.103  
This survey found the following prices (on average) for insulin in Africa: public sector = 
10 (2.5 – 34) USD, private sector = 11.10 (2.5 – 36) USD, and NGO = 4.5 (2.5 – 20) USD, and 
insulin pens: public sector = 24 (6.40 – 60) USD, private sector = 60 13.60 – 80) USD, and NGO 
= 45 (30 – 60) USD. Diabetes supplies are also expensive as the median price ranges for 100 
syringes and needles in Africa  were:  public sector = 20.50 (12.8 – 33.30) USD, privates sector 
= 32.90 (18.80 – 49.30) USD, and NGO = 20 (9 – 33.30) USD. Monitoring supplies were also 
pricey with the median price ranges for blood glucose meters the region being:  public sector = 
105 (53-125) USD, private = 103 (65 – 156.50) USD, and NGO = 82.50 (1 – 125) USD while 
strips alone were on average: public sector 49.50 (18 – 62.50) USD, private sector = 41.10 (30 – 
102) USD, and NGO = 40 (39 – 40) USD. Countries were asked to rank the top four reasons for 
not testing in their country and the African countries responded that (1) cost of testing supplies, 
(2) lack of testing supplies, (3) lack of diabetes education, and (4) no patient interest were the 
major reasons for not testing.103  
Each of these items represents a large portion of an average individual’s yearly income 
and are therefore prohibitively priced. When they calculated the financial impact of diabetes care 
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in several selected countries (calculated the percentage of the GDP a person might spend a year 
on diabetes care items – assuming one 10 mL vial of insulin per month, 6 syringes per month, 
and one test strip per month) the results ranged from only 3% of the GDP in the Seychelles to 
63% for the DRC.103  
To allow countries to have their own means of assessing their barriers to insulin, the 
Rapid Assessment Protocol for Insulin Access (RAPIA) was developed. It is a series of questions 
that review the path of insulin from the moment it arrives in country until it reaches the 
patient.104 It allows each country to identify barriers and gaps in infrastructure that prevent 
diabetic patients from receiving necessary care. It has been tested in three countries 
(Mozambique, Zambia an Mali) and has acted as a catalyst in bringing diabetes care to the 
attention of the local health authorities.89  
Additional private company efforts have been made to make insulin more affordable. 
Novo Nordisk initiated an equity pricing initiative which offers insulin to the 50 poorest 
countries at prices that are less than 20% of the normal.105 However, these services are limited as 
there are several African countries that are not included in this list, the information which Novo 
Nordisk provides to these countries is often lacking or confusing and this service is not offered to 
the private sector from which most patients receive their diabetes care.92  
Efforts in individual countries are often supported by local teaching universities or 
through support from outside funders. One effort in Soweto, South Africa reduced their number 
of hyperglycemic emergency admissions rates and mortality by increasing education for their 
staff and patients, as well as developing formal treatment protocol.106 In Ghana, a restructuring 
of their care system leading to nurse-led patient education sessions also resulted in lower rates of 
hospital admissions and mortality related to diabetes.107  Significant decreases in HbA1c levels 
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were seen in rural KwaZulu-Natal in South Africa where they also used nurse-led educations 
systems in scattered primary health clinics.108 Additional programs have seen similar results in 
Ethiopia109 and Eritrea.110 There are several newer programs such as the twinning initiative 
between the Diabetes UK and Mozambique Diabetes Association111 and the new National 
Diabetes Program in Tanzania112, which are also seeking to improve care for patients with 
diabetes in Africa.  
In 2001, the LFAC program was established by the IDF in partnership with Australian 
Diabetes Council and HOPEworldwide to develop sustainable programs that provide access to 
care, education, and necessary diabetes supplies and therapy to children in developing countries. 
It is currently supporting over 4,000 children in 28 countries. LFAC works with the local 
authorities to build their capacity to address the diabetes situation in sustainable ways. There are 
several sites in Africa, including one in Kigali, Rwanda, which is operated by the Association 
Rwandaise des Diabetiques (ARD). In 2008, Eli Lilly and Company announced that it would 
donate more than 800,000 insulin vials to children in nine sub-Saharan African countries through 
the IDF’s Life for a Child (LFAC) Program. The goal of this cooperation and donation is that by 
2012, they will be able to provide life-saving insulin and supplies to up to 24,000 children.113  
 
2.8 RWANDA 
 
Rwanda is a country located in the Great Lakes Region of East Africa and has a population of 
roughly 11.05 million people living within 26,338 sq km (roughly the size of Maryland), making 
it the most densely populated country in Africa.114 Since the 1994 genocide, Rwanda has made 
great progress both economically and socially under the direction of President Paul Kagame. 
However, 56.7% of Rwandans still live under the poverty line, with 37% living in extreme 
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poverty.115 Due to the genocide and previous disease epidemics, there were 613,000 orphans 
living in Rwanda in 2001, and an estimated 101,000 children are living in child-headed 
households.116 These conditions lead to quality health care being prohibitively expensive for 
these children and thus make diagnosis of a chronic disease, like diabetes, essentially a death 
sentence in many cases.  
 The operations of the LFAC program in Rwanda are overseen by Mr. Francois Gishoma. 
Mr. Gishoma has a first-hand understanding of the ever-continuous needs of diabetic patients, as 
he himself has the disease. The Rwandan LFAC program was initiated in 2004 with the 
enrollment of 25 children at the ARD. The LFAC program originally was designed to support 
children up until age 23, but in early 2009, the cutoff age was moved to 25. Since its conception 
the program has expanded in numbers and scope. The LFAC program is now active at the ARD 
and over 18 district hospitals countrywide.  There has been a steady increase in the number of 
children participating, as 93 children were enrolled in 2007, 181 in 2008, and 301 by the end of 
2009. It is believed that the increased number of participants is a reflection of an increase in 
awareness and the seeking of care rather than an actual increase in the incidence of the disease. 
However, due to the lack of studies of incidence and prevalence in this country, it is not possible 
to know whether any increase in incidence has occurred.  
 The University of Pittsburgh Graduate School of Public Health initiated a partnership 
with the ARD in 2007, and has since been very actively providing assistance and guidance to the 
program. Every summer since 2009 a Master of Public Health Student, under the guidance of Dr. 
Trevor Orchard, has traveled to Rwanda for a period of 6 weeks to assist with the annual 
assessment of the LFAC participants, a process essential to receiving supplies from the LFAC. 
Each year, data on: date of birth, date of diagnosis, number of injections a day, units of insulin a 
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day, type of insulin used, average visits to a doctor per year, height, weight, blood pressure, eye 
function, neuropathy, HbA1c, A/C ratio, number of hypoglycemic episodes, number of 
hospitalizations, and school attendance is collected for each participant.  
 Dr. Orchard is also the principal investigator of a new comparative effectiveness clinical 
trial based in this population. The grant is funded by the National Institute of Diabetes, 
Digestive, and Kidney Disease, and aims to establish a pilot study comparing a simplified 
diabetes management protocol based, initially, on a single daily basal insulin, to the current 
conventional management which involves combined regular and NPH insulin. The trial is 
currently in recruitment phase and will hopefully improve diabetes care for youth in the 
developing world and throughout the LFAC program.  
 
2.9 SUMMARY AND SIGNIFICANCE 
 
Each year, the worldwide incidence of type 1 diabetes rises by approximately 3%.14,15 However, 
since there are geographic differences in the rates of this disease, it is important for Public Health 
officials to have an accurate estimate of the prevalence in their country. This way they will know 
the true magnitude of the burden for this disease. It is also important that each country has access 
to management methods that have been proven to work in populations similar to their own. 
These data are both vital and necessary to providing sufficient and correct care to patients. 
Unfortunately, these data are lacking or completely absent in most developing countries, which 
could benefit the most from such information.  
 The proposed study will work towards filling in several of these gaps for one specific 
developing country: Rwanda. Through our work we hope to 1) gather representative prevalence 
data from several districts across the country, allowing us to estimate countrywide prevalence 
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and look for within-country geographic variances. This data collection process will also enable 
the establishment of a youth onset diabetes registry 2) determine the short-term natural history of 
diabetes by following up all previously identified cases 3) record the effects of directed and 
monitored patient care provided by the ARD.  All together the results may help direct future 
disease management, care, and resource allocation in Rwanda, but it is hoped the findings will be 
relevant to many countries in Africa and beyond. 
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3.0 SPECIFIC AIMS 
 
The Rwandan LFAC program was initiated in 2004 with the enrollment of 25 children at the 
ARD, but has since expanded to supporting 522 children by July 2011. Data from these children 
will be used to examine the following specific aims: 
Specific Aim 1: To execute a 1-2 year follow up of the LFAC 2009-2010 cohort using HbA1c to 
evaluate the impact of regular HbA1c testing and organized, structured care on glycemic 
control. Follow up data of prevalence of complications and mortality will also be presented.  
Specific Aim 2: To document and register eligible children and youth (age 25 and younger) with 
clinically diagnosed type 1 diabetes in six representative districts and Kigali City.  
Specific Aim 3: To follow up the first 500 cases registered with the ARD from 2004 – 2011. 
Data on: utilization of the program (number and frequency of visits), losses to follow up, clinical 
characteristics, laboratory measures, complications (acute and chronic) and mortality will be 
presented. 
 
 
 
  
 
 
 
 
 
41 
 
4.0 GLUCOSE CONTROL IN CHILDREN AND ADOLESCENTS WITH TYPE 1 
DIABETES IN RWANDA FOLLOWING PROGRESSION OF CARE 
 
 
To be submitted for publication 
 
 
Sara L. Marshall, MPH1, Laurien Sibomana, MS1, Vincent C. Arena, PhD2, Ronald E. LaPorte, 
PhD1, Clareann H. Bunker, PhD1, Dorothy J. Becker, M.B.B.Ch.3, Deborah Edidin, MD4, 
Graham Ogle, MBBS5, Trevor J. Orchard, MBBCH, MMedSci1   
 
1 University of Pittsburgh Graduate School of Public Health, Department of Epidemiology, 
Pittsburgh, PA, USA  
2 University of Pittsburgh Graduate School of Public Health, Department of Biostatistics, 
Pittsburgh, PA, USA  
3 University of Pittsburgh School of Medicine, Department of Pediatrics, Pittsburgh, PA, USA 
4 Northwestern University, Feinberg School of Medicine, Pediatrics, Chicago, IL, USA  
5 International Diabetes Federation Life for a Child Program and HOPE worldwide (Australia), 
Sydney, NSW, Australia  
  
42 
 
4.1 ABSTRACT 
 
AIMS: To assess glycemic control concurrent with introduction of quarterly clinic visits with 
HbA1c testing, and increased patient and provider education with a 1-2 year follow up of the 
Rwanda Life For a Child (LFAC) 2009-2010 cohort. Additionally, patterns of HbA1c change, 
and complications were examined. 
METHODS: Participants were members of the Rwanda LFAC program (aged < 25 years) with 
first HbA1c measure between June 2009 and November 2010. Data were analyzed for the entire 
cohort and stratified by age (< 18 years, > 18 years). Trajectory analysis was performed to 
identify group trends in HbA1c change. 
RESULTS: Mean overall HbA1c decreased significantly from baseline (11.2±2.7%) to one- 
(10.2±2.6%) and two- (9.8±26%) year follow up visits. The prevalence of microalbuminuria 
(MA) did not significantly change (21.0%, 18.8%, and 19.6%), nor did nephropathy (4.7%, 
7.8%, and 5.4%), or neuropathy (2.1%, 1.2%, and 0.0%). The prevalence of hypertension 
(31.8%, 44.9%, and 40.3%), however, were higher than expected and increased significantly. 
Five HbA1c control groups were identified by trajectory analysis, and those with the worst 
glucose control monitored their glucose significantly fewer times per week.  
CONCLUSIONS: These data demonstrate that implementation of regular care, HbA1c testing, 
and increased education can result in significant improvements in glycemic control in youth and 
adolescent type 1 diabetes (T1D) patients in sub-Saharan Africa, but highlight the need for 
continued monitoring of complications.  
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4.2 INTRODUCTION 
 
Diabetes is a non-communicable disease (NCD) of increasing global concern, especially for 
resource-limited developing countries. In sub-Saharan Africa, an estimated 18.7 million people 
will be affected by this disease by 2025.2 Access to necessary insulin and management options 
are often limited in these areas. This may prevent patients from achieving adequate glycemic 
control that is necessary for the prevention/delay of disease sequelae.60,89,117  
In order to address this problem, outside support has been necessary, as access to insulin 
is greatly limited.92 One program providing such help is the International Diabetes Federation’s 
Life For a Child (LFAC) program, which is managed in conjunction with the Australian Diabetes 
Council and HOPE worldwide.  LFAC’s mission is to support the provision of the best possible 
healthcare, given local circumstances, for children and youth with diabetes (< 25 years) in 
developing countries. This is achieved by strengthening diabetes services through the provision 
of insulin, syringes, glucose monitoring supplies, HbA1c testing, diabetes education and expert 
advice and training. One program receiving assistance from LFAC is the Association Rwandaise 
des Diabetiques (ARD) in Kigali, Rwanda – the only specialized care provider for diabetic 
patients in Rwanda.  
The Rwanda LFAC program at the ARD was initiated in 2004 with 25 children receiving 
support and annual clinic visits. The program has expanded since then, and as of the end of 2011, 
634 children and young adults were enrolled. The ARD has also been aided by the University of 
Pittsburgh Graduate School of Public Health (GSPH), which sends a Masters of Public Health 
(MPH) Student each year to assist with the annual assessment of the youth.   
We previously reported on the first 286 children and youth with type 1 diabetes (T1D) in 
the LFAC Rwanda program, who had their first HbA1c test between June 2009- November 
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2010.118  The overall level of glucose control was very poor with a mean HbA1c of 11.1±2.8%, 
and 30.9% (n=88) having HbA1c above 14%. Complications were also already present in this 
population, despite the mean diabetes duration of only 3.4±3.1 years.  
Since baseline, the care provided by the ARD has evolved, with the support of GSPH, through 
the implementation of quarterly clinic visits with HbA1c testing and microalbuminuria (MA) 
assessment as needed. Additionally, patient and provider education on daily diabetes 
management has increased. The primary objective of this report, therefore, is to assess the 
change in glucose control concurrent with this evolution of care with a 1-2 year follow up of the 
Rwanda LFAC 2009-2010 cohort. We will also examine patterns of HbA1c change, determine 
the characteristics of those developing complications, and those not returning for follow-up.  
 
4.3 METHODS 
 
This report is a quality improvement project of the LFAC Program in collaboration with the 
ARD and GSPH. The University of Pittsburgh’s IRB has determined that this project is exempt 
from review under the “Existing Data” category.  
 
4.3.1 Study Population 
 
All participants in this evaluation were registered members of the Rwanda LFAC program who 
had their first HbA1c measure between June 2009 and November 2010.118 To be enrolled in the 
program, participants must be citizens of Rwanda aged < 25 years needing assistance with 
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obtaining insulin and diabetes supplies. Participants either sought out care from the ARD or were 
referred by their physicians or healthcare providers.  
Diabetes care for the LFAC participants in Rwanda has evolved over the last several 
years as outlined in table 6. This single-nurse led program started in 2004, but regular HbA1c 
testing was not available until 2009 and only annual visits were required until 2010. Since then, 
the program has expanded in size and scope through providing support to numerous district 
hospitals and development and execution of patient and care provider education sessions. While 
attempts have been made to improve provider care at hospitals, due to staff rotation and relative 
unawareness of diabetes in youths, the quality of care still remains a problem.   
4.3.2 Data Collection 
 
Baseline data were collected from June 2009 – through November 2010. Baseline and follow up 
data were collected using the LFAC forms and protocol (previously described118) either at the 
ARD or at several district hospitals supported by the program.  Follow up data were collected 
from baseline through April 30, 2012 by the ARD staff and University of Pittsburgh students. 
This timing of follow up meant that 79 subjects were not yet eligible for a two- year follow up 
visit. All assisting University of Pittsburgh students and ARD clinical staff were trained by 
authors TO and DE.   
 No data were collected for research purposes and all data reported are routinely recorded 
for clinical care purposes.  
Laboratory Data 
Blood and urine samples were processed on the Siemens DCA VantageTM by the MPH students 
or ARD staff. HbA1c and Albumin/Creatinine (A/C) ratio results were reported to the nearest 
tenth percent. The maximum HbA1c value for this machine is “>14 %,” so for data analysis 
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purposes these results were reported as “14.1.” Regular quality control testing resulted in a 
coefficient of variation for the DCA of 2.1% to 3.8% during data collection. 
Anthropometric and Blood Pressure Percentiles for Youth 
Height and weight were measured with a stadiometer and floor scale, respectively. Height was 
recorded to the nearest 0.1 cm and weight to the nearest 0.5 Kg. Blood pressure (BP) was 
assessed with a manual cuff for a portion of 2009 and then by an automatic BP machine (Omron 
Healthcare, Inc.) and cuff for the duration of follow-up. Cross-over studies showed no significant 
differences between methods, and post hoc analysis showed no trends in data due to this change.   
For those under age 18 years of age, height for age,119 systolic and diastolic BP for height 
percentile and age,120 and BMI for age121 percentiles and z-scores were calculated. It should be 
noted that the percentiles and z-scores are based on US standards as no appropriate Rwanda data 
are available. Short stature was defined as those under the 5th percentile.119 Those under the 5th 
percentile for BMI were considered to be underweight, those from the 5th to 84th were normal 
weight, 85th to 94th were overweight, and those over the 95th percentile were obese.121  For 
systolic and diastolic blood pressure, those over the 95th percentile were considered 
hypertensive.120  
For those over 18 years of age, a BMI under 18.5 was scored as underweight, 18.5-<25 
normal weight, 25-30 overweight, and over BMI of 30 obese.122  Hypertension was defined as a 
systolic BP ≥130 mmHg or diastolic BP ≥80 mmHg or a history of BP medication. The number 
of those using BP medication, however, is low due to high costs.  
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4.3.3 Patient and Provider Education 
 
Initially (2008-2010), education for patients focused mostly on proper injection of insulin, how 
to adjust insulin doses appropriately based on food availability and glucose monitoring results, 
when available, and recognizing hypoglycemia and the appropriate actions to take. Additional 
education materials and information were later (2011) introduced on: relevance of HbA1c, what 
to do when blood sugar levels are very low (hypoglycemia), when to call the clinic, possible 
complications from diabetes, proper nutrition, how to account for exercise, and what to do when 
sick with an infection. Education for care providers focused mainly on the different insulins 
available, how to properly prescribe and adjust insulin doses, and how to handle hypo- and 
hyper-glycemia. 
 
4.3.4 Complication Assessment 
 
Neuropathy  
Neuropathy was defined as failure to feel a 10g monofilament (<7 of 10 correct responses) on the 
dorsum of the great toe and/or failure to feel vibration from a 120Hz tuning fork on the dorsum 
of the great toe for longer than 10 seconds.123  
Microalbuminuria  
Microalbuminuria (MA) was defined as an albumin/creatinine (A/C) ratio of 30-299 mg/g in a 
spot urine sample, and overt nephropathy as an A/C ratio ≥ 300 mg/g. 
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4.3.5 Data Analysis 
 
Descriptive statistics including mean, standard deviation and frequencies were calculated for all 
variables. Two-sample and paired t-tests, chi squared test and Fishers Exact tests were used as 
appropriate for comparisons. Spearman correlation coefficients were used to assess the 
association between HbA1c and other continuous variables of interest at each visit. When 
examining changes in anthropometric data over time, only subjects who were >18 years for the 
entirety of follow up or <18 years for the entirety of follow up were included (thus excluding 
n=9 from baseline to visit-1(V1) and n=20 for baseline to visit-2 (V2)) to account for the few 
that were <18 years at baseline but were > 18 years at either V1 or V2. Analysis of variance was 
used to assess differences in BP by HbA1c control group and Tukey’s HSD was used for post-
hoc analyses.  
Logistic regression modeling was used to identify factors that predict MA. Univariate 
associations were first examined to identify contributors and those with significance of p < 0.2 
were then considered for inclusion in the final model. Backwards stepwise regression was then 
completed using a significance of p <0.05 for inclusion. Age was retained as a potential 
confounder.  
Trajectory analysis was performed using the PROC TRAJ macro (found at 
http://www.andrew.cmu.edu/user/bjones/) to determine if there were distinctive HbA1c 
trajectory profiles within the overall population using group-based semiparametric mixture 
modeling. This macro uses longitudinally collected data to define trajectories and then categorize 
participants into those groups based on a posterior probability.124 We used data that were 
collected at baseline and at 3-month intervals up to 24 months. Given the censored distribution of 
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our data, we used a censored normal model. To determine the number of trajectories, we used the 
Bayesian information criterion (BIC) log Bayes factor approximation:  
2loge(B10) ≅ 2(∆BIC) 
where ∆BIC is the BIC of the more complex model less the BIC of the simpler model.124  After 
participants were classified into trajectory groups, we examined differences in other factors using 
the PROC Mixed procedure in SAS.  
The analysis for this paper was generated using SAS/STAT software, Version 9.3 of the 
SAS System for Windows, copyright © 2011 SAS Institute Inc.  
 
4.4 RESULTS 
 
A total of 214 children and youth (of 286) had an HbA1c measurement one year (V1) (11.7±2.3 
months) after their baseline (BL) measurement and 144 had a follow up measurement two years 
(V2) (23.0±3.5 months) after baseline. 125 participants attended both V1 and V2 and therefore 
comprise a full compliance (FC) sub-group. Age specific measurements (<18 years/>18 years) 
can be seen in supplemental tables 1 and 2 (Appendix A).  
At baseline mean age, diabetes duration and glucose monitoring frequency were 18.6±4.5 
years, 3.4±3.1 years and 1.1±3.4 times per week, respectively (table 7). A high percent (48.2%) 
of those <18 years had short stature and 16.1% were underweight (table 7). Complications were 
already present in this cohort with MA (21.0%) and hypertension (31.8%) being the two most 
common (table 7).  
There were no significant differences in baseline characteristics for those who attended 
V1 and those who did not, although, those who attended V1 were somewhat younger at baseline 
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(p=0.07) and took more insulin per kg (p=0.07) (table 7). Height at baseline was the only 
characteristic that was borderline different at V1 for those <18 years (p=0.07) (table 7). Those 
who attended V2, however, were significantly younger at baseline (17.5±4.7 years vs 19.9±4.3 
years) and had borderline lower systolic BP (p=0.08) and more frequently monitored their 
glucose levels (p=0.06) than those who were eligible for V2 but did not attend (table 7). At 
baseline, for those <18 years, HbA1c was negatively correlated with systolic BP z-score (r=-0.2, 
p=0.03) and for those >18 years it was negatively correlated with systolic BP (r=-0.2, p=0.007) 
and positively correlated with units of insulin/kg (r=0.2, p=0.002). 
At V1 participants monitored their glucose more frequently (2.6±4.7 times per week vs 
1.0±3.2 times per week; at BL 3.3% monitored 2+ times per week, at V1 = 8.0%) and had higher 
systolic (118±16 mmHg vs 112±14 mmHg) and diastolic (77±13 mmHg vs 72±11 mmHg) BP 
than at baseline (table 8). Similar patterns were seen for the FC sub-group (data not shown). For 
those <18 years, systolic and diastolic BP z-scores were higher at V1 than baseline as were rates 
of hypertension (table 8). For those >18 years, mean systolic (115±14 mmHg at BL vs 122±15 
mmHg at V1) and diastolic (74±11 mmHg at BL vs 79±13 mmHg at V1) BP significantly 
increased (table 8). At V1 HbA1c was negatively correlated with monitoring frequency (r= -0.4, 
p=0.004 <18 years; r=-0.3, p<0.0001 >18 years) and height z-score (r=-0.3, p=0.02). 
At V2 mean glucose monitoring frequency (1.7±4.4 at BL, 2.5±4.4 at V1 and 6.6±6.9 at 
V2; at BL 6.3% monitored 2+ times per week, at V2=33.1%) per week was significantly higher 
than both previous visits. For those <18 years, mean systolic and diastolic BP z-scores were 
significantly higher at V2 than baseline. For those >18 years mean systolic (115±16 mmHg at 
BL vs 122±21 mmHg at V2) and diastolic (75±11 mmHg at BL vs 80±14 mmHg at V2) BP were 
higher than baseline but not V1 (table 3). At V2 HbA1c was negatively correlated with BMI z-
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score (r=-0.3, p=0.03) for those <18 years, and with glucose monitoring frequency (r=-0.3, 
p=0.04) for those >18 years.  
Figure 2A shows a significant decrease in mean HbA1c for the entire cohort from 
11.2±2.7% at baseline to 10.2±2.6% (P <0.0001) at V1, and to 9.8±2.3% at V2 (P <0.0001 from 
BL, P <0.0001 from V1) (table 8). Very similar changes (P <0.0001) were seen in the FC sub-
group (figure 2B). At V1, 56.1% (n=120) saw a 0.5% improvement or greater in HbA1c, and 
66.7% (n=96) saw similar improvements at V2. In the overall cohort, at baseline, only 15.7% of 
participants had HbA1c <8%, but this increased to 23.6% at V2 (p=0.04). The most striking 
change was the decrease in the percentage of participants with HbA1c >14% from 30.8% at 
baseline to 12.2% at V1 (p<0.0001), and to 9.0% at V2 (p<0.0001 from BL, not significant from 
V1, Figure 2A, table 8). Similar patterns were seen for those in the FC sub-group (figure 2B). At 
baseline, 10.8% of participants met the ADA glucose control goals for their age, 13.1% met the 
goals at V1, and 12.5% at V2.  
 
4.4.1 Trajectory Analysis 
 
In order to identify factors that were associated with improved glucose control we used trajectory 
analysis to identify different groups of participants based on their HbA1c patterns over time. Of 
the 201 participants with sufficient data, five distinct groups were identified (Figure 3): Group 1 
(N=16, 8.0%) – started low and stayed low, Group 2 (N=17, 8.4%) – started low then increased, 
Group 3 (N=54, 26.9%)– started intermediate then declined, Group 4 (N=64, 31.8%)– started 
high then declined, Group 5 (N=50, 24.9%)– started high and stayed high. There were no 
significant differences in age, age at diagnosis, or diabetes duration among the groups.  
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Repeated measures analysis was used to identify significant differences in clinical 
measures or behaviors by group. Only glucose monitoring per week was significant. Those in 
Group 5 (high-high) monitored their glucose on average fewer times per week than all other 
groups (Group 1 to 5 p=0.006; Group 2 to 5 p=0.01; Group 3 to 5 p=0.002, Group 4 to 5 
p=0.04), and those who were in Group 3 (intermediate-decline) monitored on average 
significantly more frequently than those in Group 4 (high-decline) (p=0.002).  
 
4.4.2 Complications   
 
The annual prevalence of MA remained fairly constant (21.0% at BL, 18.8% at V1, and 19.6% at 
V2), as did nephropathy (4.7%, 7.8%, and 5.4%) and neuropathy (2.1%, 1.2%, and 0.0%) (tables 
6 and 8). Hypertension, rates, however, increased significantly over time (31.8% at BL, 44.9% at 
V1, and 40.3% at V2).  
In the FC sub-cohort, eight cases of MA were noted at V1, comprising 4 new cases; 1 
who had improved from nephropathy at baseline, and three cases with continued MA from 
baseline. Ten cases of MA were noted at V2, comprising 7 new cases and 3 cases with 
continuing MA. The tentative estimate of the annual incidence of MA was therefore 16.6% (95% 
CI 7.0-42%) and the annual regression rate was 23.5%. One new case of nephropathy was 
identified at V1, which had progressed from MA at baseline. At V2, there was 1 additional case 
that previously had MA at baseline. The annual incidence of nephropathy was, therefore, 4.9% 
(95% CI 0.8-17%). The total N for those with complications was too small to design any 
meaningful models to identify predictors. 
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We stratified weight, systolic BP, and diastolic BP by the HbA1c control groups in the 
FC subgroup to see if HbA1c control impacted hypertension (table 9). While there were no 
overall significant differences, BP increased the most for Group 2 (low-increased) and the least 
for Group 1 (low-low), while BP for Group 3 (intermediate-low) remained fairly constant. 
Although BP also increased for Group 4 (high-declined), it was likely as a result of improved 
health, as previously described for this cohort,118 since weight also increased as HbA1c 
decreased. Our total N was too small to detect any significant correlations between HbA1c 
control groups and BP, but BP increased with worsened HbA1c control (Group 2), and lessened 
with improved HbA1c control (Group 3). Even with improvements in control, Groups 3 and 4 
still had higher BP than Group 1 which had consistently low HbA1c. Rates of hypertension also 
decreased with alterations in the definition of hypertension, with the biggest change due to 
adjustments to diastolic BP requirements (table 8).  
Rates of MA, neuropathy, and nephropathy did not differ significantly by trajectory 
group; however, the sample size and event N were too small for analysis.  
 
4.5 DISCUSSION 
 
In this follow up of children and youth (<25 years) with diabetes in Rwanda after the 
introduction of more systematic care, regular HbA1c testing, and education, we saw significant 
increases in glucose monitoring and blood pressure, and significant decreases in overall mean 
HbA1c (BL=11.2±2.7%, V1=10.2±2.6%, V2=9.8±2.6%) (tables 7 and 8). While the percentage 
of those meeting ADA glucose control goals for their age increased, the rates in Rwanda are still 
significantly lower than those seen in the US (under 6 years=64%%, 6-<13years =43%, 13-<20 
years =21%).125 We did not find any baseline predictors of V1 attendance, but those who 
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attended V2 were significantly younger at baseline than those who did not attend V2. Except for 
MA and hypertension, prevalence rates of complications were low, and did not change 
significantly over the follow up period. 
We also identified five distinct HbA1c control groups through trajectory analysis, and 
these groups differed by frequency of glucose monitoring per week, with those with the worst 
control (Group 5; high-high) measuring significantly fewer times per week than all other groups. 
As HbA1c decreased with each follow-up visit, it was negatively correlated with monitoring 
frequency. These findings suggest that higher emphasis should be placed on more frequent 
glucose monitoring to improve glycemic control.  
In support of our results, similar studies in sub-Saharan Africa report using education and 
HbA1c measurements to improve glucose control. These studies of older diabetes patients - one 
in Eritrea (n=350, mean age 50.5±15.5 years and duration 8.6 years),110 and another in Kwazulu 
Natal, South Africa (n=284 with 197 completing; mean age 56±11 years and mean duration 7±6 
years)108 showed that improving the availability of HbA1c measurements and implementation of 
educational programs for physicians and diabetes educators, led to significant decreases in 
HbA1c (from 9.2±2.5% to 8.7±2.3% in Eritrea with mean follow up of 153 days; and from 
11.6±4.5% at baseline to 8.7±2.3% by 6 months and 7.7±2.0% at 18 months in South Africa).  
A further study from Kenya also showed improvements in glucose control through increases in 
glucose monitoring and regular contact with community diabetes care workers. At baseline, 43 
participants had a mean HbA1c of 13.2% (95% CI 12.8-13.5), but this had fallen to 10.5% (95% 
CI 9.8-11.1) by 3-6 months.126  Though there were no demographic data presented for 
comparison to our cohort, this study in Kenya highlights the importance of not just HbA1c 
knowledge, but also use of regular glucose monitoring to adjust insulin doses. In our population 
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we saw a significant negative correlation between glucose monitoring and HbA1c at V1 and V2, 
suggesting that improvements in glucose monitoring frequency were associated with improved 
glucose control. Studies from the developed world, for example Germany and Austria, also 
support these findings, showing that glucose monitoring frequency is associated with 0.20%127 
and 0.26%128 reductions in HbA1c.  
Several of these previous studies included both type 1 and 2 diabetes patients, thus 
limiting any direct comparisons. Only 59% in Eritrea were taking insulin and even fewer were in 
South Africa (4%).108,110  In the current study we believe the vast majority of our patients are 
type 1, based on their age at onset, lack of obesity, and insulin dependency. However, formal 
antibody testing and c-peptide testing were not available in our, or the other studies. However, 
the current study would thus appear to be the first report of improved diabetes control with 
regular HbA1c testing and education in a predominantly T1D population in sub-Saharan Africa. 
The incidence of MA and nephropathy were estimated to be 16.6% and 3.3%, 
respectively. However, with the high rates of missing A/C data, patterns are uncertain. The 
incidence rates in our population appear quite high, especially in a young population with such 
short diabetes duration, and are almost 8x as high as those seen in Denmark (MA=1.9%)129 and 
higher than in Australia (MA=4.6/1,000 person years)130; even with a shorter duration (~ 4 years 
for Rwanda vs 12.2 for Denmark and 6.7 years for Australia). However, HbA1c in Rwanda 
(11.2% vs 9.7%) was higher and was likely the driving factor for the higher rates.60,131,132  The 
prevalence of MA in Rwanda, however, was slightly lower than reports from a Pittsburgh cohort 
aged 6-21 years with 5 years of diabetes duration (similarly aged Rwanda cohort MA=15.1%; 
Pittsburgh=21.0%),133 suggesting that there may not be any actual increased prevalence of MA in 
Rwanda.  
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This population was lean and short based on US standards. Rates of obesity and 
overweight in those <18 years were very low (0.0-3.2% obese; 3.9%-7.2% overweight) in 
comparison to US youth with T1D in the SEARCH study (13.0% obese; 21.2% overweight).134 
Although the low rates are likely due to insulin deficiency and uncontrolled diabetes, many of 
these children and youth were born during or just after the Rwandan genocide, which could also 
have contributed to their small stature.   
The mean values for SBP and DBP (112±14 and 72±11 mmHg) at baseline were similar 
to those for African American (AfAm) youth with T1D (112±11 and 73±11), but the rates of 
hypertension at baseline were significantly higher in Rwanda (AfAm=9.8%, Rwanda 30.8%).11 
An additional study of T1D in youth in the US (aged 6-21 years, 5 years duration) also showed 
significantly lower rates of hypertension than seen in Rwanda (% sbp >120 mmHg Pittsburgh 
USA =11.9% Rwanda=28.6%; % dbp >80 mmHg Pittsburgh=10.2%, Rwanda=42.8%).133  The 
increased rate of hypertension was likely driven by the high number of Rwandans with a 
diastolic BP of exactly 80 mmHg (n=30; 20%). When hypertension was defined as 130/85 
mmHg, the percent of hypertensive Rwandans (16.4%) was much more similar to that in the US 
(table 8). We saw sizeable drops in hypertension prevalence at each visit when the definition of 
hypertension was increased by 5 mmHg for diastolic BP (130/85), though the same changes were 
not seen for a 10 mmHg increase in systolic BP (140/80). This suggests that most of the excess 
hypertension in this population is due to the high percent of Rwandans with diastolic BP around 
80 mmHg.  
It is likely that poor glucose control was the driving force for the increased rates, as 
evidenced by the increased BP for those whose control worsened (Group 2) and the decrease for 
those with improved care (Group 3). It is important to note that even with improved control, BP 
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remained higher than for those with constant tight control.  This implies that there was a residual 
effect of poor control, even after improvements. Previous work from a US cohort of youth with 
T1D (mean age 12.5±4.4 years, mean duration 4.5±3.3 years) showed a significant positive 
correlation between HbA1c and diastolic BP.135  However, due to the small N, as well as the 
potential for hypovolemia in those with very poor glycemic control we saw no such significant 
correlations between HbA1c and diastolic BP in our population.  
It is possible that other factors also contributed to the excess hypertension in this 
population. Previous studies found that the prevalence of hypertension in those under age 45 
years was higher in sub-Saharan Africa (SSA) than the US and the UK (SSA=10.7%, UK=5.6%, 
US=8.2%).136  Diet may be a factor, as salt is often used in food preparation and preservation in 
SSA.136 However, no dietary records were kept for our population, so we were unable to 
determine its impact. Unfortunately very few participants were taking BP medication due to 
prohibitive prices. This represents a considerable constraint on furthering care for those in need, 
and additional funds are needed to address this issue.  
The major strength of this report is that it is the first such study showing that 
improvements in glucose control can be obtained in children and adolescents with T1D in sub-
Saharan Africa. We have also been able to provide preliminary estimates of the incidence and 
prevalence of MA and nephropathy in this population.  
While 74.8% of our original cohort attended V1 and 84.7% of those eligible were seen at 
V2, these rates are lower than desired, and give rise to concern as to the current vital status of 
those who did not attend. Though, several of the participants (N=10 at V1, N=16 at V2) would 
have been over age 25 at both visits, follow up of the remaining missing participants is a major 
focus of our current plans.  
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Complication assessment is limited, as only a small proportion have had their A/C 
measured (41.2% at baseline, 29.9% at one-year, and 38.9% at two-years), which is a reflection 
of lack of supplies and examination logistic issues. Assessment of neuropathy was also limited 
because it was only recorded on the annual LFAC form and not the quarterly form. Additionally, 
we were unable to assess retinopathy at this time, though we are currently working to address 
this for future care. Some clinic data were self-reported (monitoring frequency and units of 
insulin taken per day), so there is no way of monitoring compliance or the accuracy of these 
reports.  
Though this cohort is representative of the LFAC program in Rwanda, it is possible that it 
does not reflect the true diabetes population. We believe, that due to poverty and lack of access 
to insulin, almost all cases are referred to the LFAC program for care and supplies, however, it is 
likely that we are missing undiagnosed cases as well as those who died before diagnosis. This 
would mean our cohort likely represents more of a survivor cohort. 
In summary, our data from the 1-2 year follow-up of the 2009-2010 LFAC cohort 
demonstrate that implementation of regular HbA1c testing, provision of more regular care, and 
increased education may result in significant improvements in glycemic control in young (<25 
years) T1D patients in sub-Saharan Africa. Trajectory analysis allowed us to identify sub-groups 
within our population that follow different control patterns and we identified glucose monitoring 
frequency as a potential specific area of intervention for improving glycemic control. In the 
future, use of this statistical method could result in more tailored management plans specific to 
each control group. While we have reported improvements, it is clear that there is still a great 
need for further increases in glucose control in Rwandan youth and adolescents with T1D, as 
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there are still several participants in this cohort with HbA1c >14%, and we saw a high 
prevalence of hypertension and early onset of complications. 
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4.6 TABLES 
Table 6. Evolution of the LFAC program in Rwanda. 
Year Status 
2004-2007 - Initiation of insulin availability 
- No organized clinical records or management protocol 
2008 - Files organized for patient based follow-up 
- One-page LFAC form adopted 
- First University of Pittsburgh visit 
2009* - First MPH student visit 
- Addition of HbA1c and A/C ratio testing 
- Plan developed for quarterly follow-up  
- Provider and patient education sessions 
- Addition of several district hospitals 
2010* - Quarterly follow-up implemented 
- Additional training/mentoring for ARD staff 
- Development of additional education for LFAC participants 
- Increase in availability of testing supplies (intermittent since) 
- Expansion of number and frequency of district hospital visits 
2011 - Further development of education materials 
- Further increase in number of hospitals 
- Increased frequency of education sessions by ARD staff 
2012 - Program now covers 23 other hospitals across the country 
* Baseline HbA1c measures were collected during these years 
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Table 7. Baseline characteristics of the 2009-2010 LFAC cohort overall, stratified by 
attendance at V1 (one-year) and V2 (two- year) visits. 
 
 
&Includes only those who were eligible for a two-year follow –up 
$Indicates variable calculated for participants <18 years only  
¥Rates were calculated by adding those who were <18 years and >95th percentile with those who were >18 years and 
met the definition of hypertension based on BP  
 
 
* Indicates significance at α < 0.05 
ǂ Indicates borderline significance at α <0.1 
 
a=118 tested; b=180 tested; c=112 tested; d=174 tested; e=37 tested; f=62 tested, g=103 tested, h=5 tested, I=33 
tested, j=59 tested 
  
 Overall  Attendance at V1 Attendance at V2 
  Yes No Yes No& 
N 286 214 72 144 70 
Age (years) 18.6±4.5 18.3±4.4 ǂ 19.4±4.7 17.5±4.7* 19.9±4.3 
Male %(n) 46.5 (133) 44.9 (96) 51.4 (37) 35.4 (51)* 67.1 (47) 
Diagnosis Age (years) 15.1±4.8 15.0±4.7 15.7±5.4 14.2±4.7* 15.8±5.3 
Seen in 2009 %(n) 46.2 (132) 44.9 (96) 50.0 (36) 69.4 (100)* 45.7 (32) 
Duration (years) 3.4±3.1 3.3±2.9 3.5±3.8 3.3±2.8 4.0±3.4 
HbA1c (%) 11.2±2.7 11.3±2.7 11.0±2.6 11.4±2.5 11.2±2.6 
HbA1c >14% %(n) 30.8 (88) 32.7 (70) 25.0 (18) 30.6 (44) 27.1 (19) 
HbA1c <8% %(n) 15.7 (45) 16.4 (35) 13.9 (10) 11.1 (16) 18.6 (13) 
Glucose Monitor / wk 1.1±3.4 1.0±3.2 1.4±4.2 1.7±4.4ǂ 0.66±2.1 
Insulin units/kg 0.73±0.36 0.75±0.39 ǂ 0.66±0.28 0.75±0.41 0.74±0.36 
Height (cm) 154.2±14.7 153.6±14.6 155.8±15.1 151.6±14.5 156.9±17.3 
Height Z-score$ -1.6±1.8 -1.8±1.8ǂ -1.0±1.7  -1.7±1.8 -1.3±1.7 
Short Stature %(n)$ 48.2 (42) 52.3 (34) 36.4 (8) 46.2 (24) 42.9 (6) 
Weight (kg) 48.1±12.7 47.6±13.0 49.3±11.9 46.7±14.0 50.5±12.2 
BMI (kg/m2) 20.2±4.0 20.1±3.9 20.2±4.3 20.2±4.1 20.5±4.8 
Underweight %(n) 18.6 (53) 19.6 (42) 15.5 (11) 16.7 (24) 21.4 (15) 
Healthy Weight %(n) 69.5 (198) 66.8 (143) 77.5 (55) 66.0 (95) 34.0 (49) 
Overweight %(n) 5.0 (14) 5.1 (11) 4.2 (3) 6.9 (10) 1.4 (2) 
Obese %(n) 2.1 (6) 2.3 (5) 1.4 (1) 2.8 (4) 1.4 (2) 
BMI Z-score$ -0.7±1.4 -0.7±1.4 -0.7±1.1 -0.6±1.6 -0.6±0.8 
Systolic BP (mmHg) 112±15 112±14 114±18 111±16ǂ 115±15 
Systolic BP Z-score$ -0.1±1.0 -0.04±1.1 -0.4±0.7 -0.2±1.0 -0.1±0.8 
Diastolic BP (mmHg) 72±11 72±11.0 72.7±11 72±11 74±10 
Diastolic BP Z-score$ 0.5±0.7 0.5±0.7 0.4±0.6 0.5±0.7 0.4±0.6 
Hypertension %(n)¥ 31.8 (91) 30.8 (66) 34.7 (25) 28.4 (41) 38.6 (27) 
Microalbuminuria %(n) 21.0 (31)a 20.5 (23)c 21.6 (8)e 20.4 (21)g 21.2 (7)i 
Nephropathy %(n) 4.7 (7)a 6.2 (7)c 0.0 (0)e 3.9 (4)g 3.0 (1)i 
Neuropathy %(n) 2.1 (5)b 2.3 (4)d 1.6 (1)f 1.8 (2)h 5.1 (3)j 
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Table 8. Clinical characteristics of one (V1) and two (V2) year follow up visits as compared 
to baseline and one-year data. 
 V1 V2 
 Baseline V1 Baseline V1 V2 
N 214 214 144 126 144 
Male % (n) 44.9 (96) 44.9 (96) 35.4 (51) 36.5 (46) 35.4 (51) 
Overall HbA1c (%) 11.3±2.7 10.2±2.6* 11.4±2.5 10.5±2.7 9.8±2.3◊* 
HbA1c >14% %(n) 32.7 (70) 12.2 (26) 30.6 (44) 12.7 (16)* 9.0 (13) 
HbA1c <8% %(n) 16.4 (35) 24.8 (53) 11.1 (16) 20.6 (26)* 23.6 (34) 
Glucose Monitor / wk 1.0±3.2 2.6±4.7* 1.7±4.4 2.5±4.4 6.6±6.9◊* 
Insulin units/kg 0.75±0.39 0.72±0.31 0.75±0.41 0.72±0.29 0.76±0.34 
Height (cm) 153.6±14.6 155.7±14.4 151.6±14.5 154.5±15.2 154.4±14.3 
Height Z-score$ -1.8±1.9 -1.8±1.9 -1.3±1.6 -1.8±1.8 -1.4±2.0 
Short Stature %(n)$ 55.4 (31) 52.5 (31) 39.4 (13) 40.7 (11) 37.8 (14) 
Weight (kg) 47.6±13.0 49.8±12.3 46.7±14.0 49.6±12.6 49.9±12.4 
BMI (kg/m2) 20.1±3.9 20.2±3.1 20.2±4.1 20.4±3.2 20.6±3.3 
Underweight %(n) 19.5 (40) 18.8 (38) 15.3 (19) 13.9 (15) 14.5 (18) 
Healthy Weight %(n) 66.8 (137) 70.7 (145) 66.9 (83) 72.2 (78) 75.0 (93) 
Overweight %(n) 4.9 (10) 6.8 (14) 6.4 (8) 7.4 (8) 8.9 (11) 
Obese %(n) 2.4 (5) 0.5 (1) 2.4 (3) 0.9 (1) 0.0 (0) 
BMI Z-score $ -0.7±1.4 -0.6±1.4 -0.4±1.4 -0.4±1.6 -0.4±1.1 
Systolic BP (mmHg) 112±14 118±16* 111±16 117±15* 118±19◊ 
Systolic BP Z-score$ -0.07±1.0 0.3±1.3* -0.3±0.9 0.7±1.3* 0.6±1.2◊ 
Diastolic BP (mmHg) 72±11 77±13* 72±11 76±13* 80±19◊* 
Diastolic BP Z-score$ 0.4±0.7 0.8±1.0* 0.5±0.7 0.8±1.0 1.4±1.0◊* 
Hypertension (130/80) %(n) ¥ 30.8 (66) 44.9 (96)* 27.8 (40) 38.8 (49) 40.3 (58) ◊ 
Hypertension (130/85) %(n) ¥ 16.4 (35) 34.6 (74)* 15.3 (22) 28.6 (36)* 31.3 (45) ◊ 
Hypertension (130/90) %(n) ¥ 15.4 (33) 28.5 (61)* 13.9(20) 23.0 (29) 25.7 (37) ◊ 
Hypertension (140/80) %(n) ¥ 29.4(63) 41.6 (89)* 27.8 (40) 35.7 (47) 39.6 (57) ◊ 
Hypertension (140/90) %(n) ¥ 10.7(23) 21.0 (45)* 10.4 (15) 14.3 (18) 25.0 (36) ◊* 
Microalbuminuria %(n) 20.5 (23)a 18.8 (12)c 20.4 (21)e 18.8 (8)g 19.6 (11)k 
Nephropathy %(n) 6.2 (7)a 7.8 (5)c 3.9 (4)e 4.6 (2)g 5.4 (3)k 
Neuropathy %(n) 2.3 (4)b 1.2 (1)d 1.8 (2)f 1.4 (1)h 0.0 (0)m 
 
 
* Indicates significance at α = 0.05 to year before 
◊ Indicates significance at α = 0.05 to two -years before 
 
a – 112 tested; b – 174 tested; c – 64 tested; d- 85 tested; e -103 tested; f -112 tested; g -44 tested; h -69 tested; k -56 
tested; m- 5 tested.  
 
$Indicates variable calculated for participants <18 years only  
 
¥Rates were calculated by adding those who were <18 years and >95th percentile with those who were >18 years and 
met the definition of hypertension based on BP  
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Table 9. Weight, BP, and HbA1c stratified by HbA1c control group for those >18 years 
who had full compliance. 
 Group 1 Group 2 Group 3 Group 4 Group 5 
 Low- 
Low 
Low- 
Increased 
Intermediate-
Decline 
High-
Decline 
High- 
High 
N 7 6 23 23 17 
Age at Baseline 20.4±1.8 20.2±1.5 20.4±1.6 20.8±1.5 19.6±2.0 
Baseline systolic BP (mmHg)  117±17 107±15 120±10 111±16 117±16 
Change BL-V1 6.7 24.0 0.2 6.3 4.6 
Change BL-V2 -1.43 18.17 1.04 11.74 8.06 
Baseline diastolic BP 
(mmHg) 
79±13 70±9 78±10 72±11 74±15 
Change BL-V1 -3.9 19.5$ 1.4◊ 3.4 3.2 
Change BL-V2 -2.3 9.8 -0.1 10.2 7.8 
Baseline weight (kg) 52.6±8.5 51.8±8.9 53.0±7.3 50.9±10.5 53.2±12.0 
Change BL-V1 0.6 5.2 0.6 3.6 0.1 
Change BL-V2 0.3 2.9 -0.2 2.7 2.9 
HbA1c (%)  6.5±1.1 8.6±1.1 10.7±1.6 12.9±1.3 13.5±1.0 
Change BL-V1 -0.3 0.6 -2.1 -2.4 0.1 
Change BL-V2 -0.2 1.2 -2.6 -3.2 -2.0 
 
*Indicates significantly different than Group 1 
◊Indicates significantly different than Group 2 
$Indicates significantly different than Group 3 
ǂ Indicates significantly different than Group 4 
¥ Indicates significantly different than Group 5 
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4.7 FIGURES 
A 
 
 
B 
 
Figure 2. Mean HbA1c for A) overall cohort (n=286) and B) those who had full compliance 
(n=125), and % of population at each time with HbA1c over 14% 
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Figure 3. HbA1c Groups, as identified by trajectory analysis. A total of five different 
groups were identified. Group 1 N=16 (8.0%), Group 2 N=17 (8.4%), Group 3 N=54 
(26.9%), Group 4 N=64 (31.8%), Group 5 N=50 (24.9%). 
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5.1 ABSTRACT 
 
AIMS: To determine prevalence and incidence estimates for documented (clinically recognized) 
cases of T1D in the Life For a Child Program (LFAC) (with onset <25 years) from six 
representative districts and the capital of Rwanda. 
METHODS: Cases were identified from the LFAC/ARD registry and visits to district hospitals. 
Denominators were calculated from district level population surveys.  Period prevalence data 
were collected from August 1, 2011 through July 31, 2012 and annual incidence rates were 
calculated, retrospectively, from 2004-2011. 95% confidence intervals were calculated using a 
Poisson distribution.  
RESULTS: The prevalence of known T1D in seven districts in Rwanda for ages 0-25 years was 
16.4 [14.6-18.4]/100,000 (0-15 years 4.7[3.5-6.1]/100,000), which was significantly lower than 
other regional reports. Prevalence was higher in females (18.5[15.8-21.4]/100,000) than males 
(14.1[11.8-16.7]/100,000; P = 0.01) and rates increased with age. The annual incidence rate 
ranged from 0.79 [0.4-1.4]/100,000 in 2004 to 2.7[2.0-3.6] /100,000 in 2010, a 4 fold increase. 
Incidence rates were higher in females than males. 
CONCLUSIONS: Our report of known cases of T1D shows lower rates in Rwanda than the US 
and the limited data from other African Countries. Incidence of recognized cases has increased 
over time, but has recently stabilized. However, the likelihood of missed cases due to death 
before diagnosis and misdiagnosis is high and therefore more definitive studies are needed. 
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5.2 INTRODUCTION 
 
Diabetes is an emerging problem in developing countries as they move through the 
epidemiological transition,1 and an estimated 18.7million people in sub-Saharan Africa will be 
affected by this disease by 2025.2  Type 1 diabetes is one of the most frequently seen non-
communicable disease (NCD) in children and should therefore be of great and increasing 
importance to public health officials,28 especially those in developing countries where access to 
insulin is low.89  
The global incidence of type 1 diabetes (T1D) is rising 3% annually, but geographic 
variations are known to occur.2,14,15  Unfortunately the true burden of this disease in Africa is not 
clear, as there are currently very few prevalence and incidence studies, especially of T1D in 
children and young adults.  Only three prevalence studies23,29,30  and five incidence 
surveys22,26,30–32 focus on the rates of T1D in this age range, and none have been within the last 
10 years. The prevalence rates in these countries range from 27/100,000 in Algeria (for ages 0-15 
years),30 to 95/100,000 in Sudan (for ages 7-14 years),23 and incidence rates range from 
1.5/100,000 in Tanzania (ages 0-19 years),31 to 10.1/100,000 in Sudan (ages 0-15 years),22 
highlighting the geographic variation in these rates. Additionally, these studies are from 
primarily Arab countries, and therefore provide little information on what rates may be in sub-
Saharan countries.  
There have been no such prevalence studies in the East African country of Rwanda, even 
though diabetes awareness and support has increased in recent years.118  Prevalence estimates 
that have been previously reported for Rwanda are extrapolated from studies from “similar” 
populations, but this is an imprecise process and most likely results in inaccurate rates of T1D in 
this country.2  
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In Rwanda, there are 41 district hospitals and 400 health centers with 0.05 physicians and 
0.42 nurses per 1,000 citizens.137 Specialized diabetes care and supplies are often not available. 
To address this gap, the International Diabetes Federation’s Life For a Child (LFAC) program, 
which is managed by the Australian Diabetes Council and HOPE worldwide, has been working 
since 2004 with the Association Rwandaise des Diabetiques (ARD) based in Kigali, by donating 
insulin, glucose monitoring supplies, education materials, and specialist training. Due to the 
overall limited access to insulin and prohibitively high prices, almost all diabetes cases are 
referred to the ARD for assistance. To receive assistance, children and adolescents must register 
with the LFAC program and have, at minimum, a yearly clinic evaluation. The ARD currently 
provides care to patients in Kigali and over half of the district hospitals in Rwanda.  
 To assist in closing this gap in prevalence and incidence knowledge, yet recognizing this 
report is not a full epidemiologic study, we present prevalence and incidence estimates for 
documented (clinically recognized) cases of T1D in youth and adolescents (<25 years) from six 
representative districts and the capital, Kigali City, of Rwanda. We also compare these rates to 
those of other countries from the region and the US. 
 
5.3 METHODS 
 
This report comprises data from a quality improvement project of the LFAC Program in 
collaboration with the ARD and GSPH. The University of Pittsburgh’s IRB determined that this 
project was exempt from review under the “Existing Data” category.  
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5.3.1 Study Population 
 
All participants of this project are registered in the Rwanda LFAC program which was started in 
2004. To be enrolled, participants must be citizens of Rwanda aged 25 years and younger 
needing assistance with obtaining insulin and other diabetes supplies. 
Selection of Districts  
The districts for this report were selected based on the following characteristics: ability to 
determine the size of the less than 26 year population, at least one district hospital where diabetes 
patients in that district would go for care that are currently being serviced by the ARD/LFAC 
program. Table 10 lists the selected districts and their hospitals.  
 
5.3.2 Case Ascertainment  
 
To identify cases, we used a combination of data extracted from the previously documented 
cases from the LFAC registry and data collected from new patients identified during our visits to 
the selected district hospitals. Age, date of birth, date of diagnosis and district of residence data 
were extracted from LFAC clinical charts. We believe we have covered all sources of insulin 
(primarily ARD and district hospitals) available to residents in those districts, excluding only 
those who obtained insulin from outside of the country, a practice we believe to be minimal. 
Unfortunately, hospitals do not keep official records on diagnosed cases of diabetes.  
Capture/recapture was not therefore possible as no other secondary source was identified. Yearly 
incidence estimates were based on self/family reported year of diagnosis and was not verifiable 
by hospital or other medical records. 
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Overlapping catchment  
To maximize case identification for each district we also visited hospitals from the neighboring 
districts. Only patients who physically lived in a district of interest (or lived there when they 
developed diabetes) were included for this project. Those who were identified as new cases, but 
did not live in a selected district, were added to the LFAC registry for further follow up. 
Population denominators  
In 2006 the Rwandan government underwent a district re-alignment and the country is now 
divided into 4 Provinces plus Kigali City, 30 Districts, 416 Sectors, 2,148 Cells, and 14,837 
Villages. To account for the new division of the population, a census/survey was initiated for 
each district in 2006.138  
The population of each District was reported for males, females, and overall, in 5 year 
age groups (ex. 0, 1-4, 5-9, 10–14, etc.). Therefore, we summed the 0-24 year age ranges, and 
then to account for those aged 25 years, we calculated the number of 25-29 year olds that were 
25 years using the percentage (23%) of 25-29 year olds that were 25 years in the Population 
Projection data.139  
No data were available for the Eastern Province (Rwamagana) from this survey; 
however, the local government soon after performed their own mini-census.140 Population data 
were also presented in age groups, however these were not as uniform (<1, 1-5, 6-13, and 14-35). 
To account for this, we summed the population counts for 0-13 years and then calculated the 
number of those who were 14-25 years from the 14-35 year age group, again using the 
appropriate percentage (46%) from the Population Projection data.139,140  
The calculated populations for 2006 were then used as a base for estimation the annual 
population for each year from 2004-2012, by assuming a 2.8% increase/decrease in population 
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for each subsequent/previous year, which is consistent with data from the Population Projection 
data and censuses.139  
 
5.3.3 Data Analysis   
 
All data were de-identified and entered into an electronic database. Period prevalence rates were 
calculated using identified cases that were under age 26 years between August 1, 2011 through 
July 31, 2012 and the mean population of years 2011 and 2012. Annual incidence rates were 
calculated using the number of self-reported diagnosed cases for each year (2000-2011) over the 
estimated population (<25 years) for that year. Cases from 2012 were not included in incidence 
calculations as data collection stopped as of July 2012. 95% confidence intervals for rates were 
calculated using a Poisson distribution. Demographic data (poverty rate, percent ever attended 
school, literacy rate, percent orphans, percent of homes with phones or radios, mean distance 
from health center, employment rates) for each district were also examined for associations with 
rates as possible mediators of within-country variation.141  
Mean and standard deviation of age at diagnosis were calculated for the overall 
population, and by district, by sex and by age group. Statistical comparisons of age at diagnosis 
were completed using t-tests and ANOVAs and chi square test comparisons were used to 
compare rates. A nominal p-value of P <0.05 was used to denote significance.  
The expected number of total type 1 diabetes patients was calculated by applying our 
estimated prevalence rate to the total population under 26 years (or 0-15 years) of age in 
Rwanda.  
The analysis for this paper was generated using SAS/STAT software, Version 9.3 of the 
SAS System for Windows, copyright © 2011 SAS Institute Inc.  
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 5.4 RESULTS 
 
5.4.1 Prevalence 
 
A total of 306 type 1 diabetes cases (under age 25 years) were identified in Rubavu (N=17), 
Gakenke (N=37), Rusizi (N=36), Huye (N=28), Rwamagana (N=21), Muhanga (N=41) and 
Kigali (N=126) from August 1, 2011 through July 31, 2012 (table 11). The mean overall age at 
diagnosis was 15.1±5.0 years, and ranged from 14.4±5.5 years in Muhanga to 16.5±5.5 in Rusizi. 
Prevalence estimates range from 7.5 [4.4-12.0]/100,000 in the North-Western District, Rubavu, 
to 22.1 [18.4-26.3]/100,000 in the Capital City of Kigali (table 11). Surprisingly, the Southern 
District of Muhanga also had a high prevalence (20.1 [14.4-27.2]/100,000) - close to that of the 
urban Kigali setting. The overall crude prevalence of type 1 diabetes in Rwanda for 0-25 years 
was thus estimated to be 16.4 [14.6-18.4]/100,000 (prevalence for 0-15 years was 4.7[3.5-
6.1]/100,000).  
Prevalence rates of type 1 diabetes were significantly higher in females (18.5[15.8-
21.4]/100,000) than males (14.1[11.8-16.7]/100,000) overall (p = 0.01) (table 11). The same 
trend was seen in each district except for Rubavu and Huye, which had higher rates for males. 
However, only the Gakenke District had a significant difference between the sexes (6.7 [3.1-
12.8]/100,000 males; 18.8[12.4-27.4] /100,000 females, p=0.003) (table 11). There were no 
significant differences (p=0.40) by sex in mean age at diagnosis overall or by district (data not 
shown).  
Prevalence rates increased with age (Supplemental table 3; Appendix B). The lowest 
prevalence was for the 1 – 4 year age group (0.6 [0.07-2.1]/100,000), while the highest was for 
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the 20 – 24 year age group (54.1 [46.0-63.1]/100,000). For Rusizi and Muhanga Districts, the 25-
year age group had the highest prevalence rate (Rusizi 84.8 [31.1-183.8]/100,000; Muhanga 79.3 
[25.4-185.5]/100,000), while Rubavu, Gakenke, Huye and Kigali City had the highest prevalence 
rates in the 20 – 24 year age group (Rubavu 33.3 [16.6-59.6]/100,000; Gakenke 43.4 [23.6-
72.9]/100,000; Huye 50.1 [28.0-82.5]/100,000; Kigali City 50.7 [39.0-64.9]/100,000). Only two 
cases were identified in the 1 – 4 age group, both from Kigali. In the Rwamagana district, only 
one case was identified in the 6 – 13 year age group (1.9 [0.04-10.5]/100,000), while the rest 
were in the 14 – 25 year age group (46.0 [27.6-72.0]/100,000) (data not shown). The only district 
demographic variable that was correlated with prevalence was the percent of those who ever 
attended school, but this was only of borderline significance (r=0.74, p=0.054).  
 
5.4.2 Incidence 
 
 A total of 260 registered cases of type 1 diabetes in youth under age 26 years were diagnosed 
from 2004 - 2011 in these selected districts (an additional n=93 cases were diagnosed prior to 
2004 or had unknown diagnosis dates). The annual incidence rate from 2004 to 2011 ranged 
from 0.79[0.4-1.4]/100,000 in 2004 to 2.7[2.0-3.6]/100,000 in 2010 (table 13), a 4 fold variation. 
Overall incidence rates were higher in females than males, except for 2005- 2007. However, the 
only significant sex differences were in 2010 (1.9 [1.1-3.1]/100,000 for males; 4.0 [2.7-
5.6]/100,000 for females, p=0.004) and 2011 (1.5 [0.8-2.6]/100,000 in males; 3.4 [2.2-
4.9]/100,000 for females, p=0.04) (table 13).  
Annual incidence rates increased over time, with the highest rates seen in the older age 
groups in more recent years (Supplemental Table 4; Appendix B). The highest incidence rate, 
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however, was seen in 2008 for those aged 15-19 years (8.1 [5.0-12.4]/100,000). Sample size was 
too small and our timeline too short to perform any age-period-cohort analyses at this time.  
 
5.5 DISCUSSION 
 
Our report of known cases of T1D in Rwanda suggests that the prevalence may be significantly 
lower in Rwanda than other African countries23,29,30 and less than a tenth of those for US African 
Americans.11 Though incidence of recognized cases has increased over time, it has recently 
stabilized at a rate similar to that reported in Tanzania in 1991. However, the likelihood of 
missed cases due to death before diagnosis and misdiagnosis is high, suggesting that our results 
are an underestimation of the true burden of this disease, while early mortality may also distort 
the yearly incidence estimates from the early years. 
 
5.5.1 Prevalence 
 
The overall crude prevalence rate of type 1 diabetes in Rwanda, for those aged 25 years or less, 
is 16.4 [14.6-18.4]/100,000. This rate ranged from 7.5/100,000 in the rural district of Rubavu to 
22.1/100,000 in Kigali City. These estimated rates are significantly lower than previous 
prevalence studies from sub-Saharan Africa and the US (table 12). The estimated prevalence 
rates in Rwanda are 11x lower than the Sudan, 3x lower than Nigeria, 6x lower than Algeria, 47x 
lower than African Americans aged 0-9 years, and 11x lower than African Americans aged 10-
19 years.11,23,29,30   
There were, however, some major differences between our study and the previous work 
that could have contributed to such differing prevalence rates. The studies from Sudan23  and 
76 
 
Nigeria29 were surveys given to schoolchildren asking about diabetes symptoms, not hospital 
surveys as ours was. While the prior studies allowed for identification of previously unknown 
cases, our methodology limited our cases to those who are clinically recognized and recorded in 
the LFAC registry. Using only the previously known cases in Sudan and Nigeria (excluding 
those newly identified by screening), the prevalence rates decreased to 78.8/100,000 and 
17.8/100,000 respectively.23,29 These rates are considerably closer to those in Rwanda – 
especially for Nigeria, which is only 1.8X higher when only considering previously known cases. 
This suggests that if we had the ability to screen for cases, our rates may be more similar to the 
previous reports. However, a school based survey also has weaknesses and biases and may not 
truly reflect national prevalence either, in countries with relatively low school attendance as in 
Rwanda. Attendance for a cohort of T1D patients in Rwanda has been reported to be 51.4%, 
suggesting that a school survey would have resulted in many missed cases as well.  
As with other studies from sub-Saharan Africa,23,28,29 the prevalence rate in Rwanda 
increased with age (Supplemental Table 3; Appendix B), and was higher in females (table 11). 
Similar sex differences (females 112/100,000; males 79/100,000) and increases in prevalence 
with age were seen in Sudan.23 Nigeria also had increasing rates with age (3/100,000 for those 
aged 5 – 9.99 years to 74/100,000 in those aged 14-17 years). However, the Nigeria study was 
different from ours as they saw an opposite pattern by sex, with males having a higher crude 
prevalence rate (38/100,000) than females (25/100,000).29 In Ethiopia, the mean age at diagnosis 
was 10.1 years (for those diagnosed before age 15 years), while in Sudan there was a bi-modal 
distribution with peaks at 14 and 7 years.28 Similarly, the mean age at diagnosis for a likewise 
aged population in our study was 11.1±3.9 years. Trends in age at diagnosis suggest that cases 
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are being detected at earlier ages than previously, possibly due to increased knowledge of 
diabetes and its symptoms.  
 
5.5.2 Incidence 
 
Our inability to screen for new cases and thus, dependence on clinically diagnosed cases, and our 
reliance on self-reported dates, and the high likelihood of missed cases because of pre or post 
diagnosis mortality may have affected our incidence rates. The annual estimated incidence rate 
ranged from 0.79[0.4-1.4]/100,000 in 2004 to 2.7[2.0-3.6] /100,000 in 2010. Comparing annual 
incidence rates of comparable age ranges to previously estimated incidence rates in Africa, the 
rates in Rwanda are lower than rates seen in Sudan, Tunisia, Libya and Algeria (table 
12).22,26,30,32 The incidence rates in 2011, however, are similar to the annual rate in Tanzania 
from 1979-1988.31  In comparison to US African American incidence rates, the rate in Rwanda 
for those 0-9 years is 1/63 of the rate in the US, and ¼ of the rate for those 10-19 years in the US 
(table 12).11  
Methodological differences may again have contributed to the lower incidence rates in 
Rwanda, as several of the prior studies were based on data from national or province registries 
(Algeria30, Tunisia26 and Libya32), while we were limited to only cases reported to the LFAC 
registry. However, the generalizability of the previous studies is also limited, as the majority of 
them were for only one city or a few districts in each country and they were located in 
predominantly urban areas. It is of particular note, that the country located the closest to Rwanda 
and with the most similar ethnic background– Tanzania – has the most similar incidence rate.  
Incidence rates also increased over time in our population - a pattern seen globally14,15  
and locally in sub-Saharan Africa [Sudan (5.9/100,000 in 1987 to 10.1/100,000 in 1992)22, Libya 
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(7.0/100,000 in 1981 to 7.8/100,000 in 1990)32, and Algeria (1.6/100,000 in 1981 to 8.1/100,000 
in 1998)30]. There were no significant changes over the 5-year study in Tunisia,26 and no time 
trends were reported for Tanzania.31 The only country that found a significant difference by sex 
was Libya, where females had a higher incidence (9.1/100,000) than males (6.6/100,000).32 In 
Tunisia incidence was lower in those aged 0-4 years (3.3/100,000) than those 10-14 years 
(11.5/100,000)26  and similar increases with age were seen in Tanzania (0.5/100,000 for 5-9 
years, 2.2/100,000 for 10-14 years, and 3.4/100,000 for 15-19 years).31  
Even though the hospitals in Rwanda are visited on a quarterly basis, due to high nurse 
turnover, long travel distances for patients, lack of scheduled consultations, and continued 
utilization of traditional healers, it is likely that some known cases are not recorded. A failure to 
diagnose diabetes in fatal cases further complicates the situation, for as shown in a previous 
study in Tanzania, 21 of 199 patients diagnosed with cerebral malaria actually had coma due to 
uncontrolled diabetes.142 Another study in Tanzania found that poor record keeping along with 
low awareness can lead to misdiagnosis of diabetes.143  Of 35 people who presented with diabetic 
ketoacidosis, no diabetes symptoms were recorded in over 40% of patients after their referral 
visit or a visit to the casualty department, and a correct diagnosis for only 13 of 33 (39.4%) 
people was made at the referral level, and only 37.1% (n=13/35) at the casualty department. It is 
highly likely that children with type 1 diabetes in Rwanda died before they were formally 
diagnosed. This is supported by the low incidence at younger ages in our population and the 
knowledge that until 2009, most district hospitals did not have a glucose meter available to them. 
Additionally, anecdotal reports have shown that some children/adolescents in Rwanda have an 
apparent ability to survive with high HbA1c levels and little to no insulin. It is therefore possible 
that there are undiagnosed children and adolescents living relatively normal lives. 
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Typology was not used to confirm diagnosis in any of these studies. While we believe 
that the majority of our cases are type 1 based on age at onset and their dependence on insulin, 
no formal antibody or c-peptide testing was available. Therefore, it is possible that some cases 
are actually type 2 or another form of diabetes. Additionally, diagnosis dates were often self-
reported and were sometimes unknown.  
While there are thus several reasons that case reporting may be low in Rwanda, district 
hospitals and the ARD are where diabetes patients will likely seek, or be directed for, care. Even 
those who can afford insulin are referred for clinical consultations and management guidance. 
Therefore, we believe that we have a fairly representative cohort of known T1D cases in Rwanda 
through use of routinely collected clinical data. Thus, it is possible that rates of type 1 diabetes in 
Rwanda are truly lower than expected. As previously mentioned, geographic variations in 
general have been identified14,15 which may span a range of 350 fold. The cause of this variation, 
derived from standardized registry data, is likely due to a combination of genetics, environment, 
and autoimmune factors.7 The previous African studies were in primarily Arab countries, which 
have been shown to have very high rates of diabetes.2,14,15  Since the percent of the Arab 
population in Rwandan is significantly lower than these countries, one might expect to see much 
lower rates of diabetes in Rwanda. This is further supported by the fact that the data from 
Rwanda most closely matches the data from Tanzania. Unfortunately, genetic testing was not 
available at this time, however, this should be considered in future studies as differences in the 
distribution of specific genes (ex. HLA-DQβ) have been implicated in the geographic variation in 
rates of type 1 diabetes.144  
Early exposure to cow’s milk has also been linked to the global differences in diabetes 
rates,145,146 as increased consumption of cow’s milk is associated with increased incidence of 
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type 1 diabetes.  In previous Demographic and Health Surveys, reported rates of exclusive 
breastfeeding are higher in Rwanda (91.4% for 0-1 months to 75.7% for 4-5 months) than, for 
example, Nigeria (2.1% for 0-1 months to 0.1% for 4-5 months) and Tanzania (55.2% for 0-1 
months to 8.0% for 4-5 months).147–149  Higher rates of prolonged breastfeeding in Rwanda 
might, therefore, translate to lower T1D risk.  
Despite the high probability of under-ascertainment and the non-formal epidemiologic 
analysis, this first survey of known T1D cases in youth and adolescents in Rwanda suggests that 
the local rates are lower than those of other African countries and US African Americans. 
Estimates of rates of this disease are needed to ensure that necessary support is being provided 
for these countries where insulin and other management necessities are hard to obtain. Based on 
our estimates, there may be 1,192 T1D cases under the age of 26 years in Rwanda (95% CI 
1,061-1,337) (239 under 15 years (95% CI 178-309)), each of which will require guidance and 
additional healthcare over their lifetime. However, due to the high likelihood of missed cases due 
to death before diagnosis and misdiagnosis, more definitive studies are needed to determine if 
our estimates are true or an underestimation due to missed cases.  
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5.6 TABLES 
 
Table 10. Table of selected districts and their associated hospitals. 
Region of Country District Hospitals in District 
North West Rubavu Gisenyi 
South West Rusizi Gihundwe, Mibirizi 
Central South Muhanga Kabgayi 
Far South Huye CHUB, Kabutare 
North Gakenke Nemba, Ruli 
East Rwamagana Rwamagana   
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 Table 11. Prevalence estimates (per 100,000) of clinically diagnosed type 1 diabetes in six 
districts and Kigali City, Rwanda, overall and by sex. 
 25 and under Cases 
Overall 
Prevalence 
(95% CI) 
Age at 
Diagnosis Males (95% CI) Females (95% CI) 
Rubavu 227,556 17 7.5 (4.4-12.0) 14.6±5.2 9.9 (5.0-17.8) 5.1 (1.9-11.1) 
Gakenke 277,103 37 13.4 (9.4-18.4) 15.3±4.2 6.7 (3.1-12.8) 18.8 (12.4-27.4)* 
Rusizi 266,724 36 13.5 (9.4-18.7) 16.5±5.5 11.0 (6.1-18.1) 16.1 (10.0-24.7) 
Huye 183,028 28 15.3 (10.2-22.1) 16.2±4.8 15.5 (8.4-26.0) 15.1 (8.2-25.3) 
Rwamagana 136,253 21 15.4 (9.5-23.6) 16.1±3.9 14.9 (7.1-27.4) 14.4 (6.9-26.6) 
Muhanga 204,092 41 20.1 (14.4-27.2) 14.4±5.5 16.0 (9.1-26.0) 24.0 (15.5-35.4) 
Kigali 569,587 126 22.1 (18.4-26.3) 14.5±5.1 19.3 (14.5-25.1) 24.9 (19.4-31.5) 
Total 1,864,342 306 16.4 (14.6-18.4) 15.1±5.0 14.1 (11.8-16.7) 18.5 (15.8-21.4)* 
* Denotes significantly different rate from males at p<0.05 
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Table 12. Prevalence and incidence estimates (per 100,000) of clinically diagnosed type 1 
diabetes in other countries compared to similarly aged Rwandan populations. 
  
Population (age) Study Year(s) 
Prevalence/ 
100,000 
Prevalence/ 
100,000 
In Rwanda 
(95% CI) 
Incidence/ 
100,000 
Incidence/ 
100,000 
In Rwanda (2011) 
(95% CI) 
Sudan  
(7 – 14 years) 1987 95 8.7 (6.3-11.8) - - 
Nigeria   
(5 – 17 years) 1990 33 10.0 (7.9-12.3) - - 
Algeria  
(0 – 15 years) 1979 - 1988 27 4.7 (3.5-6.1) 4.4 1.3 (0.7-2.2) 
US African 
Americans  
(0 – 9 years) 
2001 57 1.2 (0.6-2.3) 15.7 0.25 (0.03-0.9) 
US African 
Americans  
(10 – 19 years) 
2001 204 18.6 (15.2-22.5) 15.7 4.0 (2.6-6.1) 
Sudan  
(0 – 15 years) 1987 - 1990 - - 10.1 1.3 (0.7-2.2) 
Tunisia  
(0 – 19 years) 1990 - 1994 - - 6.95 1.8 (1.2-2.7) 
Libya  
(0 – 14 years) 1991 - 2000 - - 8.3 1.1 (0.6-2.0) 
Tanzania 
 (0 – 19 years) 1982 - 1991 - - 1.5 1.8 (1.2-2.7) 
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 Table 13. Annual incidence estimates (per 100,000) of clinically diagnosed type 1 diabetes, 
overall and by sex. 
Year New Cases Overall Rate (95% CI) Males (95% CI) Females (95% CI) 
2004 12 0.79 (0.4-1.4) 0.40 (0.08-1.2) 1.4 (0.6-2.6) 
2005 23 1.5 (0.9-2.2) 1.8 (1.0-3.0) 1.3 (0.6-2.5) 
2006 21 1.31 (0.8-2.0) 1.5 (0.8-2.6) 1.3 (0.6-2.4) 
2007 39 2.4 (1.7-3.2) 3.1 (2.0-4.5) 2.0 (1.1-3.3) 
2008 41 2.4 (1.7-3.3) 2.0 (1.2-3.2) 3.3 (2.1-4.8) 
2009 35 2.0 (1.4-2.8) 1.7 (1.0-2.9) 2.6 (1.6-4.1) 
2010 48 2.7 (2.0-3.6) 1.9 (1.1-3.1) 4.0 (2.7-5.6)* 
2011 41 2.2 (1.6-3.0) 1.5 (0.8-2.6) 3.4 (2.2-4.9)* 
* denotes significantly different rate from males at p<0.05 
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6.1 ABSTRACT 
 
AIMS: To report on the natural history of type 1 diabetes (T1D) for the first 500 cases in the 
Life For a Child (LFAC) program in Rwanda from 2004 – 2011. We present information on: 
program utilization, losses to follow up, complications, and mortality. 
METHODS: Participants were children and youth (diagnosed < 25 years) enrolled in the LFAC 
program before 2011. The number and frequency of visits and HbA1c testing was determined, 
while vital status was assessed as of Nov 1, 2011. Participants not recently seen or located were 
censored as of their last visit. Mortality rates were calculated for those with known vital status 
(n=361).  
RESULTS: Of the first 500 participants, 54.8% (n=270) were female and 45.2% (n=233) were 
male. Mean age at last visit and mean duration of diabetes were 20.5±4.7 years and 4.9±3.2 
years, respectively. Five-year survival was 93.8 while crude mortality was 6.9% (25/361; 95% 
CI, 4.5 – 10.2%) or 13.9/1,000 (95% CI 9.0-20.6/1,000) person years of diabetes, and was 
directly associated with age at diagnosis, and inversely to year of first visit, BMI, and monitoring 
frequency. However, since vital status is unknown for 134 participants, mortality could be as 
high as 32.1% or 40.2/1,000 person years of diabetes. 
CONCLUSIONS: These data demonstrate that mortality associated with T1D in Rwanda is 
similar to other African T1D populations, but higher than in developed countries. Delayed 
diagnosis of T1D may be contributing to this excess risk, but improvements in survival over time 
suggest that advancements are being made. Hypertension and early development of 
complications remain issues and need to be addressed. Additionally, we hope that by identifying 
and addressing barriers to care will lead to more thorough and timely care in the future. 
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6.2 INTRODUCTION 
 
Diabetes is a disease of growing concern in the developing world. An estimated 18.7 million 
people in Africa will be affected with diabetes by 2025,2 posing a potentially large problem for a 
population that already has limited access to healthcare. In order for a person with type 1 
diabetes (T1D) to survive and prevent complications, they need access to the necessary insulin 
and other glucose testing supplies.60 However, this necessary care is often not accessible in 
African populations.89 
 Help for these countries usually come in the form of external support. One such program 
is the Life For a Child (LFAC) program, which is managed by the International Diabetes 
Federation in conjunction with the Australian Diabetes Council and HOPE worldwide. LFAC’s 
mission is to support the provision of the best possible diabetes healthcare, given local 
circumstances, by supplying children and adolescents (< 25 years) in developing countries with 
the necessary insulin, and glucose testing supplies, and with HbA1c testing capability. The 
program also offers diabetes education, and advanced training and advice to both patients and 
local healthcare providers. The only requirement for those supported by the program is that they 
complete yearly LFAC clinical examinations that include, when possible, laboratory measures 
such as HbA1c and albumin/creatinine ratios.  
 The Association Rwandaise des Diabetiques (ARD) is a diabetes association located in 
Kigali City, Rwanda, that receives support from the LFAC program. The program there was 
initiated in 2004 with 25 children, and has expanded over the years and now provides support for 
over 630 children. HbA1c testing was first made available to the ARD by the University of 
Pittsburgh’s Graduate School of Public Health (GSPH) in the summer of 2009. 118 At that time, 
Quarterly Review clinical visits were also added to the regular practices of the ARD in order to 
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provide the staff access to more timely and representative information to enable them to make 
better and more informed adjustments to each patient’s management regimen.  
The short-term effects of these additions have been previously reported,118 but little is 
known concerning the natural progression of the disease in the members of the Rwanda LFAC 
program who have been enrolled since its inception. In order to provide the best care to their 
patients, it is also helpful to document participants that have been lost to follow up, so as to 
identify the barriers to receiving ARD care, or alternatively, to identify other care options in 
order to not duplicate efforts.  
The objective of this report is, therefore, to follow up to 8 years, the first 500 cases 
registered with the ARD from 2004 – 2011. We report on the natural history of T1D in Rwanda 
by presenting information on: utilization of the LFAC program (number and frequency of visits), 
losses to follow up, clinical characteristics, laboratory measures, complications, and mortality. 
 
6.3 METHODS 
 
This report comprises data from a quality improvement project of the LFAC Program in 
collaboration with the ARD and GSPH. The University of Pittsburgh’s IRB determined that this 
project was exempt from review under the “Existing Data” category.  
 
6.3.1 Study Population 
 
This report focuses on the first 500 children and youth enrolled in the LFAC program from 2004 
-2011. All participants of this program evaluation are registered participants of the Rwanda 
LFAC program. To be enrolled, participants must be citizens of Rwanda, aged 25 years or 
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younger, needing assistance with obtaining insulin and other diabetes supplies. Participants 
either sought care from the ARD or were referred by their healthcare provider.  
 
6.3.2 Data Collection 
 
Data were extracted from several different clinical forms. The first version of the LFAC annual 
form was used from 2005-2007. Data on sex, district, date of birth, diagnosis date, insulin 
regimen, glucose monitoring frequency, height, weight, systolic and diastolic blood pressure 
(BP) and frequency of reported yearly clinic visits were extracted from these forms. These LFAC 
forms were later condensed to a one-page form that has been used since 2008. The above data, 
along with tuning fork vibratory sensation and monofilament response tests, HbA1c, and 
albumin creatinine ratios (A/C ratios) were extracted from these forms. In 2009 use of a 
Quarterly Review form was also implemented to document interim visits and allow for 
additional data collection. Data on glucose monitoring frequency, insulin regimen, height, 
weight, systolic and diastolic BP, HbA1c and A/C ratio (when required) are recorded on these 
forms. Clinical data and vital status were extracted through December 2012. No data were 
collected for research purposes as all data reported are routinely recorded for clinical care 
purposes.  
 
6.3.3 Laboratory data 
 
Blood (finger prick) and urine (spot samples) were collected from each patient and processed on 
the Siemens DCA VantageTM  (which reports DCCT equivalent values) by University of 
Pittsburgh Graduate School of Public Health MPH students (who visit annually to assist in this 
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process) or ARD staff.  Data for HbA1c and A/C ratio were collected from these samples. The 
maximum HbA1c value for this machine is “>14 % (>130 mmol/mol),” so for data analysis 
purposes these results were reported as “14.1% (131 mmol/mol).” The inter-assay CV range for 
the HbA1c measures was from 2.1% to 3.8% during the data collection. 
 
6.3.4 Complication Assessment 
 
Neuropathy  
Neuropathy was defined as failure to feel a 10g monofilament (less than seven of ten correct 
responses) on the dorsum of the great toe and/or failure to feel vibration from a 120Hz turning 
fork placed on the dorsum of the great toe for 10 seconds. 123 
Microalbuminuria  
Microalbuminuria (MA) was defined as an albumin/creatinine (A/C) ratio of 30-299 mg/g in a 
spot urine sample, and overt nephropathy as an A/C ratio > 300 mg/g.  
Hypertension  
Hypertension was defined as having systolic BP ≥130 mmHg or diastolic BP ≥80 mmHg or a 
history of BP medication. The percent of those using BP medication, however, is low due to 
limited availability. 
 
6.3.5 Utilization Assessment  
 
All previous clinical records were analyzed to determine number and frequency of visits and 
HbA1c testing for each participant. We attempted to contact participants who had not recently 
(within the last 15 months i.e. since November 1, 2011) attended clinic either by phone, through 
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contacts at the local hospital, or by further investigation by a forensic epidemiologist (WR). 
Those who were not able to be located were deemed to be “lost to follow up” and were censored 
as of their last clinic visit.  
 
6.3.6 Vital Status Assessment 
 
Vital status was determined through clinic attendance, deaths reported to the ARD, hospital 
surveys, and additional follow up by a forensic epidemiologist. For crude mortality estimates, 
vital status was assessed as of November 1, 2011. A participant was considered to be alive if: 
he/she had attended clinic between November 1, 2011 and December 31, 2012, he/she was 
known to be alive by other contact with hospital staff or other participants, or he/she was 
determined to be alive after investigation by a forensic epidemiologist. Autopsies are not 
customary in Rwanda and death certificate data is likewise sparse. Thus, cause of death for this 
cohort were collected through contact with local hospitals and communications with families, but 
is limited in both quality and completeness.  
 
6.3.7 Data Analysis 
 
Descriptive statistics, including mean, standard deviation and frequencies were calculated for 
clinical and utilization data. ANOVA, two-sample and paired t-tests were used for comparisons 
of continuous variables, while X2 tests and Fisher’s Exact tests were for comparisons of 
categorical varibles. Tukey’s HSD test was used for any post-hoc pairwise comparisons. A p-
value of 0.05 with appropriate Bonferroni corrections was used to assess significance for 
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multiple comparisons. Time between visits was calculated assuming that a year had 365.25 days 
and a month had 30.44 days.  
An overall crude mortality rate was calculated for this cohort and cause-specific mortality 
was assessed where possible. Person years of diabetes were calculated for those with known vital 
status (n=361; total known person years of diabetes = 1,792 years). For those with unknown vital 
status, person years of diabetes were calculated as of last known follow up. Ninety-five percent 
confidence intervals were computed assuming a Poisson distribution. Kaplan-Meier curves were 
constructed to estimate cumulative survival and Log-rank tests were used to test for significant 
differences in survival between sub-groups. Cox regression models were used to examine 
differences in survival for all continuous demographic and clinic variables, as well as 
simultaneously adjusting for multiple variables (Model 1). The proportional hazards assumptions 
of the models were confirmed by testing time-dependent interaction variables. All hazard ratios 
(HRs) are reported per increase of 1 unit of measure.  
All statistical analysis was performed using SAS 9.2 (SAS Institute, Cary, NC) statistical 
software.  
 
6.4 RESULTS 
 
Of the first 500 LFAC participants, 54.8% (n=270) were female, 45.2% (n=233) were male, and 
seven were of unrecorded sex. Mean age at last visit (range June 2009 – December 2012) was 
20.5±4.7 years when mean duration of diabetes was 4.9±3.2 years. Only 18 (3.8%) of 
participants were diagnosed before age 5 years, while 186 (39.3%) were diagnosed between the 
ages of 15-19 years (figure 4). Twenty three percent (n=114) were 25 years or older as of 2012, 
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and will no longer be eligible for support from LFAC in the next year (n=39), or already are not 
(n=75). Fifty two (10.5%) were from the Eastern Province, 57 (11.5%) from the North, 84 
(16.9%) from West, 123 (24.8%) from Kigali, and 180 (36.3%) were from the South.  
Within the last year (since November 1, 2011), 319 (63.8%) of the first 500 participants, 
have been seen. Of the 181 (36.2%) who have not been seen, 33 are known to have died, 5 are 
known to be duplicate IDs, and 17 are known to be alive (figure 5). Forty of those not seen in the 
last year are 26 years or older and have, thus, aged out of the LFAC program. The most common 
reasons for non-attendance (from those we later contacted by phone or forensic epidemiologist) 
were: being away at boarding school (n=4), lack of transport (n=3), sick on day of visit (n=3), 
did not hear radio announcement (n=2), were pregnant (n=2), or no longer believed they had 
diabetes (n=2).  
 
6.4.1 Utilization 
 
Since the beginning of the LFAC program, 2,411 clinic visits have been recorded for the 
first 500 participants (271 during 2005-2008; 2,140 for 2009-2012). A total of 488 (97.6%) 
participants have attended at least one recorded clinic visit, while 12 were registered by name 
only (no demographic or clinical data). These participants received insulin, but never completed 
a full clinic visit. Visit frequency has increased over the last several years (n=23 in 2005; n=763 
in 2012), as has utilization of HbA1c testing (n=170 in 2009; n=629 in 2012). Seventy-seven 
(15.4%) participants had not attended a clinic visit since 2008 and 53 (10.6%) had only one visit 
from 2009-2012, while 370 (74.0%) had multiple visits from 2009-2012 (table 14). Those who 
had only one visit from 2009-2012 were significantly older than those with multiple visits and 
were diagnosed at an older age than participants with no visit (table 14). A larger percentage of 
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people from the North province attended multiple visits (84.2%) compared to those in other 
provinces, but this was not significantly different.  
 A total of 1,883 HbA1c tests have been recorded. Eighty two percent of the first 500 
(n=409) have had at least one HbA1c measurement, with a mean number of HbA1c tests per 
person of 4.6±2.5 (range 1-11). For those with multiple measurements, the mean time between 
tests was 6.1±4.6 months. Several (14.2%) tests were taken more frequently than the 
recommended 3 months, while other tests (26.1%) were taken more than 6 months apart.  
For those with multiple clinic visits, the average time between visits was 5.7±4.6 months. Some 
participants attended clinic multiple times within 3 months (17.8% of visits), while others waited 
longer than 6 months (24.7% of visits). The mean number of visits for each person was 5.1±2.8 
(range 1-12 visits). For those with multiple visits, mean HbA1c decreased significantly from 
11.1±2.7%, at first visit, to 9.5±2.5% at the most recent visit.  
At the most recent visit, 3.5% (n=2/57) had neuropathy, 10.1% (n=10/99) had 
nephropathy and 18.2% (n=18/99) had microalbuminuria (MA). These rates, however, were not 
significantly different from those seen at the first visit (neuropathy 2.2%, n=5; nephropathy 
5.3%, n=8; MA 18.5%, n=28, table 15). The prevalence of hypertension, however, increased 
significantly over time (39.0% to 46.6%). Similar results were seen for those who were tested at 
both time points (data not shown). At the most recent visit there were 8 new cases of MA, 7 new 
cases of nephropathy, 82 new cases of hypertension, and 1 new case of neuropathy. The 
estimates of annual incidence of complications were therefore, 6.4% (95% CI, 2.7-12.6) for MA, 
5.6% (95% CI, 2.2-11.5) for nephropathy, 10.5% (95% CI, 8.4-13.1) for hypertension, and 1.4% 
(95% CI, 0.03-7.8) for neuropathy.  
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6.4.2 Vital Status  
 
A total of 25 participants (n=15 (60.0%) females; n=10 (40.0%) males) were known to have died 
as of November 1, 2011. Thus, the known crude mortality for this cohort was 6.9% (25/361; 95% 
CI, 4.5 – 10.2%) or 13.9/1,000 person years of diabetes (95% CI 9.0-20.6/1,000). However, since 
an additional 8 participants died in 2012, a more accurate estimate of mortality is 9.1% (33/361; 
95% CI 6.3-12.8) or 18.1/1,000 person years of diabetes. The actual mortality rate, however, 
could be significantly different since vital status was unknown for 134 (26.8%) participants. In a 
worst-case scenario (assuming all had died), the mortality rate could be as high as 32.1% 
(159/495; 95% CI 27.0-37.1%) or 40.2/1,000 (95% CI 32.0-49.9/1,000) person years of diabetes; 
the most optimistic (assuming all are alive) would be 5.0% (25/495; 95% CI 3.3-7.4) or 
12.3/1,000 (95% CI 7.9-18.1/1,000) person years of diabetes.  
For those who died as of Nov 1, 2011, cause of death was unknown for 16 (64.0%), with 
hypoglycemia being the most common known cause (n=4, 16.0%), and renal failure accounting 
for 2 (8.0%) deaths. Single deaths resulted from gastroenteritis, pneumonia, pulmonary 
embolism, rectal hemorrhage/hepatitis, and hyperglycemia. Unfortunately, none of the reported 
deaths had an official autopsy. There were no significant differences in sex, province, age, age at 
diagnosis, or diabetes duration for those with and without known causes of death (data not 
shown).  
Mean age at time of death was 19.4±4.0 years (range 12-25 years), mean age at diagnosis 
for the deceased was 14.1±5.0 years (range 1-23 years) and mean diabetes duration was 4.5±3.5 
years (range 0-11 years), which were not significantly different from those alive (data not 
shown). Twenty-two of the deceased (88.0%) recorded having no glucose meter at home versus 
33% (n=99) of those who were seen in the last year (p<0.0001). Eleven of those who died had a 
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recorded HbA1c value (mean 9.8±2.0%; 83±22 mmol/mol), with a mean number of HbA1c 
measures of 2.1±2.0 per person. This was significantly fewer than those alive (p=0.002). On 
average, the deceased waited 7.6±5.9 months between readings, though this was not significantly 
different than those alive. There were no significant associations between Province and 
mortality, though the Western Province had the highest number of deaths (n=9).  
 Five-year survival for this cohort was 93.8% (85.1% worst-case scenario) and 10-year 
survival was 82.5% (66.2% worst-case scenario) (figure 6A). Survival curves were censored at 
10 years, as less than 20% of the original cohort remained after this duration. Survival did not 
differ significantly by sex, province, year of first visit, year of diagnosis, year of birth, diagnosis 
before or after 15 years of age, or complication status (data not shown). However, those whose 
first visit was in 2009 had significantly higher mortality rates than all subsequent years combined 
(p=0.03) (figure 6B).  
Results from Cox regression models are shown in table 16; only variables which were 
significant univariately were reported.  Age at diagnosis, BMI, monitoring frequency, number of 
injections and weight at last clinic visit were univariately (all negatively except for age at 
diagnosis) related to survival, as was weight at baseline (table 16). In a multivariable model, each 
additional year in age at diabetes diagnosis resulted in a 15% higher mortality risk (HR 1.15, 
95% CI 1.03-1.29) when also controlled for weight at baseline and monitoring frequency. With 
the same model, each additional unit of BMI, decreased the risk of death by 22% (HR 0.78, 95% 
CI 0.67-0.91), and each additional monitoring per week decreased risk by 7% (HR 0.93, 95% CI 
0.86-0.99).  
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 6.5 DISCUSSION 
 
In this study of the Natural History of the first 500 participants registered in the IDF’s LFAC 
program in Rwanda, we estimated the crude mortality to be 6.9% (or 13.9/1,000 person years of 
diabetes), and determined that mortality was directly associated with age at diabetes diagnosis, 
and inversely to year of first visit, weight at baseline, and monitoring frequency. However, since 
vital status is unknown for 134 participants, mortality could be as high as 32.1% (or 40.2/1,000 
person years of diabetes). For the 310 with multiple visits, we saw a significant decrease in 
HbA1c (11.1±2.7% to 9.5±2.5%) and consistent rates of complications except for hypertension, 
which saw a significant increase. The majority of participants were returning within the 
recommended time frame of 3-6 months for clinic visits (57.5%) and HbA1c tests (59.7%).  
Our estimated mortality and survival rates (5-year survival=93.8-85.1%; 10 year 
survival=82.5-66.2%) are consistent with previous studies from other youth cohorts with T1D in 
Africa (table 22). They are similar to those in Ethiopia (mortality=15.5/1,000 person years)56 and 
South Africa (10-year survival=84%),65 though survival in Tanzania was significantly poorer (5-
year survival 71-60%).42 Studies of mortality in youth with T1D from developed countries, 
however, reported much lower rates than Rwanda and ranged from 0.06% in the UK 150 to 
6.1/1,000 person years of diabetes in Lithuania.151–153 A 30-year mortality report from the US 
showed that African Americans with T1D had a mortality rate of 15.8/1,000 person years of 
diabetes,87 which was higher than in Rwanda, but within our worst-case scenario range. Follow 
up time for several of these studies, however, was considerably longer than ours, so any direct 
comparisons would likely be limited.  
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Another mortality study that estimated life expectancy for newly diagnosed T1D patients 
in Mozambique and Zambia identified associations between life expectancy, location (urban vs 
rural) and diagnosis age.89 The shortest life expectancy was seen in rural Mozambique, where 
those diagnosed before age 15 years had only a mean expectancy of 0.6 years. The longest life 
expectancy was seen in the urban capital city of Zambia, where life expectancy was on average 
27.0 years. In Rwanda, however, we found no relationship between location and mortality. 
Although a somewhat higher percentage of those who died were from the Western province, the 
difference in survival was not significant.  The observed higher rate in the West was not likely 
due to worse care, but rather to better reporting, as the local staff has been exceptionally 
consistent with regular follow-up and reporting.  
While we found no difference in survival by diagnosis before or after 15 years of age, we 
did find differences with the continuous variable for age at diagnosis. Each additional year of age 
at diagnosis conferred a higher risk of mortality. Though this seems to contradict the results from 
Mozambique and Zambia (which reported longer life expectancy with older age at diagnosis), we 
believe that the increased risk of mortality in Rwanda with advanced age at diagnosis may 
partially be due to the effects of surviving for several years with undiagnosed diabetes. We 
hypothesize that by the time these participants are formally diagnosed, they are in especially 
poor condition and therefore at a higher risk of complications and death. Our findings that higher 
BMI and weight at baseline is protective, however, support this hypothesis, as we have 
previously found that those in worse control have lower weight consistent with lack of insulin 
and dehydration/hypovolemia.118 Mortality data from T1D in Estonia, Lithuania, and Finland 
also found a similar association between age at diagnosis and mortality (14%), consistent with 
our findings.151  
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Though we have limited follow up data to document temporal improvements in survival, 
the data so far are encouraging, and suggest that as awareness of and care for diabetes increases, 
so does survival.  This is consistent with the general improvement of life expectancy in T1D in 
developed countries.154  
The majority of those who were deceased previously reported not having a meter at 
home. Having no meter makes it very hard to regulate diabetes control and greatly complicates 
the process of adjusting insulin properly. Thus, it is not unexpected that the main known cause of 
death was hypoglycemia. This finding is also consistent with many others that indicate that 
within the first 10 years, cause of death is primarily due to acute causes.87 Sixteen percent of 
deaths (n=4) in our cohort were due to hypoglycemia, which is considerably higher than rates 
seen in Dar es Salaam (5%; n=2 with 5 years follow up)58  and Ethiopia (7.1% with 15 years 
duration). 56 These results underscore the importance of ensuring that all LFAC members have 
access to glucose meters and strips and appropriate education, especially in light of the high rate 
of food insecurity in this population. It is, however, very likely that several of the deaths due to 
unknown causes were from DKA, but were not properly identified as such. Therefore, we cannot 
say that hypoglycemia is the most common cause of death, as over half were due to unknown 
causes.   
Although 18.8% of our initial cohort has been lost to follow up, similar results were 
reported from the other mortality studies in Africa. In Tanzania 11% of the cohort had not been 
heard from for 3+ years58 while even higher percentages were lost to follow-up in Ethiopia 
(33.4%)56 and Soweto (27.3%).65,155 They each reported difficulties due to a country-wide lack of 
official home addresses, incorrect contact information, and movement from the area, which were 
also major barriers in our study. The most frequently provided reasons for non-attendance in 
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Rwanda were: being away at school, lack of transport, and no knowledge of the visit dates. 
Radio announcements have been the preferred method of announcing clinic visit dates, but this 
requires that the participants have access to a radio. Unfortunately at this time, we are unable to 
provide services through schools, but are working on developing awareness programs within 
schools, working with local nurses to help provide for transport, and developing local support 
groups of children that provide phone chains and social incentives to attend visits. It is also 
unclear at this time as to whether children are receiving care elsewhere between visits. However, 
due to the lack of insulin and high prices of diabetes care, we believe this is unlikely. 
The high turnover rate of the nursing (and medical) staff at the district hospitals has also 
limited our follow up of LFAC participants, and many of the new nurses have never seen the 
patients we are trying to locate. The support groups have worked towards limiting the impact of 
the nurse turnover, and even in locations where the nursing staff has been stable, the children are 
usually the best source of information on missing members.  
Over the course of the LFAC program, several individuals have come back to the clinic 
years after their last insulin dose (n=21 after 2 years; n=2 after 3 years). This phenomenon has 
also been recorded in children with T1D in Ethiopia who had interrupted insulin supplies (for 
9±12 weeks; range 1-78 weeks), of whom only 4% developed any DKA. 156 While these 
individuals were in poor condition when they returned, the fact that they survived so long 
without any exogenous insulin suggests that there may be a different type of diabetes (with some 
significant residual beta cell function) present in this population. This would be consistent with 
results from other studies from Ethiopia, suggesting the previously recognized “Malnutrition-
related Diabetes” (MRDM) should be re-considered in Africa.47,157,158 
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The prevalence of neuropathy in our cohort (3.6%) was lower than those in other African 
countries (Addis Ababa, Ethiopia =7.9%;56 and Soweto, South Africa =35.3%).65 Also, the 
prevalence of microalbuminuria (18.2%) was lower than in Soweto, South Africa (26.3%; mean 
duration 13.6 years; Dipstick test)155 and Tanzania (29.3%; mean age of 21 years and duration of 
3 years; MICROTEX).76 The annual incidence of MA was significantly higher than that from 
Denmark (1.9%; 12.2 years duration)129 and other developed countries (Australia 4.6/1,000 
person years; 6.7 years duration).130 A direct comparison of complication rates is limited due to 
the differing means of assessment.  However, as duration of diabetes was significantly shorter in 
our population than the other African studies, this raises concern that the rates of 
microalbuminuria in our population are indeed higher.  
The prevalence of hypertension increased over time and was also elevated in this 
population in comparison to rates reported in US African Americans (AfAm=9.8%, Rwanda 
46.6%).11  We have previously postulated that this is due to the poorer glucose control in 
Rwanda, as those whose control worsened overtime saw more dramatic increases in BP over 
time than those who were in good control or who saw improved control (Marshall, Paper 1). 
However, BP was still higher in those who saw improvements in glucose control than those who 
had constant tight control, suggesting a residual effect. Additional studies from sub-Saharan 
Africa have shown that rates of hypertension for those under age 45 are higher than the US and 
the UK (SSA=10.7%, UK=5.6%, US=8.2%), and that it may be due to excess salt in food 
preparation.136 This increase in hypertension prevalence, and the positive association between 
hypertension and microalbuminuria, highlights the need for improved BP control in this cohort 
for complication and mortality prevention.  
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The key limitation for this study was our use of routinely collected clinic data instead of 
study data. This meant we were restricted to the data collected on the LFAC forms and had to 
rely on unconfirmed dates of birth, diagnosis and death, as well as self-reported data for 
monitoring frequency and insulin dosage. Complication assessment was also limited due to 
logistical issues (eg. microalbuminuria testing supplies). Mortality data was also limited due to 
lack of autopsy data and a formal national death index. This, therefore, led to the wide range of 
possible mortality rates and highlights the importance of establishing better follow up protocols 
for the future. 
The major strengths of this study are that our cohort consists of 500 participants, which is 
the largest cohort for which mortality of T1D in sub-Saharan Africa has been reported. In 
addition we have compiled a large amount of temporal data that spans eight years (2004-2012). 
This is also the first follow-up and mortality report for diabetic youth and adolescents in 
Rwanda.  
In summary, these data demonstrate that mortality rates for those with T1D in Rwanda 
are similar to other African T1D populations, but higher than those in developed countries. 
Delayed diagnosis of T1D may be driving the increased risk seen in those diagnosed at an older 
age, thus highlighting the importance for increased awareness and timely diagnosis. However, 
the improvements in survival since 2009 are encouraging. Utilization of the LFAC program in 
Rwanda has increased significantly since its inception in 2004, and HbA1c has decreased 
considerably as a cumulative result of its efforts. Hypertension, however, remains an issue in this 
population and is increasing overtime. This needs to be further investigated and addressed 
appropriately. Although several of our participants have died and more have been lost to follow-
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up, we hope that by recognizing and addressing the identified barriers, more thorough and timely 
care will be available in the future.  
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6.6 TABLES 
 
Table 14. Characteristics of participants with multiple clinic visits from 2009-2012, those 
who only had one clinic visit, and those who have no recorded clinic visits. 
 Visit Status 
 Multiple-visits One Visit No visit$ 
N 370 53 65 
Age at Diagnosis (years) 15.4±4.9 16.8±5.1 12.7±5.8* 
Male  (column% (n)) 43.0 (156) 43.4 (23) 44.6 (29) 
Age in 2012 (years) 20.8±4.6 22.3±5.0 20.7±4.9 
Province (row% (n))    
     East 73.1 (38) 7.7 (4) 19.2 (10) 
     Kigali City 71.5 (88) 9.7 (12) 18.7 (23) 
     North 84.2 (48) 8.8 (5) 7.0 (4) 
     West 76.2 (64) 15.5 (13) 8.3 (7) 
     South 72.2 (130) 10.6 (19) 17.2 (31) 
Year of First Visit % (n)    
     2009 159 (87.4) 23 (12.6) - 
     2010 126 (87.5) 18 (12.5) - 
     2011 82 (88.2) 11 (11.8) - 
     2012 3 (75.0)  1 (25.0) - 
* Significantly different from those with multi-visits and one visit  
$ Excludes an additional 12 with no visit, but with no demographic or clinical data reported 
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Table 15. Clinic data from the first and most recent clinic visit for participants who had 
multiple visits between 2008-2012.  
 
 First Clinic Visit Most Recent Clinic Visit 
Time Between Visits (months)  26.6±10.8 
Age (years)  18.6±4.5 20.6±4.5* 
Male %(n) 43.0 (156)  
Age at Diagnosis (years) 15.4±4.9  
Duration of diabetes (years)  3.0±2.9 5.0±3.1* 
Glucose Monitoring (per week)  1.3±3.9 8.0±8.0* 
HbA1c (mmol/mol) 98±30 80±28* 
HbA1c (%) 11.1±2.7 9.5±2.5* 
     <8.0% 17.0 (55) 28.9 (96)* 
     8-11.9% 40.9 (132) 51.5 (171)* 
     12-14% 14.6 (47) 9.6 (32)* 
     >14% 27.6 (89) 9.6 (32)* 
Insulin Injections (per day) 1.8±0.6 2.0±0.5* 
Units of Insulin (per day) 32.4±15.7 37.8±15.4* 
Units of insulin per kilogram  0.70±0.37 0.75±0.30 
Weight (kg) 47.6±12.6 51.6±11.6* 
Height (cm) 154.5±14.3 156.7±12.8* 
BMI (kg/m2) 19.8±3.5 20.7±3.2* 
Systolic BP (mmHg) 113±16 120±17* 
Diastolic BP (mmHg) 73±12 79±12* 
Neuropathy %(n) 2.2 (5) a 3.5 (2) b 
Microalbuminuria %(n) 18.5 (28) c 18.2 (18) d 
Nephropathy %(n) 5.3 (8)c 10.1 (10)d 
Hypertension %(n) 39.0 (141)f 46.6 (167)g* 
* Significantly different from first clinic visit (p<0.05) 
a n tested=230 
b n tested=57 
c n tested=151 
d n tested=99 
f n tested=362 
g n tested=358 
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Table 16. Cox regression models for mortality. HRs and their associated 95% CIs are 
reported. 
 Variables that 
were univariately 
significant 
Model I 
 HR  
(95% CI) 
p HR  
(95% CI) 
P 
Age at Diagnosis 
(years) 
1.12 
(1.01-1.2) 0.01 
1.15  
(1.03-1.29) 0.01 
BMI at most recent 
visit  
0.80 
(0.70-0.92) 0.002 
0.78 
(0.67-0.91) 0.001 
Monitoring Frequency 
at most recent visit 
 (times per week)  
0.91 
(0.85-0.97) 0.006 
0.93 
(0.86-0.99) 0.046 
Number of injections 
at most recent visit 
(per day) 
0.50 
(0.26-0.98) 0.03 N/S - 
Weight at baseline 
(kg) 
0.96 
(0.93-0.99) 0.02 N/S - 
Weight at most recent 
visit (kg) 
0.94 
(0.91-0.97) 0.002 N/S - 
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6.7 FIGURES 
 
 
Figure 4. Histogram of diagnosis age for the first 500 LFAC program participants, by sex. 
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Figure 5. Flow chart outlining participant follow-up and vital status. 
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Figure 6. Survival by Sex (A) and Year of First Clinic visit (2009 vs all subsequent 
years) (B). 
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 7.0 DISCUSSION 
 
7.1 SUMMARY AND CONCLUSIONS 
These data represent the first attempt to describe the magnitude (incidence/prevalence) and 
natural history of type 1 diabetes (T1D) in Rwandan youth. This dissertation also assesses the 
impacts of the Life For a Child program on this growing issue in this economically challenged 
country. Though we were unable to undertake a true epidemiological study with screening for of 
the incident and prevalent cases of T1D in Rwanda, our data still suggest that the rates in 
Rwanda are relatively low as compared to other sub-Saharan African countries31 and African-
Arabic countries.22,23,26,29,30,32 Incidence of recognized T1D has, however, increased 4-fold over 
the last several years, portending a larger Public Health issue in the near future. We now know 
that additional efforts are needed to ensure proper and timely diagnosis, as it appears very likely 
that many cases are dying before diagnosis, or are being misdiagnosed, especially in those less 
than 5 years of age. 
This study was the first to describe the natural history of T1D in Rwanda and identified 
hypoglycemia as a major cause of death. While the mortality rate in Rwanda was similar to 
several other African countries [Ethiopia56, Tanzania58, South Africa155], it was significantly 
higher than rates seen in developed countries.87,150–153 Rates of complications, specifically 
hypertension and microalbuminuria, were higher in Rwanda than other African T1D youth 
cohorts56,65,76 and suggested an earlier development of complications. These findings raise 
concerns for the future health of this population.  
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 In the face of these negative outcomes, we did, however, demonstrate that glycemic 
control could be improved in a country with limited resources, and confirmed increased glucose 
monitoring as a potential intervention point. Application of trajectory analysis to our data 
allowed us to identify glycemic control sub-groups and future use of this technique could lead to 
more targeted interventions based on current control.  
Though these results are promising, it is clear that further research and interventions are 
still needed to adequately address T1D in Rwanda. Additional efforts are needed to address the 
issues of balancing glycemic control and fear of hypoglycemia, especially in this population 
where food insecurity is common. Outreach to other regional hospitals and education for 
patients, their caregivers and other community members needs to be improved to ensure this 
disease is properly addressed. We must also take steps to further improve prevention, diagnosis, 
and treatment of complications of T1D. Finally, additional strides need to be taken towards 
making this program more sustainable long-term, so that proper care may be available well into 
the future.  
7.2 GENERAL FINDINGS 
 
7.2.1 Context of Data Collection 
 
The Life For a Child (LFAC) program in Rwanda started in 2004 at the Association Rwandaise 
des Diabetiques (ARD) with only 25 children. While the program focused on providing support 
to allow for the best possible clinical management for children with T1D, an important early goal 
was ensuring that every district hospital had access to a glucometer. Prior to this initiative, 
almost no hospitals in Rwanda had access to meters, thus severely limiting their ability to 
diagnose diabetes. Parallel to this movement, the World Diabetes Foundation provided monetary 
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support for education sessions for doctors and nurses on how to properly recognize diabetes 
cases as well as provide proper management. Since doctors in Rwanda reportedly receive less 
than 32 hours of training on the endocrine system as a whole, yielding very little time to address 
diabetes, these training sessions were critically needed.  
 In 2007, Dr. Trevor Orchard, from the University of Pittsburgh’s Graduate School of 
Public Health (GSPH), voluntarily became involved with the Rwanda LFAC program. This 
program is primarily focused on assisting local health care providers - particularly diabetes 
associations - provide insulin, diabetes care and education to youth with diabetes. Dr. Orchard’s, 
and therefore GSPH’s, involvement was thus concentrated first and foremost on addressing the 
urgent humanitarian needs of the diabetic youth and the public health concerns, with research 
being only a secondary aim. Early in this process Dr. Orchard worked early with Dr. Graham 
Ogle (the LFAC General Manager) in revising and standardizing the LFAC data collection 
protocol and forms. After an initial assessment of the diabetes care available in Rwanda (2008) – 
taking into account the current lack of knowledge, awareness, and treatment options of diabetes - 
Dr. Orchard made the executive decision to build on the current system of collecting clinical data 
for the LFAC program, and to not complicate the situation and divert resources from the 
humanitarian need by collecting any research data. This approach also concentrated the limited 
resources on care and education.  
 Though this decision allowed for a smooth transition and a continuation of aid and 
routinely collected data, that did not require consenting, it also negated the benefit afforded by 
“formal” research which collects high quality data. Thus, dates (birth, diagnosis, and death) are 
not fully confirmed as is also true for self-reported data for monitoring and treatment. Indeed, on 
the initial 2008 assessment, it was found that while the ARD did a heroic job in the face of little 
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resources, basic concepts of patient care (eg. maintaining individual patient charts) were not in 
operation. The on-going nature of this project evaluation, in combination with incomplete data 
due to loss to follow-up, means that no single true intervention could be examined, as 
improvements in care and education were staggered as resources permitted, and clinic data for 
some participants was scarce, if available at all.  
 Thus, the data available for this doctoral thesis, much of which I personally collected 
during seven visits to Rwanda, is limited to the routine clinical data available in a very 
impoverished country (Rwanda’s GDP (nominal) is ranked number 141 out of 190 by the World 
Bank, and 44.9% live in poverty; average life expectancy=58.8 years)114,141 with limited 
resources where such basic records as birth and death certificates are not routinely available, 
indeed many individuals do not know even their birth date. The impacts of the 1994 genocide are 
also still felt, as several participants are orphans and are left to care for themselves and 
sometimes for their siblings. This places an additional stress on the patient, and often results in 
extreme poverty. 
 Though the decision to use clinic data rather than study data had its drawbacks, it allowed 
us to focus primarily on providing care to participants and afforded us a large amount of data for 
a large cohort of T1D patients, which may not have been possible with a formal research project. 
The major weaknesses we saw in our data (uncertainty about dates, limited mortality data, self-
reported data) would still have been present if we had undertaken a formal research study, as 
there exist no records of these dates and no formal way of eliminating self-report of some data 
points. Therefore, we believe the chosen path provided us with the best possible and most 
generalizable dataset for this population, while allowing us to focus on care and keep costs low.  
114 
 
That being said, the LFAC program has since expanded in scope, quality, and magnitude. 
As of December 2012, the LFAC registry included 820 children and adolescents from over 26 
district hospitals. Although several have already aged out from the official program, many 
remain in contact with the ARD staff for management advice. Data collection frequency has 
increased from annually to quarterly, and official protocols for data collection and reporting have 
been adopted. Tests for glycemic control (HbA1c) and proteinuria (albumin/creatinine ratio; A/C 
ratio) are now available, and efforts to introduce retinopathy screenings are underway. Education 
sessions are now regularly held for both caregivers and patients, and support groups are being 
formed.  
 This partnership among the LFAC, the ARD, and GSPH, has resulted in over five years 
of directed diabetes management and data collection – data which we were then able to use to 
describe the current magnitude and burden of T1D in Rwandan children and adolescents, and to 
document improvements in glycemic control. This report, though limited in several aspects, is 
the first report on these items, and has the potential to impact future diabetes care in Rwanda as 
well as other developing countries. 
 
7.2.2 Variations in T1D incidence/prevalence 
 
Global variations in rates of T1D have been previously described and may span a 350-fold 
difference.14,15 Even within Africa, prevalence and incidence rates of childhood T1D have ranged 
from a reported prevalence rate of 27/100,000 in Algeria30 to 95/100,000 in Sudan23 and an 
incidence of 1.5/100,000 in Tanzania31 to 10.1/100,000 in Sudan.22  
Our study found that the prevalence of clinically recognized T1D in Rwanda was 
significantly lower than previous reports from Africa23,29,30 and was less than a tenth of those for 
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African Americans.11 The incidence rate of T1D was lower in Rwanda than the highly Arabic 
countries of Sudan, Tunisia, Libya and Algeria22,26,30,32, but was similar to those in Tanzania31, 
highlighting potential ethnic variations in rates of T1D. 
In Rwanda, we also noted a 4-fold increase in the incidence over the last 7 years, with 
stabilization within the last 5 years. Temporal trends in incidence of T1D have been previously 
noted. The global incidence of T1D is estimated to rise 3.0% annually.15 In Africa, incidence 
rates also increased over time in Sudan,22 Libya,32 and Algeria,30 but no changes were seen in 
Tunisia26 or Tanzania.31 Due to the potential for missed cases (under-diagnosis, death before 
diagnosis, or misdiagnosis) and the recent increased awareness of diabetes in Rwanda, it is 
impossible to determine if this is a true increase or an artifact, especially with the recent 
stabilization. It is of additional interest that during this time period, though overall incidence has 
stabilized, we have noticed a possible time*gender interaction as incidence for males has 
decreased and increased for females. Though this was not significant, it warrants further follow 
up.  
Our report from Rwanda showed an overall higher prevalence in females (18.5/100,000) 
than males (14.1/100,000), and a similar pattern in incidence rate (females=3.4/100,000; 
males=1.5/100,000). On the whole, there are no significant global sex differences in incidence or 
prevalence of T1D.14,15 However, several studies from Africa have shown these rates differ by 
sex. Sex differences in prevalence were seen in Sudan (females higher than males) and Nigeria 
(males higher than females),23,29 but not in Algeria,30 while a difference in incidence by sex was 
seen in Libya (females higher than males).32 While the gender results from Rwanda were 
different than the overall global results and several countries in Africa, they were similar to some 
data from the US. In the US, no sex differences have been seen for the overall population,159 but 
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for African Americans aged 10-14 years, the incidence (females=26.1/100,000; 
males=16.7/100,000) and prevalence (females=210/100,000; males=150/100,000) of T1D was 
higher in females than males.11 Furthermore, previous studies in the US Virgin Islands and the 
US, non-hispanic blacks have not seen a pubertal rise in incidence for males in blacks.11,160 
While we did not note this pubertal sex difference, it is clear that the excess female cases in 
Rwanda is primarily due to the higher rate of females diagnosed between the ages of 14-18 
years, which might reflect a similar phenomenon.  
There was a notable positive age trend in rates in Rwanda. Prevalence ranged from 
0.6/100,000 for those 1-4 years, to 54.1/100,000 for those aged 20-24 years, and incidence in 
2011 increased from 0.0/100,000 for ages 1-4 years to 5.2/100,000 for those 20-24 years. Global 
age trends in rates have been reported.15 Incidence rates by age group are significantly different 
for most countries, with incidence increasing with age. In the US, the highest incidence rates of 
T1D were seen in those aged 10-14 years (25.9/100,000),12 and prevalence was higher for those 
aged 10-19 years (228/100,000) than those 0-9 years (76/100,000).159 Similar patterns by age 
were seen for prevalence of T1D in African American youth (0-9 years=57/100,000; 10-19 years 
= 204/100,000), though no significant differences were found for incidence.11 Similar patterns 
were seen in Africa, where prevalence increased with age in Sudan and Nigeria,23,29 and 
incidence increased with age in Tunisia and Tanzania.26,31  
There are several theories as to what is causing this global variation in incidence and 
prevalence of T1D. One theory is based on unreliable case ascertainment. The thought is that 
early reports missed cases either due to under-diagnosis or misdiagnosis, and that as time has 
passed, awareness of T1D has improved and thus diagnosis and reporting have improved as well. 
We believe this may be a possible reason for the previously low rate of recorded cases under the 
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age of 5 years in Rwanda, and the recent increases in prevalence and incidence. However, the 
majority (>80%) of the studies used for global comparisons make use of the capture-recapture 
method, and therefore the impacts of this upon their noted global variation were likely limited.15 
Unfortunately, due to the short time period of data collection that was covered in the global 
comparisons (~5 years), it is impossible to tease out the impacts of data collection/under-
ascertainment from other possible causes of variation. 
Differences in T1D incidence/prevalence rates have also been ascribed to genes, 
environment, viral infections, dietary exposures, behavioral stressors, changes in hygiene, and 
exposure to childhood infections.7,144–146,161,162 Since these increases in incidence of T1D have 
been seen over such short time periods (~5-10 years) it is highly unlikely that the changes can be 
completely due to genetic shifts in susceptibility, thus suggesting that further work be done to 
examine environmental impacts or gene-environment interactions. Changes in BMI have also 
been implicated, as an association between early obesity and increased T1D has been seen,163 
though it is unlikely that this is a driving factor in Rwanda, as no significant changes in BMI 
have been seen and less than 10% of our cohort was overweight or obese. Psychological stress 
has also been linked to diabetes-associated auto-antibodies in children.164 While this may not be 
especially relevant globally, it could be an issue of interest in Rwanda, considering the on-going 
regional political unrest and the lingering impacts of the 1994 genocide.  
Early exposure to cow’s milk may be another potentially important factor to consider 
when comparing rates of T1D in Rwanda to other countries. In previous reports, rates of 
exclusive breastfeeding were higher in Rwanda147 (91.4% for 0-1 months to 75.7% for 4-5 
months) than Nigeria148 (2.1% for 0-1 months to 0.1% for 4-5 months) and Tanzania149 (55.2% 
for 0-1 months to 8.0% for 4-5 months). This lower rate of early exposure to cow’s milk may 
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contribute to the lower risk of developing T1D in Rwanda than the other African countries. 
Genetics may also play a role in the lower rates in Rwanda, as the previous African studies were 
in primarily Arab countries, which have been shown to have very high rates of diabetes.2,14 As 
the majority of the Rwandan people are not of Arab descent, the rate of T1D might therefore be 
expected to be lower in Rwanda than the previous studies. This idea is supported by the fact that 
the rates seen in Rwanda were most similar to those in Tanzania, which has a more similar 
genetic profile.  
Due to this uncertainty surrounding the cause of the geographic variations of T1D and the 
evolution of diagnostic criteria, it is necessary to continue to monitor the rates of T1D. As we 
work to determine the etiology of this disease as well as the determinants of variation due to 
time, age, sex and race, it may behoove researchers to study the impacts of social events as well 
as genetic and environmental factors.  
 
7.2.3 Managing Diabetes in Africa 
 
In light of these increasing rates of T1D, resource poor countries will have to make major 
adjustments in their healthcare systems to be able to properly diagnose and manage patients with 
T1D. Seeing as prior to 2004, hospitals in Rwanda did not have access to glucometers and that 
only 18% and 8% of healthcare centers in Mozambique had access to glucometers and ketone 
tests, respectively, diagnostic procedures will need to be addressed first.89 However, once a 
patient has been diagnosed with T1D, access to insulin becomes another issue. 50-70% of T1D 
patients in the Congo, DRC, Cote d’Ivoire, Madagascar and Togo, 25-49% of those in Mali and 
Uganda, and 1-24% of patients in Nigeria and Senegal were unable to access insulin because it 
was too expensive, was not available, or had issues with storage.103 We saw the same barriers to 
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care in Rwanda, as insulin was primarily unobtainable outside our program due to low 
availability and prohibitively high prices. The same issues were true for the remaining 
management supplies (meters, strips, and syringes).  
The LFAC has worked to address these barriers to care in developing countries, through 
provision of education materials, insulin and diabetes management supplies. In order to continue 
their efforts globally, they need to ensure that their resources are being properly used to manage 
diabetes appropriately. One way to achieve this is through twinning of newer diabetes centers in 
developing countries with well-established programs in developed countries, such as the 
agreements between the Diabetes UK with Mozambique Diabetes Association111 and the 
National Diabetes Program in Tanzania.112 Our partnership with the ARD was initiated with the 
same goals in mind – to provide advice and direct assistance to the ARD staff, and maximize the 
proper use and allocation of resources supplied by the LFAC program.  
In order to assess the effectiveness of the LFAC program in Rwanda, we used HbA1c 
testing as a marker of glycemic control. At baseline, mean HbA1c was 11.2±2.7% and 30.8% of 
the cohort had very poor glycemic control (HbA1c >14%). However, as the LFAC program 
evolved through the addition of education sessions, more frequent clinic visits and regular 
HbA1c monitoring, mean HbA1c fell to 10.2±2.6% 12-months after baseline and to 9.8±2.3% 
24-months after baseline. The proportion of those with HbA1c over 14% also fell to 12.2% at 12 
months and 9.0% at 24 months. We also identified more frequent glucose monitoring as a 
potential point of intervention for improving glycemic control. This finding confirms the need 
for consistent availability of glucose meters and strips for proper management of T1D, as well as 
the need for knowledge of how to properly adjust insulin regimens based on glucose monitoring 
results.  
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The improvements we have seen in HbA1c control in Rwanda have resulted in a lower 
cumulative glycemic exposure. In order to estimate this exposure, a variable named A1months 
was developed that accounted for both magnitude and duration of exposure. This variable is 
calculated by summing the number of months from diagnosis to the current reading X the HbA1c 
units above the normal.165 For the cohort we followed, those who attended all three visits saw a 
total reduction in A1months of 3,363 months, with an average of 26.9 months per person (range 
0-122.4 months). This decrease in glycemic exposure will likely result in delayed development 
of complications and reduced mortality.165–168  
 Though these initial improvements in Rwanda are encouraging, it is apparent that 
additional work still needs to be done. While mean HbA1c has decreased since 2009, there are 
still patients who have un-measureable (>14% HbA1c) glycemic control, and a number of 
participants still have HbA1c’s that are well above the recommended goals of 8.5% for those 
younger than 6 years, <8.0% for those 6-13 years and <7.5% for those over 13 years.5 Hopefully 
in the future, these patients can be identified and be provided targeted care, specific to their 
situation and home life. That being said, the efforts and improvements that have been seen are 
commendable considering the lack of resources and low education and organization of the 
general healthcare system in Rwanda. It is very likely that without the LFAC, ARD and GSPH 
intervention the status of the majority of these patients would be definitively worse.  
A previous study from Kenya showed improvements in glucose control with increases in 
glucose monitoring and regular contact with diabetes caregivers.126 Additional studies from 
Eritrea and South Africa have shown that a combination of education programs and HbA1c 
testing can result in improved glycemic control.108,110 However, these studies were done in 
significantly older populations and were primarily for those with type 2 diabetes. Therefore, our 
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study appears to be the first documentation of improved glycemic control in children and 
adolescents with type 1 diabetes in sub-Saharan Africa. Our results show that despite the 
previously identified barriers, glycemic control can be obtained with outside support from 
organizations such as the LFAC program.  
Though programs like LFAC may assist in providing supplies for the management of 
diabetes, the hospitals will also have to make adjustments in their approach, as they will have to 
provide long-term treatment instead of the usual short-term treatment for communicable 
diseases. Hospitals will have to improve upon their current record systems to allow for easy and 
effective patient follow-up.  
 
7.2.4 Complications of T1D in children and adolescents  
 
Though we’ve seen improvements in glycemic control in Rwanda, complications due to diabetes 
are still present, or in the case of hypertension, are on the rise.  
Our reports show that the rates for microalbuminuria (MA), nephropathy, and neuropathy 
in Rwanda have not increased significantly over the last several years. Unfortunately, due to 
differing definitions and means of assessment, direct comparison of rates of complications is 
difficult. Duration is a well-established risk factor for microalbuminuria131,132,169 while 
neuropathy,170 and poor metabolic control are also associated with increased risk of complication 
development.60  Similar associations were found in our analyses as well.  
In Rwanda, we saw rates of neuropathy that ranged from 0.0% - 3.6%, which is lower 
than those reported from Ethiopia and South Africa (10.4% and 35.3%, respectively).56,109  
Unfortunately, comparison to other studies is complicated as the reported rates of T1D peripheral 
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neuropathy range from 7-57%, with the wide range due to different diagnostic methods and 
criteria.171  
While the prevalence of MA did not change overtime, it was more commonly seen than 
nephropathy (MA=18.2-21.0%). Table 17 compares rates of MA for Rwanda and other youth 
and adolescent T1D populations, as well as mean diabetes duration and mean HbA1c (or % of 
population with HbA1c <8%).56,57,129,133,155,172,173. Though each of these studies was performed in 
similar ages, duration of diabetes, glycemic control (HbA1c) and MA rates were quite different.  
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 Table 17. Comparison of rates of microalbuminuria, duration of diabetes and HbA1c by 
country. 
Country 
Duration 
(years) 
HbA1c 
(%) 
 
% with 
HbA1c 
<8% 
Testing Method 
Microalbuminura 
(% n) 
Rwanda 5.0 11.2±2.7 - A/C ratio 30-299 mg/g 18.2-21 
Tanzania 
4.76 10.65±2.1 
- MICROTEX (albumin >2.5 
mg/dl) 
29.3 
South Africa 13.6 - - Dipstick albumin >30 mg/L 26.3 
Australia 6.8 8.5±0.7  - AER >20-150 µg/min 6.0 
Denmark 12.2 9.7±1.7 - AER >20-150 µg/min 9.0 
US Overall 
(0-17 years) 
3.7 - ~30% 
A/C ratio >30mg/g 
9.2* 
US Af Americans 
(0-17 years) 
3.7 - ~30% 
A/C ratio >30mg/g 
9.6* 
Rwanda Youth 
(0-17 years) 
3.8 - 18.9% 
A/C ratio >30mg/g 
13.3* 
Pittsburgh  
(6-21 years)  
5.0 11.8±1.4 
- AER >20-150 µg/min 
21.0 
Rwanda  
(6-21 years) 
5.0 10.1±2.4 
- A/C ratio 30-299 mg/g 
15.1 
*Rates of all elevated A/C levels (ACR) (both MA and nephropathy combined) are presented 
 
Based on the known relationship between both MA and neuropathy with duration, one 
would therefore expect the prevalence of MA and neuropathy in Rwanda to be lower than all the 
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previous studies with the exception of Tanzania. However, while rates of neuropathy were lower 
than previous studies, the rates of MA in Rwanda are actually higher than all but Tanzania. One 
potential cause of this unexpected relationship with MA may be due to the other predictor of MA 
– glycemic control. Our Rwanda cohort had very poor glycemic control at baseline with a mean 
HbA1c significantly higher than those seen in developed countries, but comparable to those in 
Africa. The higher HbA1c could therefore account for some of the difference in prevalence of 
MA, and supports our findings of rates that are closer to those seen in other African countries.  
The differences in diabetes duration and glycemic control likely do not, however, account 
for all of the additional risk seen in Rwanda. One other factor that may be contributing to this 
excess risk is hypertension. The true association between hypertension and MA has still not been 
determined, as hypertension has been reported as both a causative factor for and a result of 
MA.132,174,175  In Rwanda, however, we have reported increases in risk of MA with increases in 
blood pressure,118 which this is supported by other work in Africa,176 and developed 
countries.170,172,173 This is an especially important relationship to be aware of in our Rwanda 
population, as rates of hypertension (28.5-45.3%) are high in comparison to other T1D 
populations (Australia=16.0%,172 US overall=5.9%, US AfAm= 7.8%,134 Pittsburgh, USA133;% 
sbp >120 mmHg =11.9%; Rwanda=28.6%; % dbp >80 mmHg Pittsburgh=10.2%, 
Rwanda=42.8%) and rates of MA are already elevated.  
The reason for the elevated hypertension in this population is likely due in part to the 
poor glycemic control. In Rwanda, while there were no overall significant differences by HbA1c 
control groups, BP increased the most for Group 2 (low-increased) and the least for Group 1 
(low-low), while BP for Group 3 (intermediate-low) did not change significantly. Although BP 
also increased for Group 4 (high-declined), it was likely as a result of improved health, as 
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previously described for this cohort,118 since weight also increased as HbA1c decreased. 
Previous studies have also found an association between poor glycemic control and higher rates 
of hypertension.134,177,178 Additionally, prior studies found that in the general population the 
prevalence of hypertension in those under age 45 years was higher sub-Saharan Africa (SSA) 
than the US and the UK (SSA=10.7%, UK=5.6%, US=8.2%).136 Diet may contribute to this 
additional risk, as salt is often used to prepare and preserve foods in SSA. Unfortunately we had 
no dietary information for this cohort, so we were unable to determine the actual salt intake for 
those in the LFAC program.  
If hypertension is not addressed in this population, it is very likely that the overall rates of 
long-term complications will rise even higher. Therefore, BP control should become a focus of 
future management efforts in Rwanda.  
 
7.2.5 Mortality of T1D in children and adolescents  
 
 We estimated the mortality rate in Rwanda to be between 3.75-18.9/1,000 person years of 
diabetes, with a 5-year survival rate of 93.8% (10-year survival=82.5%). This is consistent with 
the results of other mortality studies of T1D in Africa (Ethiopia=15.5/1,000 person years of 
diabetes,56 South Africa=84% 10-year survival155) but higher than rates from Tanzania (60-71% 
5-year survival).58 Studies from developed countries have reported lower mortality rates than in 
Rwanda (e.g. 0.06% in the UK),150–153 though reported rates from Lithuania are within the same 
range as Rwanda (6.1/1,000 person years of diabetes).151  30-year mortality rate of African 
Americans with T1D is 15.8/1,000 person years of diabetes87 which is similar to results seen in 
Rwanda, though with a much longer follow-up period. Unfortunately, background death rates are 
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unavailable in Rwanda (there is no official death index), so we were unable to calculate SMRs 
for our population. Though, with the high rate of background death due to communicable 
disease, malnutrition and violence, the SMR in Rwanda may be relatively low. 
While hypoglycemia was the most commonly reported cause of death in Rwandan T1D 
patients, diabetic ketoacidosis (DKA) was the main cause of death in most studies from 
developed countries150–153,179 and Africa.56,58 A diagnosis of DKA as a cause of death would have 
been very difficult to make in Rwanda, since most deaths occurred outside of a hospital, and 
autopsies are rarely done. Additionally, over half of those who died had an unknown cause of 
death so it is quite possible that hypoglycemia was not actually the main cause of death in 
Rwanda. Even so, it is clear it is an issue that needs to be addressed in this population. This 
problem, however, is further exacerbated by the high rate of food insecurity in this population 
and the low frequency of at home glucose monitoring. These circumstances make it very difficult 
to achieve optimal glycemic control while avoiding hypoglycemia and possible death.  
In our Rwanda cohort we saw a 24-28% increased risk of mortality with each additional 
year in age at diagnosis. A somewhat smaller (14%) association with age at diagnosis was seen 
in a study of mortality of T1D in Estonia, Lithuania, and Finland.151 While the study from the 
Baltic region did not propose a reason for this conferred risk, we hypothesize that the excess risk 
associated with advanced age at diagnosis in our cohort was actually due to the effects of 
surviving for several years with undiagnosed diabetes. Therefore, by the time diabetes was 
finally diagnosed, the patient was in very bad health and therefore at increased risk of dying. Due 
to lack of records from time of diagnosis, we cannot confirm this at this time, however our 
additional findings that higher weight at baseline was protective supports this idea as we have 
previously documented that those with worse control have lower weight which is likely due to 
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lack of insulin and dehydration hypovolemia.118 This finding further emphasizes the importance 
of improved diagnosis and diabetes awareness in this population.  
Though the mortality rates in Rwanda are higher than desired, we have also identified 
some temporal improvements in survival, as other studies have.152,154 Those who were first seen 
for a clinic visit in 2009 had a higher mortality rate than those seen in years since, suggesting 
that adjustments to management and care made in the years since, have reduced the risk of 
mortality. Seeing a significant change in such a short time, gives hope to future and further 
decreases in mortality risk in this population.  
 
7.3 STRENGTHS AND LIMITATIONS 
 
There are several strengths of the current study that should be noted. This is the very first report 
on the current status of youth and adolescents with T1D in Rwanda.  We are the first group to: 
attempt to estimate the burden of this disease (incidence and prevalence), to estimate the 
prevalence of complications, and to estimate the mortality due to this disease in Rwanda. To 
complete this study we used multiple years of clinic data from over 500 participants with T1D, 
and this appears to be the largest cohort of T1D youth to be studied in sub-Saharan Africa. Even 
with the earlier reported issues with loss to follow-up, we saw similar loss to follow-up (18.7%) 
as in Tanzania (11%),58 and less than rates reported from Ethiopia (33.4%)56 and South Africa 
(27.3%).155 These reports also present a unique contemporary review of the T1D situation in 
Africa, as most of the previous work was completed over a decade ago.  
 Several additional weaknesses should also be noted. Unfortunately, our studies were 
limited to data from cases that were previously clinically diagnosed. We had no screening ability 
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and were therefore unable to identify any new cases on our own. This left us completely 
dependent on the local hospital staff for diagnosis. As mentioned before, this limits the 
generalizability of our rates, and it is very likely that our rates are an underestimation of the true 
burden of T1D due to the likelihood of death before diagnosis, misdiagnosis, and under-
diagnosis, particularly in the earlier years.  
 Complication status was also not fully or consistently ascertained in this population. A/C 
ratios were to be collected annually (or more frequently if they had been abnormal), but it 
appears this was not done consistently, partly due to reagent supply logistics. Additionally, there 
were logistical issues with limited availability of testing reagents. Therefore, due to irregular 
testing and lack of follow up for positive results, the rates of complication in this population may 
be quite different than what we have reported. We were also unable to screen for retinopathy in 
this population. Previous studies from developed countries and Africa (Ethiopia=9.5%56, 
Tanzania=22.2%57, South Africa=58.8%65) have reported the presence of retinopathy in youth 
cohorts, and therefore it is highly likely that there are children in Rwanda that are affected by this 
complication. This is especially true with the elevated HbA1c and hypertension present in our 
population, as they have both previously been identified as risk factors for retinopathy.66 In 
Rwanda, we have already noted the presence of several visual complications such as reported 
cataract surgery and significantly impaired visual acuity. However, recent efforts have been 
made to make screening available to address this issue further. Additionally, screening for 
cardiovascular complications was limited. We were not able to collect any lipid data, nor were 
we able to perform any additional cardiac evaluations. While it is good that we have not had 
reports of macrovascular events, considering the young age and short duration of diabetes in our 
cohort, previous studies from developed countries have found that 23% of children and 
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adolescents with T1D (mean age 14 years, diabetes duration of 6 years) have longer QTc 
intervals which is a sign of possible cardiac autonomic neuropathy.180 Thus, suggesting that early 
signs and symptoms may already be present in our cohort.  
 It is likely that our data have been affected by a survival bias. Due to the likelihood of 
missed and undiagnosed cases, as well as loss to follow-up, our results likely represent those of a 
survivor cohort. Therefore, our results may actually report a better current status than is true. It is 
likely that the true T1D situation in Rwanda is one of worse control, higher complication rates, 
and higher mortality.  
 
7.4 FUTURE WORK 
 
Future work with T1D in Rwanda should be focused on continuing the practices that have 
already been shown to be effective (home monitoring of glucose, use of HbA1c tests, increased 
education, and frequent clinic visits), and addressing the aforementioned limitations.  
 The first step should involve the initiation of either a national diabetes registry or official 
and regular record collection on T1D at the hospital level. We have seen such registries and data 
collection at hospitals for communicable diseases such as HIV, malaria, and tuberculosis. 
Therefore, we know the staff has the knowledge and ability to collect such data regularly. 
However, government involvement and mandates will likely be necessary in order to motivate 
and direct this effort. This type of system would allow for confirmation of previously reported 
dates (birth, diagnosis) and future collection of data at the time of diagnosis, not several years 
post. Providing proper diabetes care as well as follow-up of patients would also be easier to 
conduct from a local district hospital rather than from the ARD location in Kigali City. This 
would allow for more thorough follow-up, more consistent care, and better mortality reporting.  
130 
 
 This formal diabetes registry and systematic data collection could then be used as the data 
source for a more formal evaluation of the prevalence and incidence of T1D in Rwanda. With 
financial support from the government or an official outside funding source, these more complete 
datasets could then be used to expand upon our 6-district estimation to allow for a countrywide 
report on T1D rates for all ages and not just children and youth. Additionally, the differences in 
sex, age at diagnosis, cause of death and level of glycemic control and hypertension could be 
further examined to see if they persist. These reports would be much more generalizable and the 
systematic data collection would limit the current effects of survivor bias by promoting earlier 
and more correct diagnosis.  
 Additional efforts should be made to ensure that all hospitals and T1D patients have 
access to glucometers or urine glucose testing supplies. The LFAC program could continue to 
assist with supplying these meters and the ARD staff can distribute and train the local staff on 
proper use. This increased availability would need to be supported by availability of testing strips 
and education on how to properly adjust insulin doses based on testing results. If glucometers are 
not practical, hospitals should at the very least be supplied with the less expensive urine glucose 
testing supplies. Additionally, a protocol should be in place at each point of care to test the 
glucose levels of all sick children.  
General diabetes education should also be a major focus of community work to increase 
awareness of diabetes in the medical society, allowing for more timely and correct diagnoses. 
Additional education efforts should be focused on the families, schools, and communities around 
those with T1D so that some of the stigma associated with diabetes may be removed, and more 
proper management can be obtained.  
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 Laboratory resources need to be improved to allow for better, more regular, and more 
thorough complication assessment. Official ledgers should be kept that document the status of 
the stock of DCA reagents, and there needs to be a system in place to order supplies in a more 
timely fashion to avoid any times where the supplies are not available. Clinic files should be 
regularly referenced for the date and result of the last complication screening to promote regular 
screening and confirmation of positive results. Data on lipid profiles, cardiac and additional 
neuropathy risk factors, and retinopathy need to be collected in the future. C-peptide levels as 
well as other immune markers need to be quantified to allow for proper classification of diabetes 
type, so that the best clinical care may be provided. This is especially important in this 
community given the previous descriptions of atypical diabetes in Africa.  
 Such a systematic and regulated program would require involvement, support, and 
oversight from the government, which to this date, they have been hesitant to provide. However, 
in order for such care to be sustainable long-term, these adjustments will need to be made. As 
developing countries progress through the epidemiologic transition from focusing on 
communicable diseases to chronic, they will need to re-assess their current healthcare systems 
and make the necessary changes to allow for provision of long-term care.  
 
7.5 PUBLIC HEALTH IMPLICATIONS 
 
Each year, an estimated 8-14 million people die of non-communicable diseases in developing 
countries (Diabetes Atlas, 2009). The WHO predicts that this rate will rise by 17% in the next 
several years, with the greatest increase in African countries (27%) of low- and middle- income. 
An estimated 285 million people had diabetes in 2010 and is expected to increase to 483 million 
by the year 2030.2 Of these cases, 480,000 were under 14 years of age and had T1D, with 76,000 
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more diagnosed each year. In Rwanda, we estimate that there are 1,192 (95% CI, 1,061-1,337) 
children and adolescents under the age of 26 years with T1D, with an annual incidence rate of 
around 2.2% (95% 1.6-3.0), indicating the total number of cases will rise into the future. Thus, 
this is a public health issue of growing importance in developing countries as they will have to 
work to balance the need to provide care for both communicable and chronic diseases. Even with 
improvements in diabetes care and management, patients with T1D continue to develop 
complications, and mortality due to T1D is higher than the general population. This disease 
continues to put a strain on healthcare systems, and will become an even larger problem as the 
incidence increases with time. In resource poor developing countries, this will likely put an 
additional strain on an already taxed healthcare system. Therefore, in order to accurately address 
the growing issue of T1D in Rwanda, we need to better understand the true burden of the disease 
(incidence/prevalence), how it presents and progresses, and how to prevent early mortality. We 
have also identified the need for a more sustainable, government supported, program that will 
result in more complete coverage of the country and will ensure the provision of proper care 
long-term.  
 Through our work in Rwanda, we have identified gaps in current care and research, as 
well as several practices that have proved to be effective. We have also shown that even in a 
resource poor area, education, HbA1c testing, self-monitoring of glucose and proper insulin 
adjustments along with regular clinic visits can lead to improved glycemic control. We have 
identified hypertension and hypoglycemia as complications that need to be addressed in the near 
future. Our work has also highlighted the need for complete, clean, and regular data collection as 
well as thorough follow-up practices for improved retention. Unfortunately, due to the current 
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lack of typology determining resources in Rwanda, we cannot confirm the type of diabetes 
present in this population, which limits our ability to provide the best care to all patients.  
We hope our findings will assist in directing future public health diabetes care efforts in 
Rwanda as well as other countries as they work towards improving the quality and length of life 
for children and adolescents with T1D. Though much work still needs to be done to provide the 
best care to these patients, we believe that our work will provide the groundwork for future 
efforts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
134 
 
APPENDIX A: SUPPLEMENTAL TABLES AND FIGURES FOR PAPER 1 
 
Table 18. Baseline characteristics of the 2009-2010 LFAC cohort overall, stratified by 
attendance at one- and two- year visits and age. Data are stratified by age (over 18 years, 
under 18 years). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
&Includes only those who were eligible for a two-year follow -up 
 
* Indicates significance at α < 0.05 
ǂ Indicates borderline significance at α <0.1 
 
 Overall  Attendance at V1 Attendance at V2 
  Yes No Yes No& 
<18 years (N) 93 71 22 57 15 Height Z-score -1.6±1.8 -1.8±1.8 -1.0±1.7 ǂ -1.7±1.8 -1.3±1.7 Short Stature %(n) 48.2 (42) 52.3 (34) 36.4 (8) 46.2 (24) 42.9 (6) Normal Stature %(n) 47.1 (41) 44.6 (29) 54.6 (12) 51.9 (27) 50.0 (7) Tall Stature %(n) 4.6 (4) 3.1 (2) 9.1 (2) 1.9 (1) 7.1 (1) BMI Z-score -0.7±1.4 -0.7±1.4 -0.7±1.1 -0.6±1.6 -0.6±0.8 Underweight %(n) 16.1 (14) 16.9 (11) 13.6 (3) 15.4 (8) 14.3 (2) Healthy Weight %(n) 74.7 (65) 72.3 (47) 81.8 (18) 71.2 (37) 85.7 (12) Overweight %(n) 5.8 (5) 6.2 (4) 4.5 (1) 7.7 (4) 0.0 (0) Obese %(n) 3.4 (3) 4.6 (3) 0.0 (0) 5.8 (3) 0.0 (0) Systolic BP Z-score -0.1±1.0 -0.04±1.1 -0.4±0.7 -0.2±1.0 -0.1±0.8 Normal Systolic BP %(n) 88.5 (77) 86.2 (56) 95.5 (21) 90.4 (47) 92.9 (13) Pre-Hypertension %(n) 9.2 (8) 10.8 (7) 4.6 (1) 5.8 (3) 7.1 (1) Hypertension %(n) 2.3 (2) 3.1 (2) 0.0 (0) 3.8 (2) 0.0 (0) Diastolic BP Z-score 0.5±0.7 0.5±0.7 0.4±0.6 0.5±0.7 0.4±0.6 Normal Diastolic BP %(n) 82.8 (72) 83.1 (54) 81.8 (18) 80.8 (42) 92.9 (13) Pre-hypertension %(n) 13.8 (12) 12.3 (8) 18.8 (4) 13.5 (7) 7.1 (1) Hypertension %(n)  3.4 (3) 4.6 (3) 0.0 (0) 5.8 (3) 0.0 (0) 
> 18 years (N) 192 143 49 87 55 BMI 21.1±4.0 21.0±3.8 21.2±4.6 21.4±3.9 21.2±5.0 Underweight %(n) 21.2 (39) 22.8 (31) 17.0 (8) 20.0 (16) 24.1 (13) Healthy Weight %(n) 72.3 (133) 70.6 (96) 76.6 (37) 71.2 (58) 68.5 (37) Overweight %(n) 4.9 (9) 5.2 (7) 4.3 (2) 7.5 (6) 3.7 (2) Obese %(n) 1.6 (3) 1.5 (2) 2.1 (1) 1.2 (1) 3.7 (2) Systolic BP (mmHg) 116±16 115±14 120±19 115±16 118±15 Diastolic BP (mmHg) 74±11 74±11 75±12 75±11 76±10 Hypertension %(n) 16.5 (31) 15.7 (22) 18.4 (9) 16.1 (14) 14.5 (8) 
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Table 19. Clinical characteristics of one- and two- year follow up visits as compared to 
baseline and one-year. Data are stratified by age (over 18 years, under 18 years). 
 V1  V2  
 Baseline V1 Baseline V1 V2 
<18 years (N) 62 62 37 29 37 
Height Z-score -1.8±1.9 -1.8±1.9 -1.3±1.6 -1.8±1.8 -1.4±2.0 
Short Stature %(n) 55.4 (31) 52.5 (31) 39.4 (13) 40.7 (11) 37.8 (14) 
Normal Stature %(n) 41.1 (23) 44.1 (26) 57.6 (19) 55.6 (15) 56.8 (21) 
Tall Stature %(n) 3.6 (2) 3.4 (2) 3.0 (1) 3.7 (1) 5.4 (2) 
BMI Z-score  -0.7±1.4 -0.6±1.4 -0.4±1.4 -0.4±1.6 -0.4±1.1 
Underweight %(n) 16.1 (9) 18.3 (11) 9.1 (3) 10.7 (3) 13.5 (5) 
Healthy Weight %(n) 73.2 (41) 70.0 (42) 78.8 (26) 78.6 (22) 78.4 (29) 
Overweight %(n) 5.4 (3) 10.0 (6) 6.1 (2) 7.1 (2) 8.1 (3) 
Obese %(n) 5.4 (3) 1.7 (1) 6.1 (2) 3.6 (1) 0.0 (0) 
Systolic BP Z-score -0.07±1.0 0.3±1.3* -0.3±0.9 0.7±1.3* 0.6±1.2◊ 
Normal Systolic BP %(n) 87.5 (49) 79.3 (46) 93.9 (31) 73.1 (19) 75.0 (27) 
Pre-Hypertension %(n) 10.7 (6) 5.2 (3) 3.0 (1) 3.8 (1) 11.1 (4) 
Hypertension %(n) 1.8 (1) 15.5 (9)* 3.0 (1) 23.1 (6)* 13.9 (5) 
Diastolic BP Z-score 0.4±0.7 0.8±1.0* 0.5±0.7 0.8±1.0 1.4±1.0*◊ 
Normal Diastolic BP %(n) 83.9 (47) 67.2 (39) 75.8 (25) 65.4 (17) 47.2 (17) 
Pre-hypertension %(n) 12.5 (7) 10.3 (6) 18.2 (6) 7.7 (2) 11.1 (4) 
Hypertension %(n)  3.6 (2) 22.4 (13)* 6.1 (2) 26.9 (7)* 41.7 (15)◊ 
> 18 years (N) 143 143 87 79 87 
BMI 21.0±3.8 21.0±2.6 21.4±3.9 21.4±2.5 21.6±2.8 
Underweight %(n) 22.8 (31) 19.6 (27) 20.0 (16) 16.2 (12) 15.3 (13) 
Healthy Weight %(n) 70.6 (96) 74.6 (103) 71.2 (57) 75.7 (56) 75.3 (64) 
Overweight %(n) 5.2 (7) 5.8 (8) 7.5 (6) 8.1 (6) 9.4 (8) 
Obese %(n) 1.5 (2) 0.0 (0) 1.2 (1) 0.0 (0) 0.0 (0) 
Systolic BP (mmHg) 115±14 122±15* 115±16 121±14* 122±21◊ 
Diastolic BP (mmHg) 74±11 79±13* 75±11 78±14* 80±14◊ 
Hypertension %(n) 15.7 (22) 56.9 (82)* 16.1 (14) 55.7 (44)* 50.6 (44)◊ 
 
* Indicates significance at α = 0.05 to year before 
◊ Indicates significance at α = 0.05 to two -years before 
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Figure 7. Changes in the distribution of Systolic and Diastolic BP from Baseline to V1 (A) 
or V2 (B). 
 
 
 
A. Baseline – V1 
B. Baseline – V2 
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Table 20. Age-specific prevalence rates of clinically diagnosed type 1 diabetes in six 
Districts and Kigali City, Rwanda and mean age at diagnosis. 
 Rubavu Gakenke Rusizi Huye Muhanga Kigali TOTAL 
1-4 Years 0 0 0 0 0 2 2 
Per 100,000 0.0 (0.0-8.0) 0.0 (0.0-6.4) 0.0 (0.0-6.4) 0.0 (0.0-10.7) 0.0 (0.0-9.5) 1.9 (0.2-7.0) 0.6 (0.07-2.1) 
Age at 
Diagnosis 
- - - - - 2.0±1.4 2.0±1.4 
5-9 Years 1 1 1 0 0 5 8 
Per 100,000 2.1 (0.04-11.7) 2.4 (0.05-13.3) 1.8 (0.03-10.2) 0.0 (0.0-10.0) 0.0 (0.0-8.5) 4.7 (1.5-11.0) 2.4 (1.0-4.8) 
Age at 
Diagnosis 
3.0 7.0 5.0 - - 4.8±2.4 4.8±2.0 
10-14 
Years 
2 5 3 1 4 20 36 
Per 100,000 4.7 (0.6-17.1) 13.0 (4.2-30.5) 6.1 (1.2-18.0) 2.8 (0.06-15.9) 10.4 (2.9-26.6) 23.1 (14.1-35.7) 12.4 (8.7-17.2) 
Age at 
Diagnosis 
10.0±4.2 9.4±2.6 7.3±7.0 3.0 5.2±5.2 9.4±2.6 8.6±3.6 
15-19 
Years 
3 14 9 9 6 24 71 
Per 100,000 7.6 (1.5-22.3) 34.6 (18.8-58.1) 19.7 (9.0-37-4) 28.6 (13.0-54.3) 17.7 (6.5-38.3) 25.3 (16.3-37.7) 24.8 (19.4-31.4) 
Age at 
Diagnosis 
14.0±2.6 14.6±2.3 15.4±1.3 14.4±3.1 12.8±6.4 13.4±2.8 14.0±3.0 
20-24 
Years 
11 14 17 15 26 63 158 
Per 100,000 33.3 (16.6-59.6) 43.4 (23.6-72.9) 43.7 (25.4-70.0) 50.1 (28.0-82.5) 76.9 (50.3-112.7) 50.7 (39.0-64.9) 54.1 (46.0-63.1) 
Age at 
Diagnosis 
16.6±4.2 18.2±2.7 18.0±3.5 17.8±3.9 15.6±3.2 16.7±3.6 16.9±3.5 
25 Years 0 3 6 2 5 12 29 
Per 100,000 0.0 (0.0-66.9) 40.4 (8.1-118.7) 84.8 (31.1-183.8) 34.9 (4.2-125.7) 79.3 (25.4-185.5) 43.9 (22.7-76.9) 48.8 (3.7-70.1) 
Age at 
Diagnosis 
- 19.3±3.8 22.5±1.7 19.0±5.6 20.7±4.9 19.7±4.2 20.3±3.9  
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 Table 21. Yearly incidence (per 100,000) estimate of clinically diagnosed type 1 diabetes, by 
age range at diagnosis, in Rwanda Africa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year 1-4 Years 5-9 Years 10-14 Years 15-19 Years 20-24 Years 25 Years 
2004 0.36 (0.07-2.0) 1.1 (0.2-3.3) 0.85 (0.1-3.1) 2.6 (1.0-5.6) 0.0 (0.0-1.6) 0.0 (0.0-7.7) 
2005 0.35 (0.07-2.0) 1.4 (0.4-3.7) 2.5 (0.9-5.4) 4.6 (2.3-8.3) 0.41 (0.0 -2.3) 0.0 (0.0-7.5) 
2006 0.69 (0.08-2.5) 0.0 (0.0-1.3) 2.0 (0.6-4.7) 3.7 (1.7-7.0) 2.0 (0.6-4.7) 0.0 (0.0-7.2) 
2007 0.0 (0.0-1.2) 1.4 (0.4-3.5) 3.9 (1.9-7.2) 7.9 (4.8-12.2) 1.9 (0.6-4.5) 0.0 (0.0-7.0) 
2008 0.33 (0.07-1.8) 0.33 (0.07-1.9) 1.9 (0.6-4.4) 8.1 (5.0-12.4) 4.5 (2.3-7.9) 0.0 (0.0-6.9) 
2009 0.0 (0.0-1.2) 0.97 (0.2-2.8) 0.74 (0.09-2.7) 4.5 (2.3-7.9) 6.2 (3.6-10.0) 1.8 (0.36-10.1) 
2010 0.62 (0.07-2.2) 0.94 (0.2-2.8) 2.9 (1.2-5.7) 5.8 (3.3-9.5) 6.8 (4.1-10.6) 0.0 (0.0-6.5) 
2011 0.0 (0.0-1.1) 0.61 (0.07-2.2) 3.5 (1.7-6.4) 4.6 (2.4-7.9) 5.2 (2.9-8.6) 1.7 (0.34-9.6) 
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Table 22. Mortality comparisons for Rwanda and other studies 
Country Crude Mortality 
(%) 
(95% CI) 
Mortality per 
1,000 Person 
Years 
(95% CI) 
5-Year 
Survival 
(%) 
10-year 
survival 
(%) 
Rwanda 6.9 
(4.5-10.2) 
13.9 
(9.0-20.6) 93.8 82.5 
Rwanda  
(Worst case scenario) 
32.1 
(27.0-37.1) 
40.2 
(32.0-49.9) 85.1 66.2 
Rwanda  
(Best case scenario) 
5.0 
(3.3-7.4) 
12.3 
(7.9-18.1) - - 
Ethiopia - 15.5 - - 
South Africa - - - 84 
Tanzania - - 71-60 - 
United Kingdom 0.6 - - - 
Lithuania 0.04 6.1 97.3 94.0 
Estonia 0.02 3.7 99.0 94.3 
Finland 0.006 0.8 99.8 99.1 
US African Americans  
(30-years) - 15.8 98 96 
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